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Abstract
Insulin-like growth factor-1 (IGF-1) has pleiotropic effects on various tissues during pre- and 
postnatal development by stimulating proliferation and differentiation, and plays a major role 
in hypertrophy and tissue remodeling in the fetal, perinatal, and adult organism. In skeletal 
muscle the role of IGF-1 is well established, but questions remain about the significance of 
the various isoforms that are produced from the single-copy IGF-1 gene. By the use of 
different promoters, differential splicing and post-translational modifications, at least six IGF-1 
isoforms are generated from the IGF-1 gene, that differ in the N-terminal signal peptide 
(Class) and the C-terminal E-peptide. The aim of this work was to dissect the different roles 
of IGF-1 isoforms in skeletal muscle in vitro and in vivo. Cell culture experiments revealed 
that IGF-1Ea isoforms promoted myogenic differentiation and cell hypertrophy, resulting in 
enlarged myofibers, while IGF-1Eb isoforms instead did not show an effect on fiber size but 
on proliferation of myoblasts. Correlating with the results obtained in vitro, transgenic animals 
over-expressing IGF-1Ea isoforms showed pronounced muscle fiber hypertrophy, 
accompanied by an increase in force generation and strength, while IGF-1Eb isoforms 
showed very mild effects on muscle size and no changes in muscle strength, further 
implicating the Ea-peptide in the hypertrophic response. Analysis of the intracellular signals 
transduced by the different IGF-1 isoforms revealed a complex regulatory network, excluding 
certain pathways previously implicated in the induction of skeletal muscle hypertrophy in 
response to IGF-1. Preliminary analysis of regeneration in response to IGF-1 isoforms 
demonstrated that each isoform enhanced the regeneration process, suggesting that Eb-
peptide-containing isoforms did so by stimulating the proliferation of satellite cells, while IGF-
1Ea enhanced the growth of newly forming fibers. Class 2 IGF-1Eb was found to specifically 
induce a calcineurin isoform (CnAß1) that has been linked to enhanced regeneration. In 
addition, this thesis describes the cloning of a Class 2 IGF-1En isoform that was previously 
not described in rodent species, but known to exist in humans. The present work constitutes 
the first evidence for different functions of IGF-1 isoforms in vitro and in vivo, provides an 
overview of their variable effects in skeletal muscle and a strong basis for future research into 
their specific functions. 
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Zusammenfassung
Der Insulin-ähnliche Wachstumsfaktor-1 (IGF-1) spielt sowohl in der Embryonalentwicklung, 
als auch während der postnatalen Entwicklungsphase eine wichtige Rolle. Neben der 
Fähigkeit Zellwachstum und Zelldifferenzierung zu stimulieren, hat IGF-1 eine wichtige 
Funktion bei Vorgängen wie Muskel Hypertrophie und Regeneration. Die wichtige Rolle von 
IGF-1 in der Skelettmuskulatur ist seit langem bekannt, aber dennoch verbleiben viele 
Fragen über die Funktion der verschiedenen Isoformen, die ausgehend vom IGF-1 Gen 
gebildet werden. Durch die Nutzung verschiedener Promoter, differentiellem Spleißen und 
post-translationalen Modifizierungen, werden verschiedene IGF-1 Präpro-Proteine gebildet, 
die sich in der Kombination ihrer N-terminalen Signal-Peptide (Klasse) und C-terminalen 
Extensions-Peptide unterscheiden. Die vorliegende Arbeit zielte auf eine gründlich Analyse 
der Rolle verschiedener IGF-1 Isoformen in der Skelettmuskulatur in vitro und in vivo. 
Experimente in Zellkultur ergaben, dass IGF-1Ea Isoformen einen beschleunigten 
Differenzierungsvorgang induzierten, was auch eine Vergrößerung der Musklefasern zur 
Folge hatte. IGF-1Eb Isoformen hingegen, zeigten einen Effket auf die Proliferierung der 
Myoblasten und nicht auf deren Grösse. In Übereinstimmung mit den in vitro Daten, zeigten 
transgene Mäuse, die IGF-1Ea Isoformen (Klasse 1 IGF-1Ea (=mIGF-1) und Klasse 2 IGF-
1Ea) überexprimieren, ausgeprägte Muskel Hypertrophie, die mit einer erhöten Muskelkraft 
einhergingen. Im Gegensatz dazu zeigten IGF-1Eb transgene Tiere einen sehr milden 
Phänotyp, der weder mit Hypertrophie, noch mit erhöter Muskelkraft einherging. Dies 
unterstreicht noch einmal eine Verbindung zwischen der Präsenz des Ea-Peptides und der 
Induktion eines hypertrophen Phänotyps. Die Analyse der intrazellulären 
Signaltransductionswerge ergab ein komplex reguliertes Netzwerk und führte zum 
Ausschluss von Signaltransduktionswegen, die in früheren Publikationen für die Induktion 
von IGF-1-induzierter Hypertrophie vorgeschlagen wurden. Die vorläufige Analyse der 
Regenerationsprozesse in Folge von Cardiotoxin-Injektionen demonstrierte, dass alle IGF-1 
Isoformen diesen Prozess bescheunigen konnten. Die Resultate implizieren, dass IGF-1 
Isoformen, die das Eb-Peptid behinhalten die Proliferation von Satelitenzellen stimulieren, 
während Klasse 2 IGF-1Ea die Größe der neu formenden Muskelfasern erhöhen. Klasse 2 
IGF-1Eb zeigte zurätzlich eine spezifische Induzierung der Calcineurin Isoform CnAß1, die 
bereits mit verbesserter Muskelregenerierung in Verbundung gebracht wurde. Ausserdem 
bescheibt diese Arbeit die Klonierung einer Klasse 2 IGF-En Variante, die bisher nicht in 
Nagern beschirben wurde, aber im Menschen existiert. Die vorliegende Arbeit liefert die 
ersten Beweise, dass IGF-1 Isoformen in vitro und in vivo andere Effekte hervorrufen und 
ebnet damit den Weg für die Zukunft spezifischere Fragen stellen zu können.
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1 Introduction
Recent studies on the role of insulin-like growth factor-1 (IGF-1) isoforms in skeletal muscle 
growth and differentiation have implicated IGF-1 as an important mediator of anabolic 
pathways and also provided new insights into the function of these signaling molecules in 
muscle homeostasis. Many studies suggest promising new avenues for systemic as well as 
local intervention in the defects associated with many muscle pathologies. Since IGF-1 levels 
decline with age in both humans and rodents, this growth factor has also been considered a 
promising therapeutic agent in staving off advancing muscle weakness during aging.
The introduction to this thesis is crucial to understand the work presented later on and aims 
to give an overview of development and structure of the skeletal muscle system, as well as a 
detailed description of the IGF-1 system and its role in skeletal muscle. 
1.1 Skeletal muscle development and structure 
1.1.1 Overview of muscle development.
Skeletal muscle development results from a cascade of events leading to mesoderm 
formation (reviewed in [1-3]). The mesoderm is subdivided into four compartments: axial, 
paraxial, intermediate and lateral plate mesoderm. In the developing embryo, the paraxial 
mesoderm, which is located between axial structures (neural tube and notochord), and 
lateral structures (intermediate and lateral mesoderm), gives rise to the somites (reviewed in 
[4]), which are the main source of all skeletal muscle cells in vertebrates. In response to 
positive and negative signals from the notochord, the neural tube, and the dorsal ectoderm, 
the somite develops into three distinct cellular compartments: dermamyotome (DM), 
myotome and sclerotome. These compartments subsequently give rise to distinct cell fates 
(Figure 1.1). 
Figure 1.1: Fate map of a somite. The ventral medial portion of the somite (blue) gives rise to the sclerotome 
and dermamyotome. While the sclerotome cells migrate to form the cartilage of the vertebrae, the dermamyotome 
forms the dermatome and the myotome, which give rise to the dermis, all the trunk muscles, as well as to the 
muscle cells that migrate into the limb bud. [5]
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The sclerotome arises in response to positive signals from the notochord, such as sonic 
hedgehog (Shh), and gives rise to the axial skeleton and ribs, while the dermamyotome 
forms in response to positive signals from the dorsal neural tube and the notochord, as well 
as from the overlying ectoderm. Shh from the notochord acts together with basic fibroblast 
growth factor (bFGF) and members of the Wnt family, such as Wnt-1 and Wnt-3a from the 
dorsal neural tube, and Wnt-4, Wnt-6, and Wnt-7a from the surface ectoderm to induce the 
formation of the dermamyotome (reviewed in [6]). The dermamyotomal cells, while 
maintained in an undifferentiated state by negative signals from the lateral plate and surface 
ectoderm (e.g. bone morphogenic protein-4 (BMP-4), Notch, and Msx-1), continue to 
proliferate and give rise to the myotome and the dermis [7, 8] (Figure 1.2). The 
dermamyotome can further be classified into medial and lateral components, which develop 
into two lineages of adult muscle, epaxial (axial) myotome and hypaxial myotome. While the 
epaxial myotome forms the muscles of spinal column and face, the hypaxial myotome gives 
rise to the muscles of the limbs and body wall [9]. 
Figure 1.2: Signaling in myogenesis. Signals from the notochord (NC), the neural tube (NT), and the lateral 
mesoderm (LM) give rise to the sclerotome (Sc), the epaxial and the hypaxial muscles. Shh – sonic hedgehog; 
Sm – somite.
Myogenic identity is acquired as a result of the activation of the myogenic determination 
factors (MDFs), members of the basic helix-loop-helix (bHLH) family of transcription factors, 
which include myf-5, MyoD, myogenin, and MRF-4 (myogenic regulatory factor). Due to their 
ability to activate muscle-specific gene expression programs when over-expressed in 
transfected non-muscle cell types [10, 11], the MDFs are considered to be key factors of 
myogenesis. Their important role has been confirmed by transgenic, knock-out, and knock-in 
mouse models over the last decade [12-17].
By interacting with ubiquitous bHLH proteins, known as E-proteins [18], and other myogenic 
transcription factors, such as the members of the myocyte enhancing factor (MEF) family, 
MDFs mediate the activation of genes encoding structural and regulatory muscle-specific 
proteins, such as myosin light chain (MLC), α-actin, troponin I, troponin T, muscle creatine 
kinase (MCK), and the different subunits of the acetylcholin receptor (AChR) [11].
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Activation of the MDFs is dependant on the signals from the neural tube, notochord and 
dorsal ectoderm. While Wnt-1, derived from the neural tube, has been shown to activate myf-
5 expression in the epaxial myotome, Wnt-7a from the dorsal ectoderm activates MyoD and 
promotes the formation of the hypaxial muscles [19] (Figure 1.3).
Figure 1.3: MyoD and myf-5 signaling in the development of epaxial and hypaxial muscle. Positive signals 
from the axial structures induce expression of the primary MRFs in the myotome. MyoD expression in the ventral 
myotome leads to activation of the secondary MRFs, MRF4 and myogenin and finally to epaxial muscle, while 
myf-5 expression also leads to activation of the secondary MRFs, but to the development of hypaxial muscle. 
From Palmer et al. [20]
In vitro studies also revealed a role of IGF-1, IGF-2, and insulin in promotion of somite 
myogenesis [21], showing that the IGFs and insulin interact synergistically with Shh, bFGF 
and transforming growth factor-β1 (TGF-β1) to stimulate high levels of muscle development. 
The detection of insulin, IGF-2, insulin receptor, and IGF-1 receptor mRNAs in both the 
neural tube and the somites, and the detection of IGF-1 transcripts in the entire embryo but 
not in the neural tube or somites, support the role of these molecules as early myogenic 
signals during embryogenesis [21].
1.1.2 Development of skeletal muscle structure
The embryonic development of the hypaxial limb and trunk muscles occurs in two temporally 
distinct phases of so-called primary and secondary myogenesis during which muscle 
precursor cells migrate into the limb, where they form the muscle mass [22] (Figure 1.4). In 
the first wave of primary myogenesis, which corresponds to the onset of muscle formation in 
the embryo, certain mesenchymal cells in each myotome differentiate into long 
mononucleated muscle precursors (myoblasts). After a period of proliferation, myoblasts start 
to fuse into primary myofibers by forming progressively elongated multinucleated cells. It is 
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only after myoblast fusion that the myofibers start to synthesize the contractile proteins 
necessary for muscle function. The second wave of myogenesis is the result of proliferation 
and differentiation of previously quiescent myoblasts which use the primary myofibers as a 
scaffold for formation of the secondary myofibers. (Figure 1.3 and 1.4)
Figure 1.4: Primary and secondary myogenesis. Primary myofibers, expressing markers like slow myosin 
heavy chain (MyHC), fast MyHC and β-enolase, act as a scaffold for the development of secondary myofibers, 
which express markers like fast MyHC, muscle creatine kinase (MCK), β-enolase and protein kinase C (PKC). In 
the mature muscle a small pool of satellite cells is present, located between the sarcolemma and the basal lamina 
of the muscle fiber.
At the endpoint of muscle development, skeletal muscle tissue is mainly composed of very 
long multinucleated myofibers (Figure 1.5A). The cytoplasm of the myofiber is usually 
referred to as sarcoplasm and the plasma membrane as sarcolemma. Outside the 
sarcolemma lies the basement lamina (specialized extracellular matrix rich in laminins). 
Multiple elongated myonuclei are arranged at the periphery of the myofiber immediately 
beneath the sarcolemma. The sarcoplasm is filled with specialized contractile proteins 
arranged in myofibrils (Figure 1.5A). Mononucleated cells located between the sarcolemma 
and the basement lamina are called satellite cells (due to their geographical location) or 
myoblasts (due to their function) (Figure 1.5A). Satellite cells represent a reserve of muscle 
precursor cells for the mature myofibers and facilitate muscle growth and repair [23, 24]. 
The major cellular component of the myofiber is the myofibril, which is formed by an 
assembly of contractile filaments. Under the light microscope, myofibrils have a striated 
appearance, which contributes to the striations of the entire myofiber. Thick filaments form 
the so-called A band (A stands for anisotropic, because it can rotate polarized light) and have 
a greater density than thin filaments, which form the I band (I for isotropic since I bands 
cannot rotate polarized light). At both ends of the A band lays a zone of even higher density, 
the Z disc, which marks the region where thin and thick filaments meet. The interval between 
two Z discs is called the sarcomere. The dense A band consists of myosin-containing thick 
filaments and has a less dense central part (since the ends of thin myofilaments do not reach 
here), referred to as H zone. The H zone is bisected with a so-called M line. The I band 
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consists of three filaments (not shown): actin-containing thin filaments that span the I-band 
and overlap with myosin-containing thick filaments in the A-band; nebulin-containing 
filaments that extend to the same length as actin filaments and titin-containing filaments that
span half of the sarcomere. The actin, titin and nebulin filaments are anchored to the Z-discs.
Striation of myofibrils is due to a regular repetition of a basic contractile unit, the sarcomere 
[25, 26] (Figure 1.1B). 
The sarcomeric and cytoskeletal proteins are linked to the sarcolemma and to molecules in 
the basement lamina by two main classes of membrane associated molecules: integrins 
(reviewed in [27, 28]) and the dystrophin-associated protein complex (DPC) (reviewed in [29, 
30]). Both integrin α7 (the main integrin in mature muscle) and DPC bind to molecules in the 
basement lamina (laminin 2) and provide for the structural integrity of myofibers during 
contraction. The DPC represents an assembly of at least three protein complexes: 1) the 
cytoplasmic, dystrophin-containing complex; 2) the dystroglycan complex; and 3) the 
sarcoglycan-sarcospan complex (Figure 1.5C). 
Linkage between the membrane complexes at the myofiber surface and sarcomeric proteins 
within the muscle cells involves many cytoskeletal proteins including actin, ?-actinin, desmin 
and spectrin [26]. Desmin forms a 3D scaffold around the Z-disks of sarcomeres and 
interconnects the entire contractile apparatus with the sarcolemmal skeleton, the nuclei and 
other organelles (reviewed in [28]).
Individual myofibers are covered with an interstitial connective tissue referred to as 
endomysium (Figure 1.5A). The endomysium represents a dynamic complex of many 
extracellular matrix components (reviewed in [28]) and contains different structures and cells: 
blood and lymphatic vessels; nerve branches; fibroblasts; mast cells and macrophages. The 
myofibers are arranged in bundles ensheathed with the so-called perimysium. These bundles 
of myofibers are further assembled into the whole muscle covered with  the epimysium [31]
(Figure 1.5A). Muscles are attached by connective tissue and tendons to the bones of the 
skeleton. 
Skeletal muscle depends upon a signal (action potential) from a motor neuron to become 
activated and contract. The axon of a motor neuron extends from the cell body located in the 
spinal cord or the brainstem, to the muscle, where it branches and each axon terminal 
attaches to the surface of a myofiber at a neuromuscular junction called the synapse 
(reviewed in [32]).
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Figure 1.5 Skeletal muscle structure. A Skeletal muscles consist of myofibers arranged in bundles. The 
connective tissue of skeletal muscle is composed of three sheaths: epimysium covers the whole muscle, 
perimysium covers the bundles of the myofibers and endomysium covers each individual myofiber. Satellite cells 
are located between the basement lamina (not shown) and the sarcolemma of the myofiber. The sarcoplasm of 
the myofiber is filled with striated myofibrils. A segment of the myofibril located between two Z lines represents a 
sarcomere, the structural unit of the myofiber B A sarcomere contains parallel arrays of contractile filaments 
arranged in a central dark A band (Anisotropic in polarized light) flanked by two lighter I bands (Isotropic in 
polarized light). The dark A band consists of myosin-containing thick filaments and has a less dense central part 
(since the ends of thin myofilaments do not reach here), referred to as H zone. The H zone is bisected with a so-
called M line. The I band consists of three filaments (not shown): actin-containing thin filaments that span the I-
band and overlap with myosin-containing thick filaments in the A-band; nebulin-containing filaments that extend to 
the same length as actin filaments and titin-containing filaments that span half of the sarcomere. The actin, titin 
and nebulin filaments are anchored to Z-discs. Z-discs form borders on each side of the sarcomere. They are 
precisely aligned and laterally associated with cytoskeletal proteins intermediates, such as desmin and plectin. 
1.1.3 Skeletal muscle fiber types
Terminally developed skeletal muscle groups contain populations of heterogeneous fibers. 
Skeletal muscle fibers differ in their metabolic activity, which is mainly defined by the 
expression of different myosin heavy chain (MyHC) isoforms and their capacity to catalyze 
hydrolysis of adenosine triphosphate (ATP). ATP hydrolysis is required for muscle 
contraction and the kinetics of the ATP splitting reaction are directly related to the 
physiological parameters of the myofiber contraction. Slow-twitch fibers contain myosin 
isoforms which split ATP at a low rate and are characterized by slow contraction (therefore 
slow-twitch, also referred to as type I myofibers). Fast-twitch (type II) fibers instead, contain 
myosin isoforms which split ATP at a high rate are characterized by fast contraction (fast-
twitch myofibers, also referred to as type II myofibers). The splitting rate of ATP is also 
different among fast type myofibers and further distinguishes the speed of their contraction 
(type IIA, IIX, and IIB, in order of increasing rates of contraction) (reviewed in [33]). Slow-
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twitch myofibers contain many mitochondria, high levels of oxidative enzymes (e.g. succinic 
dehydrogenase) and are characterized by oxidative metabolism (breakdown of glucose to 38 
molecules of ATP, H2O, and CO2). Slow fibers contract very slowly, but show high 
endurance, while fast fibers contract more rapidly, but are easily fatigued. Fast-twitch 
myofibers contain relatively low numbers of mitochondria, low levels of oxidative enzymes 
and high levels of glycolytic enzymes: these myofibers are characterized by glycolytic 
metabolism (breakdown of glucose to lactic acid). Due to their morphological appearance, 
slow and fast-twitch myofibers are also referred to as red and white myofibers respectively.  
Adult mammalian muscles contain mixtures of all four types of myofibers, characterizing a 
certain muscle by their composition and spatial organization. While the muscles of the limbs, 
such as the quadriceps and gastrocnemius, are mainly composed of fast fibers and function 
in the production of power and force, the diaphragm and latissimus dorsi contain a higher 
percentage of slow fibers and show a higher endurance.
1.2 Physiological and pathological remodeling of skeletal 
muscle
The heterogeneous population of muscle fibers that characterizes adult skeletal muscle 
confers to it a considerable degree of plasticity (reviewed in [34]). This property makes the 
muscle capable to respond to a wide range of external and internal factors, such as physical 
activity, injury, stimulation by motor neurons, oxygen and nutrient supply, and changes in 
hormone levels. By remodeling the cytoarchitecture and/or changing of protein composition 
the muscle can adapt to environmental demands and maintain its functionality. Beneficial 
remodeling can result in skeletal muscle hypertrophy in response to increased physiological 
loading (compare 1.2.1), while detrimental remodeling, caused by disuse, aging, or systemic 
diseases results in skeletal muscle atrophy (compare 1.2.2).  
1.2.1      Skeletal muscle hypertrophy
The term “skeletal muscle hypertrophy” describes an increase of the diameter/size of 
individual myofibers, and is associated with increased content of myofibrillar protein. 
Normally, skeletal muscle develops hypertrophic fibers as a compensatory response to 
increased physiological loading in vivo. Postnatal muscle growth, including hypertrophy, 
depends on activation, proliferation and subsequent fusion of satellite cells with existing 
myofibers. Fusion of activated satellite cells into the growing (hypertrophying) myofibers can 
result in a proportional increase of the protein and DNA content of the myofiber (i.e. protein 
to DNA ratio of the myofiber remains constant) [35]. However, there are different modes of 
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hypertrophy, demonstrated by the fact that hypertrophy can also result from increased fiber 
diameter, without an increase in the number of nuclei, which might be determined by 
structural aspects of the muscle [36]. The importance of satellite cell proliferation for muscle 
hypertrophy has been shown by a study where γ-irradiation, which eliminates satellite cell 
proliferation completely, blocked compensatory hypertrophy of the extensor digitorum longus 
(EDL) muscle in rats [37]. However, other studies provide evidence, that hypertrophy can be 
uncoupled from DNA synthesis and show that increase of myotube and myofiber size can 
occur in the absence of satellite cell proliferation in tissue culture [38-40] and in vivo [41, 42]. 
In summary, muscle hypertrophy could be due to both processes: increased anabolism 
within the differentiated myofibers as well as activation and proliferation of satellite cells. 
Various signals trigger compensatory growth of skeletal muscles. Growth-inducing muscular 
activity (e.g. increased physiological loading) causes changes in the biophysical 
(temperature, contraction induced strain, cell damage) and biochemical (intramuscular 
oxygen concentrations, sarcoplasmic calcium concentrations, levels and availability of 
hormones, locally produced growth factors and cytokines) parameters in muscles (reviewed 
in [43]). Changes in these variables initiate intracellular signal transduction pathways, which 
regulate differential gene expression and facilitate responses of the muscle cells. Intracellular 
signaling pathways responsible for skeletal muscle hypertrophy are discussed in detail in
section 1.4.5.
1.2.2      Skeletal muscle atrophy
Atrophy of skeletal muscle is accompanied by a reduction of the diameter/size of individual 
muscle cells, and is caused by the rapid loss of myofibrillar proteins associated with dramatic 
changes in the biochemistry and enzymatic activity of skeletal muscle. These processes 
result (among other effects) in reduced capacity to synthesize new protein and up-regulation 
of pathways leading to increased protein breakdown. Two common causes of dramatic 
myofiber atrophy are muscle disuse [44] and denervation [45], however skeletal muscle 
atrophy also occurs secondary to different pathological conditions, such as heart failure [46], 
fasting [47], burn injury [48], sepsis [49], glucocorticoid treatment [50], diabetes [51], cancer 
[52] and AIDS [53]. Myofiber atrophy is a serious problem encountered in aging individuals 
(reviewed [32, 54]). Physiological reasons for muscle atrophy vary: in starvation and 
diabetes, glucocorticoids and low insulin levels are essential for muscle wasting [55-57], 
whereas in pathological inflammatory conditions, muscle wasting is caused by high levels of 
pro-inflammatory cytokines, such as tumor necrosis factor-? (TNF-?) and such muscle 
wasting is termed cachexia (reviewed in [58]).
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Enhancement of overall proteolysis linked to the induction of the ubiquitin-proteasome 
protein degradation pathway is a common characteristic of atrophying muscle [59]. Two main
genes (atrogenes) up-regulated in atrophic states are ubiquitin ligases MAFbx (muscle 
atrophy F box or atrogin-1) and MuRF-1 (muscle RING finger-1) [59, 60]. The expression 
pattern of atrogenes appears to be common for the catabolic states induced by different 
factors: e.g. fasting, diabetes mellitus, renal failure and tumor implantation [59].
IGF-1 has been shown to block skeletal muscle atrophy in several experimental models, 
such as the treatment of muscle cell cultures with the catabolic glucocorticoid 
dexamethasone [39, 61-63], angiotensin II-induced muscle atrophy in vivo [64], and chronic 
heart failure-induced atrophy of skeletal muscle [46].
1.2.3 Skeletal muscle aging
Muscle aging involves many processes involved in disuse or disease-induced atrophy, and is 
accompanied by an alteration of the heterogeneity of muscle fibers and therefore in muscle 
plasticity [65]. Hallmarks of aging skeletal muscle are restriction of adaptability, decline in 
muscle mass and function, as well as quality (innervation patterns, contractility, capillary 
density, and endurance), leading to a decrease in muscle strength and force output. This 
process is known as muscle wasting or sarcopenia of old age [66], common in both old 
humans and animals, and is accompanied by an early decrease in protein synthetic rates 
and a subsequent increase in protein degradation [67]. In addition, senescent muscles are 
characterized by a selective reduction in muscle fiber size, shift in fiber composition [68], 
modulation in gene expression [69] and numerous metabolic and physiological alterations 
(reviewed in [70]). In particular, selective loss of the most powerful fast glycolytic (type IIB) 
fibers over fast glycolytic oxidative fibers (type IIA and IIX) or slow fibers (type I) [68], leads to 
the decrease in the force-generating capacity, as the remaining fibers exhibit restricted 
contractile options in terms of speed and power output, although being energetically more 
efficient than type IIB fibers. 
Changes in gene expression involve the up-regulation of the myogenic determination factors 
MyoD and myogenin and the muscle-specific genes, such as AChR, MLC, and MCK that are 
activated by these MDFs [69]. MyoD and myogenin are expressed at high levels in muscles 
of newborn mice, but decline continuously during postnatal life, until they are not detectable 
anymore in the adult animals. Thus, their up-regulation in senile muscle might by a 
compensatory mechanism to maintain the muscle phenotype in aged muscle. However these 
compensatory mechanisms fail to preserve muscle function and senescent muscles undergo 
wasting processes.
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One of the highlights of age-related alterations of cellular metabolism is the accumulation of 
oxidatively modified proteins, lipids, and nucleic acids. As a result of an aerobic metabolism, 
reactive oxygen species (ROS) are produced throughout an organism’s life. The key 
enzymes protecting the cell against the damaging effects of ROS, such as catalase, 
superoxide dismutase (SOD) and glutathione peroxidase, have been reported to decrease in 
their activities with increasing age (reviewed in [71]), leading to free radical-mediated 
oxidative damage of muscle tissue [72]. Mutations in genes coding for these antioxidant 
enzymes have also been connected to neurodegenerative diseases, such as familiar 
amyotrophic lateral sclerosis (ALS), where mutated SOD1 is thought to contribute to severe 
degeneration of motor neurons [73]. In fact, transgenic mice over-expressing a mutant form 
of SOD1 develop age-dependent motor neuron degeneration, skeletal muscle weakness, 
and paralysis and die at the age of five to six months [74].  
Finally, it has been demonstrated that the expression of anabolic hormones, like growth 
hormone (GH) and IGF-1, decline with age [75]. This might contribute to the progress of 
muscle atrophy in senescence and limit the reparative and regenerative abilities of skeletal 
muscle. This assumption is supported by muscle-specific viral mediated over-expression of 
IGF-1 and in a transgenic mouse model which over-expresses IGF-1 exclusively in skeletal 
muscle (MLC/mIGF-1) [76, 77]. Both studies used the same IGF-1 isoform, Class 1 IGF-1Ea 
(compare section 1.4.2), which is the isoform that is normally expressed in skeletal muscle 
and was therefore termed mIGF-1 (muscle IGF-1). Both reports showed that muscle mass 
and strength, as well as fiber type distribution in old animals was maintained at levels similar 
to those of younger adults. In addition, Musaro et al. discovered that even in aged muscle, 
the mIGF-1 transgenic mice retained the proliferative response to muscle injury characteristic 
of younger animals [77]. mIGF-1 has also been shown to protect against free radical-induced 
damage and muscle degeneration in double transgenic SOD1/ mIGF-1 animals [78], further 
supporting a beneficial role for IGF-1 as a survival factor.
1.3 Skeletal muscle injury and regeneration
Skeletal muscle tissue has a high potential for regeneration following injury. Under normal 
physiological conditions, muscle injury can result from physical exercise and especially 
eccentric (lengthening) contractions [79, 80]. The exercise-induced injury (or micro-injury 
[81]) is initially caused by the increased strain on the myofibers and involves damage to 
myofiber ultrastructure, basement lamina and capillaries. Myofiber damage activates an 
inflammatory response and regeneration [79]. The recovery of myofibers follows a similar 
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pathway after injuries resulting from eccentric contractions [82-84], ischemia after grafting 
[85, 86], physical muscle damage [87, 88], chemical damage (e.g. cardiotoxin injection) [89], 
and muscle disease [87].
Use of the various experimental models shows that regeneration of skeletal muscle is a 
sequential process, which involves muscle necrosis, revascularisation, infiltration of 
inflammatory cells, phagocytosis of necrotic tissue, and activation, proliferation and fusion of 
muscle precursor cells to form new myofibers. Ultimately, successful functional reinnervation 
is essential for restoration of the physiological parameters of regenerated muscle. 
1.3.1 Myofiber necrosis
Muscle injury, muscle transplantation or myopathologies like Duchenne muscular dystrophies 
(DMD) and polymyositis are characterized by necrosis of myofibers followed by myofiber 
regeneration. The term “necrosis” refers to the irreversible breakdown of the sarcolemma 
and all sarcoplasmic structures. Necrosis can occur through the whole length of the myofiber 
or else only part of the myofiber can degenerate (segmental necrosis). Segmental myofiber 
necrosis is common in muscular diseases such as DMD [87] and has been shown to be 
attenuated by transgenic over-expression of mIGF-1 in dystrophic muscles, where mIGF-1 
reduced myofiber breakdown and led to a less severe necrotic phenotype [90, 91]. 
Necrosis of whole myofibers is seen after grafting of the intact whole muscles [85, 86] or 
minced muscles [92, 93], where the blood and nerve supply is completely disrupted. Injection 
of cardiotoxin (a snake venom) or other myotoxins also results in almost entire degeneration 
of the myofibers, however cardiotoxin spares satellite cells, blood vessel supply and 
innervation [89]. There are many experimental models of segmental necrosis and these 
include crush injury [88, 94], cut injury [95], and localized chemical injury [96]. Segmental 
damage of the myofibers is followed by formation of super-contracted bands of myofibrils, 
which delineate the structurally normal parts of the myofiber, usually located on both sides of 
the injury site [97]. To minimize the extent of myofiber necrosis after injury the undamaged 
stumps of the original myofiber are rapidly sealed off with newly formed sarcolemma [97]. In 
the course of necrosis, the basement lamina of the myofiber can degenerate or remain 
relatively intact and retain the appearance of a scaffold [89, 98]. Persisting basement lamina 
around necrotic sarcoplasm can be seen in transplanted whole muscle grafts [85] and 
cardiotoxin-injected muscles [89]. Severe mechanical injury, like crush [88] or muscle 
mincing [93] disrupts the basement lamina along with the other muscle structures located in 
the injury site.  
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1.3.2 Revascularization
Muscle necrosis can occur in the presence of blood vessel supply (e.g. cardiotoxin injection) 
or in conditions of ischemia. Ischemic muscle degeneration occurs in transplanted whole or 
minced muscle grafts due to the loss of vascular connections [85, 99, 100]. The efficiency of 
new blood vessel formation is a critical event for the successful regeneration of transplanted 
grafts [99-102]. If big muscles are transplanted without vascular anastomoses, the central 
core of the transplants fails to revascularize and becomes fibrotic [103-105]. On the contrary, 
muscles transfected with exogenous vascular endothelial growth factor (VEGF), which 
stimulates vascular growth, regenerate faster after transplantation than non-transfected 
muscles [102]. In rat whole muscle grafts, the original vascular network degenerates one day 
after grafting and only the basement lamina of blood vessels is maintained. 
Revascularization of the muscle grafts in rats begins two days [99] and in mice three days 
[101] after transplantation. The first blood vessels, which grow into the muscle grafts from the 
host tissue are sinusoidal thin-walled endothelial tubes with large lumens. Capillaries sprout 
from these tubes approximately one day after entering the transplant. Sprouting capillaries 
often utilize the basement lamina of degenerated capillaries to grow towards the avascular 
center of the graft. Grafted EDL muscle become fully revascularized in rats by six days [99], 
and in mice by eight days [101] after transplantation.    
1.3.3 Inflammatory cell infiltration and phagocytosis
The regeneration process is accompanied by an inflammatory reaction, during which 
distinctive populations of macrophages infiltrate the affected tissue [106]. Necrotic muscle is 
rapidly infiltrated by polymorphonuclear leukocytes (neutrophils) and macrophages, which 
mediate cellular destruction and phagocytosis of degenerating myofibers [85, 88, 96]. 
Neutrophils can exacerbate muscle injury by damaging uninjured myofibers via generating 
reactive oxygen species [107]. In necrotic muscle, which remains in its bed and maintains a 
more or less intact blood vessel supply (e.g. cardiotoxin injection, crush or cut injury, 
exercise-induced damage), massive inflammatory cell infiltration is seen by 24 hours after 
damage [84, 88, 89, 96]. In muscles of exercised rats (downhill running on treadmill), the 
numbers of neutrophils start to increase by two hours after the exercise and peak by 24 
hours and numbers of macrophages are significantly increased by 24 and 48 hours after 
exercise [84]. The detailed time-course of inflammatory cell infiltration was studied in the 
experimental model of segmental necrosis caused by localized chemical damage [96], where 
it was shown that neutrophils enter the injury site as early as three hours after injury. By six 
hours the injured segment is infiltrated with many polymorphonuclear leukocytes and 
occasional macrophages. The number of infiltrating macrophages and other phagocytic cells 
increase by 24 hours after injury and these cells carry out active destruction and elimination 
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of degenerating myofiber debris [96]. A second and later wave of macrophage infiltration is 
thought to deliver a number of growth factors and cytokines involved in promoting the 
regeneration process (reviewed in [108]). However, recent studies discuss the concept that 
muscle itself plays an active part in the interaction with the immune system (reviewed in [109, 
110]). Human satellite cells, for example, were shown to release factors that attract 
macrophages and monocytes most efficiently upon satellite cell activation [111], raising the 
possibility that activated satellite cells themselves could signal for macrophage invasion upon 
injury.
1.3.4 Skeletal muscle fibrosis and scar formation 
The inflammatory response to muscle injury eventually leads to the attraction of fibroblasts to 
the site of injury, recruited by a combination of cytokines, which are secreted by platelets 
macrophages and other cellular sources. Fibroblasts secrete high amounts of TGF-ß and are 
believed to be the major source of collagen and glycoproteins, which take part in remodeling 
of the extracellular matrix, reducing the level of vascularity, and finally in replacing the 
connective tissue with scar tissue (reviewed in [112]). Even though the formation of fibrotic 
tissue is a crucial step during skeletal muscle regeneration and provides early support for the 
rejoining of damaged myofibers, it can also lead to restriction of regeneration in pathologic 
conditions, where gradual replacement of muscle tissue with adipose and scar tissue 
ultimately leads to muscle paralysis. One such example is dystrophic muscle, which 
undergoes repetitive rounds of muscle damage and repair, resulting in exhaustion of the 
regenerative capabilities of the muscle tissue and leads to massive scar formation. This 
condition could be attenuated by the supplemental expression of the mIGF-1 transgene 
described by Musaro et al. [77] in a mouse model of DMD, the mdx mouse. mIGF-1 over-
expression by the dystrophic muscles was sufficient to increase the regeneration capacity by 
reducing the extent of fibrotic tissue formation [90], suggesting that improved healing can be 
achieved by modulating the inflammatory response and thereby reducing the formation of 
scar tissue (reviewed in [110]). 
1.3.5 Satellite cell activation and myofiber regeneration 
Skeletal muscle is a post-mitotic tissue, which limits its ability to effectively repair or to 
regenerate. Therefore an external source of mitotically active cells is required for changes in 
muscle fiber volume and number. This source is provided by a population of quiescent 
mononucleated myogenic cells known as satellite cells [23]. These cells retain their mitotic 
capacity and serve as a pool of myoblasts in postnatal life. Molecular markers used to 
identify quiescent satellite cells are M-cadherin [113], c-Met [114], CD34 and Myf5 [114], 
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Introduction page 27
syndecan-3, and syndecan-4 [115]. In Pax7 null mice, which lose satellite cells during 
postnatal development, muscle regeneration is impaired [116].
During muscle regeneration, satellite cells become activated, proliferate and fuse with each 
other to form multinucleated new muscle cells (myotubes). Myotubes further fuse with each 
other, but also with surviving parts of the myofibers (if such remain) to repair or replace the 
damaged myofiber (reviewed in [117]) (Figure 1.6 and 1.7). 
Figure 1.6:  Satellite cell activation in response to injury. In response to muscle damage, muscle satellite 
cells are activated and either MyoD or myf-5 expression is up-regulated prior to proliferation. Subsequently, most 
proliferating satellite cells express both primary MRFs. Expression of the secondary MRFs, myogenin and MRF4, 
is coincident with satellite cell differentiation and fusion to existing fibers or to form new fibers. From Palmer et al. 
[20]
If spared from degeneration, the basement lamina of the necrotic myofibers serves as a 
scaffold for new muscle formation and myoblasts proliferate and fuse into the myotubes 
along its inner surface [85, 98]. Regenerated myotubes develop their own basement lamina 
and the original one is removed via diffusion or disintegration [85]. Fusion of some myotubes 
can also occur outside any basement lamina [85].
Although satellite cells have long been considered a distinct myogenic lineage responsible 
for postnatal growth, repair, and maintenance of skeletal muscle, recent research indicates 
that they are not the only source of undifferentiated progenitors in skeletal muscle (reviewed 
in [110]). Much attention has been focused on the involvement of a muscle-derived stem cell-
like population, which can be isolated from adult skeletal muscle on the basis of Hoechst dye 
exclusion [118-120] and is considered to be distinct from the myogenic lineage [118] and 
even from mesenchymal cells [121]. Even though these cells do express some markers of 
the hematopoietic lineage, such as CD34, and Sca-1, their exact origin is still under 
investigation [119, 120, 122]. Studies using bone marrow transplantation experiments 
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Introduction page 28
suggest that hematopoietic stem cells indeed can contribute to skeletal muscle regeneration 
[123, 124]. Notably, the bone marrow contains a heterogeneous population of cells and many 
studies further selected a so-called side population (SP) of cells (reviewed in [125]) on the 
basis of various cell-surface markers (reviewed in [110]). Studies describing the 
transplantation of SP cells that have been isolated from the bone marrow or from skeletal 
muscle, could demonstrate active participation of those cells in regeneration-induced 
myotube formation [118, 120, 123, 126]. Nevertheless, apart from two specific muscles in the 
body (panniculus carnosus and extensor digitorum longus), the general frequency of 
incorporation of these cells into the myogenic lineage was too low to be significant for muscle 
replacement [126, 127]. Thus, despite the recent focus on alternative stem cell sources for 
muscle regeneration [128, 129], it appears that satellite cells remain to be the main source of 
myoblasts in postnatal muscle [24].
Figure 1.7 Regenerating tibialis anterior (TA). Longitudinal view of the regenerating TA muscle of a mouse 
seven days after crush injury immunostained with an antibody against desmin (brown) to show muscle cells. A
Low power view of the crush zone showing fusion of myoblasts (*) and myotubes (arrows) to the ends of the 
damaged myofibers (M). B-D High power view of myoblasts (* on B), fusing myotubes (arrows on C) and newly 
formed young myofibers with central nucleation (arrows on D). Kindly provided by Thea Shavlakadze.
However, the relatively low involvement of stem or progenitor cells in muscle regeneration 
might be explained by the lack of proper attraction signals and the right environment for the 
homing of circulating stem cells to regenerating skeletal muscle. Muscle-specific over-
expression of mIGF-1, for example, did not only increase the number of bone marrow-
derived stem cells to the site of injury in lethally irradiated mice, but also in mice that have 
not been irradiated [130], indicating that the presence of mIGF-1 enhanced the recruitment of 
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these cells (reviewed in [110]). Since differentiation of attracted stem cells into components 
of the host tissue has been linked to the presence of tissue-specific signals and growth 
factors [131], mIGF-1 might also provide the right environment for integration of circulating 
stem cells into the injured muscle.  
1.3.6 Reinnervation. Successful reinnervation is a key factor for restoration of functional 
parameters of regenerated muscle. Early events of regeneration, which involve 
revascularization, activation of satellite cells and their fusion into new myotubes and 
myofibers, do not require innervation. In the transplanted whole muscle grafts, which are 
disconnected from the nerve supply, myofibers are successfully restored. However, 
establishment of the functional reinnervation is crucial for histochemical differentiation of 
myofiber types and restoration of the final functional mass of the transplanted muscle [132]. 
1.4 The insulin-like growth factor system
1.4.1      The IGF-1 system
The Insulin-like growth factor (IGF) system consists of three peptide hormones (Insulin, IGF-
1 and IGF-2), cell surface receptors (insulin receptor, IGF-1 receptor and the IGF-2 receptor) 
and six IGF binding proteins (IGFBP-1, -2, -3, -4, -5, and -6). Recently IGFBP-7 has been 
identified as an annotated gene, provided by Genome Informatics, but information about the 
role of this potential IGF-binding protein is still missing. 
The insulin receptor is a main mediator of the biological functions of insulin, while the IGF-1 
receptor mainly mediates cellular responses of IGF-1 and IGF-2. It is believed that the IGF-2 
receptor does not have a major role for IGF signal transduction, but it is responsible for 
reducing IGF-2 levels during fetal development (reviewed in [133]). 
In the circulation and in the extracellular milieu, IGFs can exist in an unbound form or form 
binary complexes with specific IGF binding proteins (IGFBP). The six IGFBPs have been 
characterized: they serve as carrier molecules for IGFs, extend their half-life and modulate 
their actions [134, 135]. In the circulation, IGFBP-3 and IGFBP-5 can form a ternary complex 
with IGF and an approximately 85-kDa leucine-rich glycoprotein known as the acid-labile 
subunit (ALS) [136, 137]. Unlike binary complexes, ternary complexes cannot pass through 
capillaries to tissues, and therefore ALS further extends the half-life of IGFs due to its 
stabilizing effect and creates a circulating reservoir of IGFs. IGFBPs can inhibit or potentiate 
IGF effects and can also act independently from IGFs [138]. In vitro studies suggest that 
IGFBP-2, -4 and -6 largely inhibit IGF-1 actions, IGFBP-5 enhances IGF-1 action and 
IGFBP-1 and -3 can be either inhibitory of stimulatory (reviewed in [139]). Transgenic over-
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expression of IGFBP-1 [140], IGFBP-2 [141], IGFBP-3 [142], and IGFBP-6 [143] in vivo has 
an inhibitory effect on somatic growth of mice. Ubiquitous over-expression of IGFBP-5 from 
early development also results in inhibition of the whole body growth and muscle 
development, but increases the brain growth in transgenic mice [144].  These in vitro and in 
vivo data indicate that actions of IGFBPs are very complex and their precise function in 
regulating IGF bioavailability in tissues has yet to be fully elucidated.
Recent data suggest the existence of another level of regulation of IGF bioavailability as 
there is evidence that molecules like glycoproteins [145, 146], metalloproteases [147], and 
glycosaminoglycans [148] can also modulate IGF function. Vitronectin is a multifunctional 
glycoprotein found in plasma and extracellular matrix. Although vitronectin is structurally 
unrelated to IGFBPs, it has been shown to bind directly to IGF-2, although only minimal 
direct binding of IGF-1 to vitronectin occurs [149]. In vitro studies show that IGFBPs (IGFBP-
2, -3,- 4 and, -5) enhance binding of IGF-1 to vitronectin [145], which has a functional 
significance. For example, IGF-1 in complex with vitronectin and IGFBP-5 increases protein 
synthesis in cultured skin keratinocytes and enhances migration of these cells [146] and also 
of human breast carcinoma cell  [145]. Metalloproteases (such as ADAM12) can cleave 
IGFBP-3 and -5, which would diminish their affinity for IGF ligands [147]. 
Glycosaminoglycans can increase the availability of IGF-1 to the receptors by inhibiting 
formation of IGF-1 and IGFBP complexes. For example, heparin dissociates IGF-1 from 
IGFBP-5 and inhibits formation of IGF-1:IGFBP-5 and IGF-1:IGFBP-3 complexes [148]. 
Inhibition of IGF-1:IGFBP-5 complex formation has also been shown for sulphated 
glycosaminoglycans (heparan sulphate and dermatan sulphate) [148]. These various binding 
possibilities illustrate the complexity of molecules that regulate IGF-1 function.
Local and systemic functions of IGF-1 are essential for normal growth and development. 
IGF-1 is produced by a wide range of tissues. About 75% of circulating IGF-1 is derived from 
the liver. However IGF-1 is also expressed locally in other tissues and is supposedly 
released into the bloodstream to contribute to the other 25% of circulating IGF-1. Exactly 
which tissues release IGF-1 into the bloodstream is not known, however muscle and fat 
tissues are the likely candidates.  Expression of IGF-1 gene gives rise to multiple isoforms of 
pre-processed IGF-1, which differ by signal and termination peptides, and can exert different 
biological functions. The complexity of IGF-1 isoforms is discussed in detail in section 1.4.2
and reviewed in [150, 151].
Like other multifunctional growth factors, the insulin-like growth factors show pleiotropic 
effects on various tissue types. Early investigations into the biological actions of IGF-1 led to 
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the formulation of the somatomedin hypothesis [152], according to which the effects of GH 
on cartilage are not due to a direct interaction of GH with the target tissue, but are mediated 
by somatomedin-C, later identified as IGF-1 [153]. The idea was that growth was determined 
by GH acting primarily on the liver, which was thought to be the only source of IGF-1. This in 
turn stimulated the synthesis of IGF-1, which was then released into the circulation and 
transported to the main target organs, such as cartilage, bone, and muscle, thus acting in an 
endocrine mode. This hypothesis turned out to be an oversimplification of a complex 
biological problem, since GH has direct growth effects of its own [154-156]. In the early 
1980s, D’Ercole et al. additionally discovered that IGF-1 was also expressed in extrahepatic 
tissues [157]. This evidence for local IGF-1 production suggested that IGF-1 had an 
additional autocrine/ paracrine effect, which was supported by subsequent investigations into 
the tissue distribution of IGF-1 mRNAs and their response to GH. An analysis of postnatal 
(up to six months) growth curves of mutant mice, which lack the GH receptor gene, the IGF-1 
gene or both, showed that all these mutant strains displayed dwarfism; while mice lacking the 
IGF-1 gene were born with weight deficiency, in GH receptor knockout mice dwarfism was 
observed starting from postnatal day ten. At two weeks of age all mutant mice showed 
obvious growth retardation in the order GH receptor knockout>IGF-1 knockout>GH 
receptor/IGF-1 double knockout [158]. Several important conclusions derive from this study: 
GH is not involved in embryonic and early (at least up to postnatal day 10) postnatal growth 
regulation in mice; IGF-1 by itself makes more significant contribution to total weight than GH 
alone (35% versus 14%); overlapping GH/IGF1 function makes a 34% contribution; and body 
growth unrelated to the GH/IGF1 axis is estimated to account for ~ 17% of weight [158]. It is 
suggested that IGF-2 could be the major contributor for GH/IGF-1 unrelated growth [159].
Further evidence for the essential role of the distinct components of the IGF system in vivo
has been gained by generation of gene knockout mice, which carry null mutations for one or 
more components of the IGF system or GH/IGF axis (reviewed in [160]). While disruption of 
the IGF-2 gene revealed that IGF-2 is an important regulator of embryonic, but not of 
postnatal growth [161], disruption of the IGF-1 gene showed that normal expression of IGF-1 
is critical for normal growth and tissue development pre- and postnatally. Mice deficient in 
IGF-1 show a severe growth deficit, and are born with a birth-weight approximately 60 % of 
WT neonates, which is due to a decrease in organs, muscle, and bone mass [162]. 
Depending on the genetic background, greater than 95 % of the dwarf IGF-1(-/-) mice die 
shortly after birth due to respiratory failure, while a small percentage survives and reaches 
adulthood [163]. Surviving IGF-1(-/-) mutants are infertile, show delayed bone development 
and grow with a retarded rate, only reaching 30 % of normal weight as adults, compared to 
WT animals [164].
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Mice with a targeted deletion of the IGF-1 receptor gene are affected even more profoundly 
and die immediately after birth due to respiratory failure. They show a more severe growth 
deficiency, reaching only 45% of normal size, which is due to a generalized decrease in 
tissue cell number (hypoplasia) of the organs, the skin, and all skeletal muscle groups in the 
embryo. In addition, a delay in ossification and changes in architecture of the spinal cord and 
brain, potentially secondary to diminished numbers of non-neuronal cells [163], were 
observed. 
The Cre/loxP recombination technique was used to produce mice with partially (more or less
severely) abrogated expression of the IGF-1 gene. These studies revealed that IGF-1 affects 
postnatal growth in a gene dosage dependent manner [165]. In particular, compared to 
controls, mice with single-copy recombination of the IGF-1 locus showed ~19% and ~15% of 
the weight reduction at three and six weeks of age respectively, whereas the weight of the 
mice with homozygous IGF-1 gene recombination at the same ages was reduced by ~28% 
and ~32%.  These latter mice survived due to the incomplete recombination of the IGF-1 
gene locus [165]. 
Although studies carried out using conventional gene knockout and Cre/LoxP recombination 
mouse models shed light on the growth regulatory role of IGF-1 during embryonic and 
postnatal development, they do not distinguish between systemic and local actions of this 
growth factor. Other studies looked at the effect of circulating IGF-1 on postnatal growth by 
knocking out the IGF-1 gene specifically in liver using Cre/loxP recombination [166, 167]. 
Such abrogation of IGF-1 gene expression specifically in liver caused a 75% reduction of 
circulating IGF-1, but did not affect the postnatal growth of mice. Based on these 
observations, it was suggested that the endocrine function of IGF-1 for postnatal growth is 
minimal and that circulating IGF-1 might have its function in negative feedback effects on GH 
secretion, an effect that has been described earlier (reviewed in [133, 168]. In fact, the 
observation that GH levels are increased in the liver-IGF-1-deficient mice (LID-mice) [166]
supports this suggestion. In addition, there is evidence that circulating IGF-1 plays an 
important role as a component of overall insulin action in peripheral tissues, as the LID-mice 
display muscle-specific insulin insensitivity [169]. 
However, it later became clear that the importance of circulating IGF-1 for somatic growth 
was underestimated (reviewed in [159, 168]). In mice with liver specific IGF-1 gene 
recombination, such recombination was induced at 24 [166] and ten [167] days after birth. 
During the time the body measurements were obtained (at 53 days after birth [166] and one 
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to six weeks after birth [167]), the levels of IGF-1 in blood serum might have been decreasing 
gradually and were maintained at the level sufficient for normal growth (reviewed in [159]). 
Also, pups receive IGF-1 with the mother’s milk for up to three weeks of age, which could 
have masked any effect of IGF-1 gene recombination. In addition, further characterization of 
the liver specific IGF-1 knockout mice showed that there was a dramatic decrease of IGFBPs 
in the circulation and in fact levels of unbound free IGF-1 were similar in the knockout and 
control mice [168]. A subsequent study [158], which shows that the overlapping contribution 
of GH/IGF-1 for somatic growth in mice is about 34%, further supports the importance of the 
endocrine function of IGF-1 for somatic growth, since systemic IGF-1 is considered to be the 
main mediator of GH effects. 
1.4.2      Insulin and Insulin-like growth factor-1 gene and protein structure
1.4.2.1 Insulin versus insulin-like growth factor-1
In humans, the insulin gene is a single-copy gene and consists of three exons and two 
introns and is transcribed into a mature mRNA of 465 nucleotides coding for prepro-insulin. 
The insulin precursor contains a 24 amino acid signal peptide, a 30 amino acid A-chain, a 31 
amino acid C-chain, and a 21 amino acid B-chain. Processing of the precursor leads to 
removal of the signal peptide and to an additional protein splicing event, where a specific 
protease removes the C-domain, which results in generation of the mature insulin protein 
containing 21 amino acids of the A-chain and 30 amino acids of the B-chain connected by 
two disulfide bonds. 
Unlike the insulin gene, the single-copy IGF-1 gene locus encodes multiple precursor 
proteins, which vary in the N-terminal signal peptide sequence and the C-terminal E-domain 
amino acid sequences (discussed in detail below). The unprocessed precursor peptides 
undergo post-translational protease cleavage to generate mature IGF-1, a 70 amino acid 
single chain polypeptide with three intra-chain disulfide bridges. Mature IGF-1 differs from 
insulin by retention of the C-domain, by a short extension of the A-domain to include a novel 
domain D, and by the presence of variable C-terminal Extension peptides (E-peptides) 
(Figure 1.8 C). IGF-1 shares 62% homology with pro-insulin and 48% homology with insulin 
[170, 171]. Among mammalian species the primary structure of IGF-1 is highly conserved: 
canine [172], bovine [173], ovine [174], porcine [175], and human [170] IGF-1s are identical, 
whereas rat [176] and mouse [177] IGF-1s differ from human by three and four amino acids 
respectively and there is only one amino acid difference between these rodent IGF-1s.
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Apart from the full length IGF-1, two other protein products are thought to be produced by 
post-translational cleavage of IGF-1 precursor protein and these have been identified in the 
human brain ([178]). A truncated IGF-1 isoform (-3N:IGF-1) lacks the first three amino acids 
from the NH2-terminal end of the B domain, has low binding affinity to IGFBPs, and displays 
enhanced biological (neurotrophic) effects, which are mediated through the IGF-1 receptor 
[179, 180].  Another product from this post-translational modification of IGF-1 precursor 
protein is the tripeptide glycyl-prolyl-glutamate (GPE), which corresponds to the amino 
terminal end of mature IGF-1 [178]. In the central nervous system GPE modulates 
neurotransmitter release via N-methyl-D-aspartate type of glutamate receptor. 
1.4.2.2 IGF-1 gene structure
The human and rodent single-copy IGF-1 gene contains six exons, separated by five introns 
[176, 181-184] and spans >70 kb of genomic DNA [176, 183] (Figure 1.8A). Exons 1 and 2 
contain multiple transcription start sites and encode distinct, mutually exclusive 5'-
untranslated regions (5'-UTRs) of IGF-1 precursor mRNAs as well as different parts of the 
signal peptide sequences of IGF-1 precursor polypeptides [176, 185-187]. Exon 3 encodes 
52 amino acids: the initial 27 amino acids precede a start of a B domain of mature IGF-1 and 
comprise the terminal part of the signal peptide; the rest of the 25 amino acids comprise the 
B domain of mature IGF-1. The remainder of the coding information for the mature IGF-1 
peptide (rest of domain B and domains C, A, D) resides in exon 4. Rat exon 4 also contains 
16 codons corresponding to the amino-terminal portion of the E-domain. Exon 5 and exon 6 
each encode distinct E-peptides, termination codons, and 3'-UTRs.
1.4.2.3 Complexity of IGF-1 transcription
The IGF-1 gene underlies a complex regulation and gives rise to a heterogeneous pool of 
IGF-1 mRNAs (Figure 1.8). Such heterogeneity results from several events (or combination 
of these events): use of alternative promoters and transcription start sites located in the 
leader exons (exon 1 and exon 2) [176, 182, 185-187]; alternative post-transcriptional exon 
splicing [176, 177, 185-188]; and use of different polyadenylation sites [189, 190]. These 
multiple IGF-1 mRNAs transcripts encode different isoforms of the IGF-1 precursor peptide, 
which undergo further post-translational cleavage to release the biologically active mature 
IGF-1. Every aspect of the complex regulation of the IGF-1 gene will be discussed in detail 
below.
1.4.2.4 Transcription start sites in exon 1 and 2
Using RNAse protection and primer extension procedures multiple transcription initiation 
sites have been identified in association with the activity of each promoter [185, 186, 191, 
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192]. Exon 1 transcription can occur from at least four distinct sites in the rat and human 
genes (Figure 1.8 C): a minor site is located at ~382 bp (start site one), two major sites 
located at ~343 bp and ~245 bp (start site two and start site three respectively) and a minor 
start site locate at ~40 bp position (start site four) upstream of the 3'-end of exon 1 [185-187]. 
Simmons et al. have also identified two additional minor transcription start sites located at the 
~361 bp and ~353 bp positions upstream of the 3’-end of exon 1, however their use is 
thought to be insignificant [186]. Compared to the dispersed pattern of exon 1 start sites, 
transcription initiation for exon 2 is more localized (Figure 1.8 C). The most upstream and the 
most rarely used start site is located at ~770 bp (start site 1) upstream to its 3'-end. Two 
downstream start sites are located at ~50 bp (start site 2) and ~70 bp (start site 3) upstream 
to the 3'-end of the exon 2. The length and structure of the different 5’UTRs generated by the 
usage of different promoters and transcription start sites within exon 1 and 2 has been shown 
to affect the efficiency of translation initiation [187], in particular, translational efficiency of 
IGF-1 mRNA in vitro and in vivo is inversely proportional to the length of the 5’-UTR [187].
Figure 1.8 Structure of the rodent IGF-1 gene and protein. Colored boxes represent the open reading frames, 
which code for the different IGF-1 precursor peptides. A Genomic structure of the IGF-1 gene. Multiple 
transcription start sites in exon 1 and 2 are indicated by horizontal arrows. AUG Translation initiation codons are 
located at indicated positions –48 in exon1, -32 in exon 2 and -22 in exon 3 and encode the specific N-terminal 
part of the different signal peptides of IGF-1 precursors (red boxes). The mature IGF-1 peptide of 70 amino acids 
(dark red boxes) is translated from exon 3 and 4, while exon 4 also codes for the N-terminal part of the E-peptide 
(green). Exon 5 and 6 encode different C-terminal parts of the E-peptide. Poly(A) addition signals are indicated by 
vertical arrows. B Differential splicing of precursor RNA on th 5’- and 3’-end of the IGF-1 gene. C The different 
IGF-1 isoforms.
1.4.2.5 Differential splicing at the 5’-end of IGF-1 RNA precursors
Heterogeneity of IGF-1 gene transcripts is further determined by differential splicing of exons 
at the 5’-end of precursor mRNA (Figure 1.8 B). Transcripts initiated at exon 1 are spliced to 
produce mRNAs, which contain exon 1, but lack exon 2 and will be referred to as Class 1 
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transcripts, whereas transcripts initiated at exon 2 give rise to mRNAs which contain exon 2, 
but lack exon 1 and are therefore termed Class 2 [186, 187, 193, 194]. In addition, 
transcripts initiated at start sites one and two of exon 1 can undergo a post-transcriptional 
splicing (exon 1 spliced variant), which results in the removal of a 186 base long sequence 
(including a major transcription site three) and introduces further complexity in heterogeneity 
of IGF-1 mRNAs [191]. In rodents about 20% of liver IGF-1 transcripts are subject to this 
modification [191]. 
1.4.2.6 Alternative splicing at the 3’-end of IGF-1 RNA precursors
Additional splicing at the 3’-end of the IGF-1 gene adds further complexity to the variety of 
IGF-1 transcripts and IGF-1 isoforms translated from these transcripts. In rat and mouse liver 
two splice variants have been identified [176, 177, 188]. When exon 4 is spliced to exon 6, 
19 amino acids are added to the common 16 amino acids encoded by exon 4, thus 
generating a 35 amino acid long E-peptide, termed Ea-peptide (Figure 1.8 C). A second E-
peptide, in rodents known as the Eb-peptide, is translated when a 52 base fragment, derived 
from exon 5, is included and spliced to exon 6. This insertion encodes 17 codons and causes 
a frame shift in the reading frame, thereby introducing an earlier in-frame stop codon in the 
exon 6 sequence. The Eb-peptide contains 41 amino acids, with exon 4 coding for 16 amino 
acids, exon 5 for 17 amino acids, and exon 6 for eight amino acids [177, 188] (Figure 1.8 C).
In murine species, exon 6 encodes the 3’-UTR for both the Ea-peptide and the Eb-peptide 
which basically only differ in the presence or absence of the 52 base insertion derived from 
exon 5 (Figure 1.8 B). An important difference between the two E-peptides described in 
rodents is the presence of two potential N-linked glycosylation sites in the Ea variant which 
are absent from the Eb variant of the E-peptide [188]. An in vitro study revealed that both 
glycosylation sites were N-glycosylated and that both sites are probably used [195], 
suggesting that this post-translational modification is involved in a biological action of the 
IGF-1 isoform.
In contrast to rodents, three mRNA splice variants with alternatively spliced 3’-end have been 
described in humans. Similarly to rodents, splicing of exon 4 to exon 6 generates mRNAs 
encoding for the 35 amino acid Ea-peptide [196], which shares 91% homology with the 
rodent Ea-peptide [177], but only contains one of the two glycosylation sites described for the 
rodent Ea-peptide [171]. Other than in rodents, the human Eb-peptide is encoded by exon 4 
and exon 5, with exon 5 coding for the stop codon and a unique 3’-UTR [181, 197]. The 
human exon 4-5 splice variant encodes for an Eb-peptide of 77 amino acids with the 
common 16 amino acids coming from exon 4 and an additional 61 amino acids from exon 5. 
Even though termed Eb-peptide as well, there is no homology between the human and 
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Introduction page 37
mouse Eb-peptide [177]. The third E-peptide splice variant in humans instead, which has 
been termed Ec-peptide, is the counterpart of Eb in mouse and rat, and is generated by 
splicing exon 4 to exon 5 to exon 6. In contrast to rodents, the insertion derived from exon 5 
contains only 49 base pairs. This produces a third possible E-peptide of 40 amino acids, 
which shares 72% homology with the rat Eb-peptide sequence [198].
The possible existence of the exon 4-5 splice variant, which codes for the Eb-peptide in 
humans, was also predicted in rats [176], but since it was not detected in liver using Northern 
blot techniques, it was assumed that this splice variant does not exist in rodents. However, in 
the course of this thesis, I recently succeeded in cloning the exon 4-5 splice variant from 
mouse liver mRNA (compare section 3.1). The mouse exon 4-5 splice variant encodes a 63 
amino acid sequence of E-peptide (16 aa encoded by exon 4 and 47 encoded by exon 5), 
while the human counterpart (Eb-peptide in humans) encodes a 77 amino acids E-peptide 
(16 aa from exon 4 and 61 from exon 5) and there is only 57% homology between these two 
sequences. Most importantly predicted from the mouse sequence, the mouse exon 4-5 splice 
variant does not contain a nuclear and nucleolar localization signal, which has been 
described for the human Eb-peptide and has been shown to direct this human IGF-1 isoform 
to the nucleolus [199].
1.4.2.7 Polyadenylation signals in IGF-1 RNA precursors
Finally another level of IGF-1 post-transcriptional regulation is added by the existence of at 
least four polyadenylation sites in the 3’-UTRs of the rodent and human IGF-1 mRNAs, 
encoded by exon 6 [176, 190]. The use of several different polyadenylation sites creates size 
heterogeneity of rodent IGF-1 mRNAs and gives rise to three main IGF-1 transcript sizes: 
0.8-1.2, 1.5-2.1, and 7.5 kb [189]. The largest 7.5 kb IGF-1 mRNAs have a long (6.7-6.2 kb) 
3’-UTR, whereas the smaller 0.8-1.2 and 1.5-2.1kb IGF-1 mRNAs have a shorter (1.4-1.2 
and 0.5-0.2 kb) 3’-UTR.  It has been shown in vitro and in vivo that the half-life of IGF-1 
mRNAs is inversely proportional to the length of their UTRs with the longest transcript of 7.5 
kb having the shortest half-life [200].
1.4.2.8 Translation of Class 1 and Class 2 mRNAs
Both leader exons encode their own 5’-UTR and contain multiple in-frame AUG translation 
initiation codons [201]. By usage of alternate promoters and transcription start sites three 
distinct signal peptides can be generated from the IGF-1 gene (Figure 1.8). Exon 1 contains 
four AUG translation initiation codons. The most upstream AUG codon initiates a putative 14 
amino acid open reading frame (ORF), but no evidence for translation of this ORF exists. 
The following two AUG codons are immediately followed by UGA stop codons and might 
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function in regulation of translation initiation of the most downstream AUG at position – 48 
relative to the mature IGF-1 coding region. Three of the four described transcription initiation 
sites in exon 1 are located upstream of the Met-48 translation start codon and polypeptide 
precursors translated from these mRNAs contain a signal peptide of 48 amino acids [186, 
187]. Transcription start site four is located downstream of Met-48 codon and mRNAs 
initiated from this site encode a 22 amino acid signal peptide derived from exon 3 (which 
encodes a translation initiation codon at position -22 relative to the coding sequence of 
mature IGF-1) [187]. However, mRNAs that are translated from one of the three most 
upstream transcription start sites could theoretically also be translated from the -22 start 
codon, but in vitro studies have shown that in mRNAs containing two translation start sites, 
preference is given to the upstream one [187]. Translation of the mRNAs initiated at 
transcription start site one has not been studied, since the amount of these transcripts in rat 
liver is negligible [187]. Human exon 1 contains an additional AUG codon at a – 25 position 
relative to the IGF-1 coding region that is translated into a 25 amino acid signal peptide [196]. 
Exon 2 contains a single in-frame AUG translation start codon at position -32 relative to the 
mature IGF-1 coding sequence and all three transcription start sites reported for exon 2 are 
located upstream of this codon. Therefore exon 2 mRNAs can give rise to IGF-1 precursor 
peptides translated either from the Met-32 or the Met-22 codons, while again preference is 
given to the more upstream one [186, 187]. Throughout this thesis isoforms with the shortest 
(22 amino acid) signal peptide are termed 22-IGF-1.
In summary, rodent IGF-1 precursor peptides translated from Class 1 and Class 2 mRNAs 
can give rise to three different signal peptides of 48, 32 or 22 amino acids, which have been 
shown to be cleaved normally during post-translational processing in vitro [187]. The 48 and 
32 amino acid signal peptides generated from Class 1 and Class 2 mRNAs respectively, 
contain the same C-terminal 27 amino acids, which are encoded by exon 3, but differ at their 
N-terminus, with exon 1 coding for 21 unique amino acids and exon 2 coding for 5 unique 
amino acids.
1.4.2.9 Processing of IGF-1 prepro-peptides
It has been suggested that alternate splicing and differential promoter usage at the 5’-end of 
IGF-1 transcripts that leads to the generation of different signal peptides could affect the 
precise N-terminal cleavage site of the signal peptide [202] at a position three amino acids 
downstream of the usual cleavage site to produce the N-terminal truncation of the B-domain 
of mature or pro-IGF-1 [203, 204]. The cleavage of three N-terminal amino acids (gly-pro-glu) 
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results in the above mentioned -3N:IGF-1 (also referred to as des (1-3) IGF-1) peptide and 
the tripeptide glycyl-prolyl-glutamate (GPE) [180].
Different signal peptides have also been shown to be implicated in determination of 
glycosylation of the rodent Ea-peptide in vitro [186]. Simmons et al. could show that co-
translational processing of IGF-1 precursors with 22 and 32 amino acid signal peptides leads 
to glycosylation of the Ea-peptide, whereas co-translational processing of IGF-1 precursors 
with a 48 amino acid signal peptide is not associated with glycosylation of the Ea-peptide. 
1.4.3 Expression of IGF-1 isoforms
In rat liver, ~75% of total IGF-1 synthesis is accounted by exon 1 transcription [191], from 
which the vast majority of the transcripts (~ 70% of total liver IGF-1 mRNA synthesis) initiate 
from start sites two and three and the minority of the transcripts (~ 5% of total liver IGF-1 
mRNA) initiate at the start site four [191]. Abundance of transcripts initiated at the most 
upstream promoter (start site one) of exon 1 is extremely low [191]. Almost 90% of exon 2 
transcripts initiate from the second start site in exon two [191]. During postnatal development 
and in adult rats expression of exon 2 transcripts is more GH-dependent than expression of 
exon 1 transcripts [205, 206]. Exon 2 transcripts appear later in postnatal development than 
exon 1 transcripts, increasing especially at the onset of GH-dependent linear growth, and 
their appearance coincides with that of circulating IGF-1 [191]. Expression of exon 1 and 
exon 2 transcripts has also been studied in extrahepatic tissues of adult rats [207] and, 
similar to liver, in kidney and brain most of the exon 1 transcripts initiate from start sites two 
and three. However in testis, lung, muscle and stomach, transcription initiates primarily from 
start site three. Transcription in heart occurs only from start site three. The presence of the 
transcripts initiated at start site four is also detected in all these tissues, however at low 
levels [207]. Exon 2 transcripts are detected in testes, lung, kidney and stomach, however at 
much lower absolute levels than in liver. Exon 2 transcripts are undetectable in heart, brain 
and muscle [207]. 
IGF-1 mRNAs encoding the Ea form of the E-peptide are the major transcripts found in 
extrahepatic tissues, where they represent 95% of the total IGF-1 mRNA. In liver, IGF-1 
transcripts coding for the Ea-peptide were also detectable and represent 88% of total IGF-1 
mRNA [208]. Transcripts encoding the Eb form of the E-peptide (which contain the exon 5 
derived insertion), in contrast, are more abundant in liver [208], although also detectable in 
extrahepatic tissues to a low extent. As demonstrated for Class 2 transcripts, Lowe at al. 
showed that IGF-1 mRNA levels encoding the Eb-peptide were somewhat more sensitive to 
GH in liver than in other tissues. 
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Taken together, these results led to the hypothesis that Class 2 IGF-1Eb represents the 
endocrine form of IGF-1, as transcripts encoding the Class 2 signal peptide and the Eb-
peptide are regulated by GH and primarily found in liver, which is thought of as the main 
source of circulating IGF-1. Transcripts coding for the Class 1 signal peptide and the Ea-
peptide, in contrast, are expressed in all tissues and are less GH responsive and therefore 
might encode the autocrine/paracrine form of IGF-1.
1.4.4 Expression of IGF-1 isoforms in skeletal muscle
The predominant IGF-1 mRNA variant expressed in skeletal muscle is initiated with exon 1 
(Class 1) and carries the information for the Ea-peptide on the 3’end (exon 4-6 splice 
variant). This mRNA therefore codes for the Class 1 IGF-1Ea isoform of IGF-1 [77]. In 
muscles subjected to damage or exercise transcripts encoding an IGF-1Eb isoform (exon 4-
5-6 splice variant on the 3’-end of the mRNA) are up-regulated and the isoform as well as the 
isolated E-peptide translated from this mRNA has therefore also been called mechano 
growth factor (MGF) [209-211]. The signal peptide included in the transcripts giving rise to 
MGF has not been specified. Expression of MGF-containing IGF-1 transcripts has also been 
detected in resting muscles of rats and humans however at a much lower levels than that of 
Class 1 IGF-1Ea [210, 212]. A study on C2C12 myogenic cells suggests different roles for 
Class 1 IGF-1Ea and IGF-1Eb isoforms: while both isoforms increase myoblast proliferation, 
IGF-1Eb further prolongs proliferation and appears to block differentiation of myoblasts, 
whereas Class 1 IGF-1Ea promotes their fusion [213]. The same study suggests that other 
than Class 1 IGF-1Ea, which acts through the IGF-1 receptor (IGF-1R), MGF (either the IGF-
1Eb or the isolated Eb-peptide) might act through another, yet undefined, receptor and 
initiate a signaling pathway which is different from the one initiated by Class 1 IGF-1Ea [213]. 
It is important to point out that these tissue culture experiments employed a predicted 
synthetic MGF peptide [213], and as yet there is no evidence for the presence or function of 
isolated Eb-peptide (MGF protein) in vivo. However, involvement of IGF-1Eb/MGF in 
myoblast proliferation is also supported by in vivo studies on humans [210] and rats [214].
Robust up-regulation of IGF-1Eb mRNA (in the range from 2 to 864%) was observed within 
2.5 hours after high resistance exercise in young men, with no significant changes in Class 1 
IGF-1Ea mRNA levels [210]. Rapid up-regulation of IGF-1Eb was seen in rat muscles after 
stretch or bupivacaine injury, where the peak of IGF-1Eb mRNA preceded that of Class 1 
IGF-1Ea.  However, it should be pointed out that in these experiments the absolute mRNA 
levels of Class 1 IGF-1Ea were always much higher (~10-103 folds) then those of MGF [210, 
214].
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1.4.5    IGF-1 signaling in skeletal muscle
IGF-1 plays a central role in the control of muscle development, growth and differentiation, as 
well as in maintenance of skeletal muscle, both in culture and in live animals. IGF-1 shares 
many anabolic functions with insulin, like stimulation of amino acid uptake and incorporation 
into proteins, DNA and RNA synthesis, and regulation of glucose uptake [215, 216]. All 
members of the IGF family (IGF-1, IGF-2, and insulin) were also shown to be potent 
stimulators of cell proliferation, which is consistent with their anabolic effects (reviewed in 
[134, 215, 217]). The metabolic actions of IGF-1 differ from the metabolic effects of insulin, 
as IGF-1 stimulates whole body protein metabolism by increasing protein synthesis, as well 
as by inhibition of protein proteolysis [218, 219], while insulin acts primarily by inhibiting 
protein breakdown. In addition, insulin primarily acts as a hormone of intermediary 
metabolism, while IGF-1 primarily functions as a growth, survival and differentiation factor.
The IGFs are unique among other growth factors, as they are capable of promoting 
proliferation as well as differentiation of skeletal muscle cells, two processes that are 
mutually exclusive. Other growth factors act as mitogens while they inhibit differentiation 
(reviewed in [216]). IGF-1, in contrast, has been shown to promote both responses, but in a 
temporally separated manner, first acting upon myoblast replication and subsequently 
promoting myogenic differentiation [220-222].
In vitro studies on fibroblasts also established IGF-1 as a progression factor of the cell cycle 
(reviewed in [133, 215]). So-called competence factors, like epidermal growth factor (EGF), 
fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), were shown to 
stimulate quiescent cells to enter the G1 phase of the cell cycle, while IGF-1 effected 
progression from G1 to S-phase and therefore was termed G1-progression factor [223]. 
Although this view could not be supported in more recent in vivo studies [224, 225], as IGF-1 
null animals displayed a normal progression through G1- and S-phase, it nevertheless is 
believed that IGF-1 may be important for timely progression through later phases of the cell 
cycle. This is suggested by the finding that the IGF-1 null mice exhibited a severe retardation 
in G2/M-phase transit [225].
The intracellular signaling pathways which mediate the pleiotropic effects of IGF-1 are 
complex and inter-connected, however in broad terms, three main pathways can be identified 
downstream of the activated IGF-1 receptor: mitogen activated protein kinase (MAP-kinase) 
signaling, mainly linked to myoblast proliferation; phosphatidylinositol 3-kinase (PI(3)-kinase) 
signaling involved in muscle differentiation and survival and essential for muscle hypertrophy 
and prevention of muscle atrophy; and calcineurin signaling important for myoblast 
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differentiation and possibly involved in hypertrophic muscle growth. These pathways are 
shown in Figure 1.9 and are discussed in detail below. 
1.4.5.1 IGF-1 and IGF-2 receptors
The IGF-1 receptor (IGF-1R) is a heterotetrameric transmembrane glycoprotein, which is 
similar in topography and sequence to the insulin receptor and shares ~50% amino acid 
identity [226]. Both receptors belong to the family of ligand-activated receptor tyrosine 
kinases and are α2β2 heterotetramers with subunits of almost identical size. In case of the 
IGF-1R, a single prepro-protein is translated and after co-translational cleavage of the signal 
peptide and post-translational glycosylation, the protein is cleaved to generate an α- and a β-
subunit. These are connected by disulfide bonds to form a αβ half receptor. The mature IGF-
1R consists of two αβ half receptors that are linked together by disulfide bonds between the 
α-subunits.
The α-subunits of the insulin and IGF-1 receptor contain the ligand binding domains, which 
specifically bind to their cognate ligands, despite the structural similarities between insulin 
and the IGFs. The IGF-1R has the highest affinity for IGF-1, but also binds to IGF-2 with 
several-fold lower affinity and to insulin with more that 100-fold lower affinity. Insulin 
receptors have the highest affinity for insulin, bind IGF-1 with a 100-fold lower affinity, and do 
not bind to IGF-2 [134, 227]. 
The β-subunits of the holoreceptor contain a short extracellular domain, a membrane-
spanning region, and a large intracytoplasmic domain. The cytoplasmic portion carries a 
highly conserved tyrosine kinase catalytic domain and sites for tyrosine and serine 
phosphorylation. In response to ligand binding, both insulin and IGF-1 receptors are capable 
of autophophorylation by an intramolecular trans-reaction. The tyrosine kinase of one β-
subunit phosphorylates residues on the other β-subunit of the α2β2 holoreceptor [228-230]. 
Due to their high degree of similarity in structure and sequence, the insulin and IGF-1 
receptor can form receptor hybrids that consist of αβ dimers of the IGF-1R connected via 
disulfide bonds to αβ dimers of the insulin receptor [231, 232]. This hybrid receptor, which is 
found in several tissues [233] shows a high affinity to IGF-1 and binds insulin with much 
lower affinity [234].
Unlike the insulin and IGF-1 receptor, the IGF-2 receptor is not a tyrosine kinase, but a 
monomeric membrane-spanning receptor with a large extracellular domain, which is 
responsible for ligand binding. The IGF-2R is not considered to have a major role in IGF 
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signal transduction, but is primarily believed to be responsible for reducing the levels of IGF-
2 during fetal development [235, 236]. Moreover IGF-2R functions also as the cation-
independent mannose-6-phosphate receptor [237], which plays a major role in transporting 
lysosomal enzymes between intracellular compartments. 
1.4.5.2 Pathways downstream of the IGF-1 receptor 
The biological actions of both, IGF-1 and IGF-2 are mediated by the type 1 IGF-receptor 
(IGF-1R). Upon ligand binding, the intracellular kinase domain becomes activated and in turn 
autophosphorylates the receptor (Figure 1.9). This autophosphorylation event leads to the 
recruitment of endogenous substrates, of which the insulin receptor substrate (IRS) proteins-
1 and the src-homology containing protein (SHC), an adaptor protein with src-homology 2 
domains (SH2), play a major role [238, 239]. In addition, it was shown that IRS-2 can 
compensate for IRS-1 and may provide an alternate pathway to IRS-1 signal transduction 
[215]. Theses docking proteins bind to the juxtamembrane domain of the IGF-1R, where they 
are phosphorylated by the IGF-1R and thereby enabled to recruit other substrates that in turn 
activate different signal cascades [240, 241]. Several other docking proteins that are 
recruited to an activated IGF-1R have been described (reviewed in [215, 238]) and these 
provide a mechanism to activate distinct signaling cascades in a tissue- and cell-specific 
manner. Since the expression pattern of these proteins varies between tissues and 
throughout development, they might provide an explanation for the multiple functions of IGF-
1. Multiple other proteins, such as the adaptor proteins Nck or the Src-like kinase Fyn, are 
likely to be involved in the specificity of responses to IGF-1.
In muscle cells, IGF-1R is responsible for initiating several signal transduction pathways, 
which might occur independently or overlap. It is important to point out that most of the work 
done to unravel the intracellular signaling pathways induced by IGF-1 has been carried out in 
tissue culture and to what extent this information translates to more complex in vivo
situations remains to be elucidated. 
1.4.5.3 MAP-kinase signaling
It is suggested that MAP-kinase signaling is involved as the major pathway for IGF-1-
mediated cell proliferation [242]. Recruitment of the docking protein SHC to the activated 
receptor leads to the association of SHC with the growth factor receptor-bound protein 2 
(Grb2) via their SH2 domains. Grb2 is an adaptor protein which recruits the GTP-exchange 
factor Sos (Sons of sevenless) via an additional SH3 domain. The interaction between Grb2 
and Sos results in the recruitment of the small G-protein Ras, and in the transition of the 
inactive Ras-GDP to active Ras-GTP. Activated Ras induces sequential activation of Raf-1, 
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MAP-kinase kinase (MAPKK), and a family of MAP-kinases, namely Erk1, Erk2 (extracellular 
regulated kinase), Jun kinase, and p38 MAP-kinase (reviewed in [215]) (Figure 1.9). MAP-
kinases are thought to phosphorylate transcription factors, which increases their ability to 
induce expression of molecular markers of cell cycle progression, like c-jun, c-fos, cyclin D1, 
and cdk4 (reviewed in [215]). Cyclin D1 and cdk4 are the regulatory and catalytic 
components of a holoenzyme playing a critical role in mediating the phosphorylation of the 
retinoblastoma protein (Rb). Upon phosphorylation, Rb releases E2F, a transcription factor 
essential for activating the transcription of many proteins involved in the cell cycle. Also IRS-
1 is able to recruit Grb2 and thereby activates the MAP-kinase pathway. Inactivation of the 
MAP-kinase pathways by using the specific inhibitor PD098059 in L6A1 myogenic cells 
induced a ~90% reduction of IGF-1 stimulated proliferation [242]. Apart from cell proliferation, 
the MAP-kinase pathway may also play a role in myotube formation [243].
Figure 1.9 Overview of IGF-1/IGF-1R signaling. Binding of IGF1 ligand to the IGF-1R can result in downstream 
activation of the calcineurin (orange), CamK (purple), PI3K (red) and MAP-kinase (yellow) pathways. 
Explanations are given in the text. (From Mourkioti et al., 2005).
1.4.5.4 PI(3)-kinase signaling
The pathway downstream of PI(3)-kinase has been linked to differentiation and survival of 
skeletal muscle cells, as well as to hypertrophic growth and prevention of muscle atrophy.
Upon IGF-1R activation, IRS-1 can also interact with the PI(3)-kinase, a heterodimer 
composed of a 110 kDa catalytic subunit and an 85 kDa regulatory subunit containing a SH2 
domain. The p85 regulatory subunit directly binds to activated IRS-1 [244], is phosphorylated 
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and thereby activated as well. p85 is also capable of binding directly to the IGF-1R [245]. 
Activated PI(3)-kinase phosphorylates inositol phospholipids, which are required to induce 
several downstream targets, such as the serine/threonine kinase Akt, also known as the 
protein kinase B (Figure 1.9). 
In the myogenic response to IGF-1, the PI(3)-kinase has been shown to play a critical role 
[242, 246-248]. During the muscle differentiation process, myoblasts exit the cell cycle in 
response to the two skeletal muscle-specific MDFs, MyoD and myf-5. Both MyoD and myf-5 
are expressed in myoblasts prior to the onset of muscle differentiation [249, 250] and induce 
the expression of the third MDF, myogenin, as well as members of the MEF family which 
interact with the MDFs to activate many muscle specific structural genes, such as neonatal 
myosin, MCK, and β-enolase [251, 252].
PI(3)-kinase together with its downstream effector Akt has been implicated in activating 
factors involved in muscle differentiation and muscle cell survival, most importantly an early 
member of the MDF family, MyoD. MyoD induction consequently leads to up-regulation of 
p21 [253, 254], a cyclin-dependant protein kinase inhibitor, which blocks progression through 
the cell cycle [255, 256]. An increase in p21 is associated with an ongoing decline in cyclin-
dependant kinase activity indicating the involvement of both MyoD and p21 in the critical 
transition from the proliferative to the differentiative phase.
One of the most important effects of IGF-1 in stimulating myogenesis is its ability to activate
expression of the myogenin gene via the PI(3)-kinase and direct translocation of Akt into the 
nucleus (reviewed [215, 257]). Myogenin is the member of the MDFs which is most directly 
associated with terminal myogenic differentiation [14, 15], and is an obligatory part of 
myogenesis stimulation by IGF-1 [258]. The PI(3)-kinase pathway has also been shown to 
induce the transcription of MEF2, a myocyte enhancer factor, which acts together with the 
MDFs to activate muscle specific structural genes [259]. This is likely to be the way, by which 
the PI(3)-kinase pathway mediates the IGF-1 induced activation of myogenin, as MEF2 is 
essential for activating myogenin expression and later muscle differentiation genes. Tamir et 
al. also revealed that the MAP-kinase p38 is involved in regulating transcriptional activity of 
MEF2, but by using another, as yet unidentified signal transduction pathway [259].
Activation of the PI(3)-kinase/Akt pathway is crucial for regulation of protein synthesis in 
skeletal muscle cells and muscle hypertrophy [39, 61, 260]. There are multiple targets 
activated downstream of PI(3)-kinase/Akt. For example, a micro array analysis shows that 
treatment of C2C12 myotubes with IGF-1 (which results in their hypertrophy [39, 61]) 
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regulates at least 242 genes and LY294002 (a specific inhibitor for PI(3)-kinase)) blocks 
89.1% of the changes induced by IGF-1 [60]. IGF-1 induced hypertrophy of C2C12 myotubes 
as well as hypertrophy of the plantaris muscle in rats following functional overload is 
concomitant with increased phosphorylation and activation of Akt [39, 60, 61]. Muscle-
specific expression of constitutively active Akt in mice results in profound myofiber 
hypertrophy and decreased fat deposition [260]. Such muscle hypertrophy is obtained in 
conditional transgenic mice (when the transgene is expressed in blastocytes), as well as 
when the transgene expression is induced in adult mice using tamoxifen-dependent 
recombination [260]. 
Activated Akt can lead to up-regulation of protein synthesis in at least two ways: regulation of 
enzymes involved in carbohydrate metabolism, namely phosphorylation and inhibition of 
glycogen synthase-serine ??????? ??? ????-??) (PI(3)-kinase/Akt/GSK-??? ?? ???????? ????
phosphorylation of molecules downstream of Akt and its target mTOR (target of rapamycin) 
(PI(3)-kinase/Akt/mTOR pathway) [39, 61]. It has been shown that activation of mTOR is 
concomitant with phosphorylation and activation of p70S6K, which stimulates protein synthesis 
and phosphorylation of PHAS-1/4E-BP1 (phosphorylated heat- and acid-stable protein-1), 
which releases it from the inhibitory complex with translation initiation factor eIF4E, thereby 
permitting binding of eIF4E to eIF4D and promoting protein synthesis [39, 61]. Specific 
blocking of PI(3)-kinase/Akt/mTOR pathway with rapamycin (specific inhibitor of mTOR), 
almost completely (by 95%) prevents hypertrophic growth of skeletal muscle in vivo [61] and 
blocks all but 1% of the genes activated by IGF-1 through PI(3)-kinase/Akt pathway [60]. 
However, a recent report by Song et al. raised the possibility for an alternative, Akt-
independent pathway mediating skeletal muscle hypertrophy downstream of the PI(3)-
kinase, since it demonstrated activation of phosphoinositide-dependent protein kinase (PDK-
1), mTOR, and p70S6K without affecting Akt activity in the hypertrophic muscles of transgenic 
animals over-expressing Class 1 IGF-1Ea (mIGF-1) specifically in skeletal muscle [261].
Activation of PI(3)-kinase/Akt signaling can counteract protein degradation in catabolic states 
and reduce myofiber atrophy [60, 61, 63, 262]. Micro array analysis confirms that in C2C12 
myotubes, IGF-1 and dexamethasone (which causes myotube atrophy) inversely regulate a 
number of genes including atrophy related MAFbx [60]. Atrophying muscle is characterized 
by down-regulation of the PI(3)-kinase/Akt pathway which results in up-regulation of atrophy 
related genes via dephosphorylation (activation) of Foxo transcription factors and their 
translocation into the nucleus [60, 262]. It has been shown that Foxo3 can directly activate 
transcription from the atrogin-1(MAFbx) promoter in vivo and in cell culture and induce 
muscle atrophy [262]. Activated Akt phosphorylates Foxo transcription factors on multiple 
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sites, leading to the exclusion of phosphorylated Foxo proteins from the nucleus and 
inhibition of their transcriptional functions [263]. Treatment of atrophying myotubes with IGF-
1 prevents activation of Foxo transcription factors and suppresses expression of atrogins [63, 
262] (Figure 1.9). The anti-atrophic effect of IGF-1 is dependent on PI(3)-kinase/Akt 
activation, since transfection of myotubes with constitutively active PI(3)-kinase [63] or Akt 
[63, 262] blocks up-regulation of atrophy related genes. Suppression of atrogins by activated 
PI(3)-kinase/Akt pathways has also been demonstrated by in vivo experiments. For example, 
transfection of constitutively active Akt, blocked atrogin-1 promoter activity in the muscles of 
food-deprived (catabolic state) mice [262] and injection of IGF-1 into a short-term denervated 
muscle decreased expression of MAFbx and MuRF-1 and reduced myofiber atrophy [63]. 
Denervation-induced atrophy can also be reduced by expression of constitutively active Akt 
[61]. Taken together these data indicate a protective effect of the PI(3)K/Akt pathway on 
myofiber atrophy in different catabolic states.
The PI(3)-kinase/Akt pathway, also plays a role in inhibiting apoptosis by interacting with 
members of the Bcl-2 family (B-cell lymphoma) of proteins [264, 265], which have been 
shown to either inhibit or stimulate apoptosis (reviewed in [266, 267]). Following IGF-1-
mediated stimulation, activated Akt can either lead to inhibition of pro-apoptotic Bcl-2 
members and BAD at the earlier stage of apoptosis, and caspase 9 at later stages (reviewed 
in [257]), or to up-regulation of anti-apoptotic Bcl-2 members [268-270].
Although it is clear that the Akt pathway is the main pathway by which the activated IGF-1R 
exerts its anti-apoptotic affect, there is evidence that the IGF-1R has alternative pathways. 
One alternative pathway is the MAP-kinase pathway [271, 272], originating, at least in part, 
from another major substrate of the IGF-1R, the SHC proteins [273]. A third pathway has 
been identified by Peruzzi et al. [272], which depends on the mitochondrial translocation of 
Raf-1 and the phosphorylation of BAD. Recent work by Jin et al. shows that Raf-1 
translocation to the mitochondria and phosphorylation of BAD is mediated by p21-activated 
kinase-1 (Pak1), which phosphorylates Raf-1 at Ser-338/Ser-339 inducing an interaction with 
Bcl-2 and thereby the dissociation of Bcl-2 and BAD [274]. The same group shows that these 
signals are specific to Pak1, since Src activates Raf-1 by phosphorylating residuesTyr-
340/Tyr-341 and this leads to activation of the MAP-kinase pathway.
1.4.5.5 Calcineurin signaling 
This pathway is likely to account for several biological functions of IGF-1: muscle cell 
differentiation, muscle hypertrophy (although the results are controversial), and conversion of 
myofibers from slow to fast type. Calcineurin is a cytoplasmic serine-threonine phosphatase 
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which consists of a catalytic (A) subunit and a regulatory (B) subunit [275]. Three CnA genes 
?????????????????????????????????????????????ß, and CnA???????????? ??????????????ß are 
????????????????????????????????????????????????????????????????is. CnAß mRNA is subject to 
differential splicing, giving rise to CnAß1 and ß2 [276]. Due to the insertion of an intron, this 
isoform of CnAß lacks the auto-inhibitory domain. Calcineurin is activated by increased 
intracellular Ca2+ levels and causes dephosphorylation and nuclear translocation of 
cytoplasmic NF-ATc (nuclear factor of activated T cells) family members, which in 
combination with other transcription factors activate transcription [277] (Figure 1.9). The 
immunosuppressant drugs cyclosporin A (CsA) and FK-506 are specific inhibitors of 
calcineurin activity [275]. In skeletal muscle cells, downstream targets for calcineurin involve 
NF-ATc1, zinc finger transcription factor GATA-2 and MEF family members [278-280]. 
Involvement of calcineurin-mediated signaling in differentiation of skeletal muscle cells has 
been shown in experiments where transfection of mouse primary myoblasts with viral vector 
carrying the active calcineurin gene triggered differentiation (assessed by induction of 
myogenic markers myogenin and embryonic MyHC) and occasional fusion of these cells in 
proliferation media. Such differentiation occurred only in the presence of adequate Ca2+
levels in the media, was independent of NF-ATc1 activity and was blocked by CsA [281]. In 
general, addition of CsA to pre-differentiated myoblasts results in significantly fewer 
myotubes indicating the importance of calcineurin signaling for differentiation [39]. It is 
suggested that calcineurin serves as a downstream mediator for IGF-1-induced myoblast 
differentiation [282]. Transfection of L6E9 rat myogenic cells (which otherwise do not express 
endogenous IGF-1) with the MLC/mIGF-1 transgene (where the gene coding for Class 1 
IGF-1Ea isoform of IGF-1 is driven by MLC1/3 promoter and is expressed only after 
differentiation) enhanced differentiation assessed by induction of differentiation markers [278]
and expression of dominant negative calcineurin A or treatment with CsA (the same day 
when the cells were transferred to differentiation media) blocked IGF-1 mediated 
differentiation. 
In skeletal muscle cells, pathways activated by over-expression of calcineurin coincide with 
those activated during physical over-load and normally lead to muscle hypertrophy [280]. 
However, the role of the calcineurin mediated signaling pathway in skeletal muscles 
hypertrophy is not conclusively established and controversy exists in the published reports. It 
has been suggested that at least in tissue culture, IGF-1 might induce skeletal muscle 
hypertrophy through calcineurin in association with GATA-2 and NF-ATc1 [279, 282]. These 
downstream targets overlap with the mediators of calcineurin activity in cardiomyocytes 
[275], where calcineurin plays a central role in hypertrophy. 
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Two studies link the hypertrophic action of IGF-1 to calcineurin signaling: 
In one study, transfection of C2C12 myoblasts with plasmid encoding the IGF-1 gene 
(isoform not indicated) induced mobilization of Ca2+ within the cell, increased activation of 
calcineurin and resulted in nuclear translocation of the transcription factor NF-ATc1 [279]. 
This was concomitant with myotube hypertrophy and a switch to a glycolytic phenotype and 
both of these phenotypic responses were inhibited by CsA and FK506 [279]. Similarly, 
treatment of C2C12 cultures with human recombinant IGF-1 (250ng/ml) resulted in activation 
of calcineurin and myotube hypertrophy. However, the timing for IGF-1 treatment appears to 
be critical and myotube hypertrophy occurred only when IGF-1 was added to proliferating 
cultures or at the time of differentiation, but not one day after [279]. The same group 
suggested the involvement of calcineurin signaling in IGF-1-induced muscle hypertrophy in 
vivo, based on increased calcineurin activity after local injection of a plasmid carrying the 
IGF-1 gene into the latissimus dorsi muscle of the rat [279]. This study did not directly 
examine the effect of exogenous IGF-1 expression on myofiber hypertrophy (myofiber size), 
but concluded that muscle hypertrophy had occurred based on the presence of centrally 
nucleated myofibers [279]. It is now recognized that in transgenic mice, formation of the 
centrally nucleated myofibers might be an indication of an abnormal myogenesis rather then 
a hypertrophic growth [283]. Notably, the in vitro findings of both studies could not be 
supported by an in vivo approach [284], suggesting that additional signals are required in 
vivo to support sustained skeletal muscle hypertrophy.
In another study, endogenous IGF-1 (Class 1 IGF-1Ea isoform) expression under the 
MLC1/3 promoter (induced when cells are switched to the differentiation programme) in L6E9 
cell cultures resulted in myotube hypertrophy concomitant with enhanced accumulation of 
CnA and GATA-2 transcripts. GATA-2 protein was associated with nuclear complexes 
containing calcineurin and NF-ATc1 which was extensively dephosphorylated [282].
Involvement of the calcineurin signaling pathway in IGF-1-induced skeletal muscle 
hypertrophy was questioned by later studies which consider Akt signaling as the principle 
hypertrophic pathway [39, 61]. These authors proposed that in the earlier studies by Musaro 
et al. [282, 285] and Semsarian et al. [279] inhibition of IGF-1-induced myotube hypertrophy 
by CsA could have been due to inhibition of myoblast differentiation and fusion, since CsA 
was applied to undifferentiated myoblasts. Moreover, it has been suggested that in C2C12 
myotubes it is the Akt pathway that is responsible for the hypertrophic action of IGF-1 and
can even antagonize calcineurin signaling [39]: administration of IGF-1 (10 ng/ml) to fusing 
myotubes at day 2 of differentiation caused hypertrophy concomitant with 
hyperphosphorylation (inactivation) of NF-ATc1, which indicated that IGF-1 might be 
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inhibiting calcineurin activity [39]. Moreover, addition of IGF-1 blocked the calcium-dependent 
dephosphorylation and nuclear translocation of NF-ATc1 induced by calcium ionophore (a 
standard method for activating calcineurin [286]). Treatment of differentiated C2C12 cultures 
with CsA did not prevent IGF-1-induced hypertrophy, however CsA inhibited differentiation 
when added to pre-differentiated cultures. It was also shown that calcineurin activity is 
decreased in functionally overloaded rat plantaris muscle (in vivo) and treatment with 
calcineurin inhibitors cyclosporin A and FK506 do not prevent increase in muscle mass and 
myofiber size [61].
Disparities in the reports on IGF-1 signaling pathways indicate the complexity and 
multifunctional nature of these pathways and underline that many open questions still remain 
in this field.
1.5 Skeletal muscle-specific IGF-1 transgenic mice
In the past years various transgenic approaches, using different IGF-1 isoforms, raised many 
questions regarding the isoform specificity of IGF-1 function. The Schwartz laboratory [287]
generated a transgenic mouse over-expressing a human IGF-1 isoform initiated by exon 1 
and including the Ea-peptide (Class 1 IGF-1Ea), driven in skeletal muscle and heart under 
the control of the α-skeletal actin promoter. Over-expression of this isoform resulted in mild 
skeletal muscle hypertrophy and initially physiologic hypertrophy in the heart, which later 
became maladaptive, pathologic cardiac hypertrophy. Additionally, the human IGF-1 isoform 
was detected in the circulation, presumably secreted from heart and skeletal muscle where it 
was synthesized.
An unpublished study by Chris Goddard in South Australia used the mature human IGF-1 
???????????????????????????????????????-????????????????????-actin/hIGF-1) (reviewed in [151]). 
This expression construct was designed to contain a synthetic translation initiation signal 
from the rat somatostatin gene, lacking IGF-1 gene-derived signal sequences and 
distinguishing this mouse from the other lines described here, where native IGF-1 signal 
sequences were used. This mouse did not show skeletal muscle hypertrophy and levels of 
circulating hIGF-1 were strongly increased.
More specific restriction of the IGF-1 transgene to skeletal muscle was achieved in the 
MLC/mIGF-1 transgenic line, where a Class 1 IGF-1Ea isoform was driven by the skeletal 
muscle-specific MLC1/3 promoter and enhancer. No increase of circulating IGF-1 was 
detected in the initial description of this mouse line [77]; however significant circulating IGF-1 
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has subsequently been observed (the present study). Over-expression of Class 1 IGF-1Ea 
(named mIGF-1) caused pronounced myocyte hypertrophy and rescued the muscle from 
age-related muscle atrophy. In addition, the hypertrophic muscles retained the proliferative 
response to muscle injury, normally seen in younger animals [77], protected dystrophic fibers 
from necrosis and enhanced regeneration by recruitments of stem cells [90, 130]. The mIGF-
1 transgene also protected motor neurons from degeneration in a model of ALS [78] and 
enhanced regeneration of the affected muscle. The same transgene was restricted to cardiac 
muscle using the αMyHC promoter (MyHC/mIGF-1) and showed similar beneficial effects in 
the transgenic hearts, with physiological hypertrophy returning to control levels by six months 
of age, enhanced regeneration in response to cardiotoxin injections, and myocardial 
infarction (Santini M.P., manuscript submitted). The presence of circulation IGF-1 was not 
assessed in this study.
An additional transgenic mouse, generated in the Rosenthal laboratory (unpublished data), 
which differed from the above-mentioned MLC/mIGF-1 mouse by carrying a shorter 5’-UTR 
and an as yet unidentified C-terminal sequence, demonstrated a dramatically different 
phenotype. No skeletal muscle hypertrophy was seen, but instead the transgene caused a 
mild cardiac hypertrophy, accompanied by an up-regulation of the glucose-sensitive 
transporter Glut-4 in cardiac and skeletal muscle. In addition, the transgene was detectable 
in the circulation.
Another study [288], using a human IGF-1 isoform under the control of the cardiac muscle-
specific αMyHC promoter, reported cardiomegaly, mediated by an increased number of cells 
in the heart. These authors also detected human IGF-1 in the circulation, causing site effects 
by increasing the size of several organs, especially brain and kidney. Notably, the isoform 
used contained the human Eb-peptide, which corresponds to an En-peptide described in the 
present work (compare section 1.4.2.6). The same group reported that in this mouse model 
IGF-1 prevented activation of cell death in the viable myocardium after infarction, thereby 
limiting ventricular dilation and pathological cardiac hypertrophy [289].
These studies provide a few examples of the diverse phenotypes obtained by over-
expression of different IGF-1 isoforms, and highlight the need for a comprehensive 
characterization of the different isoforms and their normal physiologic function.
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1.6 Significance of this work
As outlined above, the IGF-1 gene has a complex expression pattern that results in the 
production of different N-terminal pre-peptide and C-terminal E-peptide combinations, 
generated by alternate promoter usage, differential splicing and post-translational 
modification. The complexity of the IGF-1 gene has complicated the analysis of the 
circulating and/or localized protein products generated from the single-copy IGF-1 gene and 
the specific functions of these IGF-1 isoforms have not been systematically described, 
although their existence had been documented in the early days of IGF-1 research about 20 
years ago. The assignment of specific functions to these isoforms is still under debate. Some 
insight into the role of IGF-1 in skeletal muscle has been gained by supplemental over-
expression of IGF-1 using transgenic mice, but the combination of different IGF-1 isoforms 
with various regulatory sequences to drive transgene transcription has generated 
discrepancies in the literature (compare section 1.5). The distinct phenotypes of these mice 
imply differences in the action of the various IGF-1 isoforms and underline the importance of 
choosing comparable conditions for a comprehensive characterization of IGF-1 isoform 
function. Parameters such as the choice of promoter, and signal peptide, can alter IGF-1 
availability and localization and therefore complicate interpretation and comparison of 
different IGF-1 transgenic mouse lines. 
The approach taken in this thesis aimed for a complete characterization of the four main IGF-
1 isoforms and their differential function in skeletal muscle in vitro and in vivo. Over-
expressing these isoforms in the similar manner by driving them from the same regulatory 
sequences was a crucial prerequisite in the design of this project to allow the comparison 
between IGF-1 isoform-induced effects. This work will have major implications for the 
development of IGF-1-based therapies in different disease conditions of skeletal muscle, a 
region of research which has been given much focus in the past years.  
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Materials and Methods page 53
2  Materials and Methods
2.1 Molecular Biology
2.1.1      DNA gel electrophoresis
For small fragments (100-200 bps) low electroendosmosis agarose (Roche, # 1685660) was 
used and dissolved to a percentage of 1.3-1.5 (w/v) in standard 1x Tris-acetate-EDTA (TAE) 
buffer. For bigger fragments normal agarose (Invitrogen, #15510-027) was dissolved in 
standard 1x Tris-borate-EDTA (TBE) buffer. Agarose was melted, cooled down, and 2 µl of 
ethidium bromide (10 mg/ml) were added per 100 ml of agarose solution. Depending on the 
gel size, gels were run at a voltage between 60 and 150 V with constant current. 
2.1.2      Extraction of DNA fragments from agarose gels. 
DNA fragments were excised from agarose gels of the appropriate percentage using a 
70%UV lamb and purified using QIAquick Gel Extraction Kit (QIAgen #28704) according to 
the instructions. After purification, DNA was ethanol-precipitated (1/10 volume 5 M Na-
acetate; 2.5 volumes 100% ethanol), washed in 70% ethanol and dissolved in the 
appropriate amount of sterile H2O. All isolated fragments were stored at –20°C until needed. 
2.1.3      Plasmid purification
All plasmids were isolated by using QIAgen plasmid purification Kits (QIAprep® Spin Miniprep 
Kit #27106; Endofree® Plasmid Maxi Kit #12362) according to the manufacturer’s 
instructions. Purified plasmids were eluted with sterile H2O and stored at -20°C.
Concentration of the DNA was determined by spectrophotometric measurement of the 
absorbance (A) at 260 nm and 280 nm.
2.1.4      Transformation of bacteria for plasmid amplification
Competent E.coli XL-1/blue cells were used for plasmid amplification. Cells were made 
competent by growing them in LB medium to an OD of 0.5 to 0.6, followed by centrifugation 
at 1000 x g for 10 min and re-suspended in 1/10 volume of freshly made transformation 
storage buffer (TSB) (LB broth pH6.5, 10% polyethylene glycol (PEG), 5% dimethyl sulfoxide 
(DMSO), 10mM MgCl2, 10mM MgSO4). After a 10 min. incubation step on ice, the cells were 
flash-frozen in liquid nitrogen and stored at –80°C. Chemical transformation was performed 
by incubating the ligation reaction in 1x KCM buffer (0.5M KCl, 0.15M CaCl2, 0.25M MgCl2) 
for 20 min on ice and 10 min at room temperature (RT). Cells were then plated on LB-plates 
containing 0.5 mM isopropyl-thio-ß-galactoside (IPTG), 80µg/ml X-Gal, and 100µg/ml 
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ampicillin and incubated over night at 37°C. Recombinant clones were identified by color 
screening and analytical restriction digests.
2.1.5      Cloning IGF-1 isoforms
All IGF-1 isoforms were cloned from three-month-old mouse liver by reverse transcription 
PCR following the manufacturer’s instructions (Promega Access RT-PCR System #A1260) 
and cloned into pGEM®-T Easy vectors based on A/T-cloning (Promega pGEM®-T Easy 
Vector System I #A1360). Specific primers were designed for amplification of Class 1 (Figure 
2.1A) and 2 (Figure 2.1B) isoforms containing either the Ea or the Eb-peptides (Class 1 IGF-
1Ea: forward 5’-CTCGATAACTTTGCCAGAAG-3’, reverse 5’-CCTCCTACATTCTGTAGGTCTTG-
3’; Class 1 IGF-1Eb: forward 5’-CTCGATAACTTTGCCAGAAG-3’, reverse 5’-CCTGCACTTCCT
CTACTTGTG-3’; Class 2 IGF-1Ea: forward 5’-AGTTTTGTGTTCACCTCGGCC-3’, reverse   5’-C
CTCCTACATTCTGTAGGTCTTG-3’; Class 2 IGF-1Eb: forward 5’-AGTTTTGTGTTCACCTCGGC
C-3’, reverse   5’-CCTGCACTTCCTCTACTTGTG-3’).
Figure 2.1 Cloning of IGF-1 isoforms from mouse liver. Primer positions are indicated by black arrows. mRNA 
sequences amplified by the different primer pairs are colored according to the protein domains they encode. Red: 
signal peptide; dark red: mature IGF-1; green: E-peptides; blue: 5’ and 3’ UTRs; grey: 186 bp region in exon 1, 
which can be spliced out in 20% of total mRNA population in liver (compare 1.3.2). A Class 1 IGF-1 isoforms B
Class 2 IGF-1 isoforms 
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2.1.5.1 Design of skeletal muscle-specific expression vectors
All isoforms were cloned into an expression vector carrying the MLC 1/3 promoter and 
enhancer sequences and the SV40 poly(A) signal (pMex). The MLC regulatory sequences 
provide skeletal muscle-specific expression of the IGF-1 isoforms (Figure 2.2). 
Primers were designed to generate 5’-SacI and 3’-SalI restriction sites for each isoform and 
inserts were amplified by PCR from the different pGEM®-T Easy/IGF-1 isoform plasmids and 
gel-purified (Class 1 IGF-1: forward 5’-GAGCTCATCTCGATAACTTTGCCAGA AG-3’; Class 2
IGF-1:  forward 5’-GAGCTCATAGTTTTGTGTTCACCTCGGCC-3’; Ea-coding: reverse 5’-GTCG
ACCCTCCTACATTCTGTAGGTCTTG-3’; Eb-coding: reverse 5’-GTCGACCCTGCACTTCCTCTA
CTTGTG-3’). IGF-1 isoforms 22-IGF-1Ea (463 bp) and 22-IGF-1Eb (489 bp) were cloned 
from plasmids pGEM®-T Easy/Class 1 IGF-1Ea and pGEM®-T Easy/Class 1 IGF-1Eb with 
primers generating 5’-SacI and 3’-SalI restriction sites (22-IGF-1: forward 5’-GAGCTCAT
GAAAATCAGCAGCCTTCCAAC-3’). All primers were purchased from Invitrogen.
The PCR fragments, as well as the pMex vector were sequentially digested with first SacI 
and then SalI (NEB #R0156, #R0138), gel-purified, and ligation was carried out over night at 
16°C. All constructs were sequenced to ensure sequence integrity and linearized by EcoRI 
(NEB #R0101) digest. 
Figure 2.2 Schematic representation of skeletal muscle-specific expression cassette. Regulatory 
sequences of the pMex-derived expression cassette are shown in silver boxes, position of the cloned IGF-1 
isoform is shown as a red box. Start of the surrounding region is shown by a black line. Position of EcoRI 
restriction sites are indicated by vertical lines. The black line marks the position of the SV40-probe used for 
Northern blot characterization of the transgene expression.
2.1.5.2 Design of doxicycline-inducible expression vectors
To achieve inducible IGF-1 isoform expression, we applied the “tet-on” system [290, 291], 
kindly provided by Professor Herman Bujard from the Centre of Molecular Biology Heidelberg 
(ZMBH) of the University of Heidelberg. This inducible system consists of two expression 
cassettes, one encoding a modified tetracycline repressor protein (reverse tetracycline trans-
activator (rtTA)) under the transcriptional control of the human CMV promoter and enhancer, 
and the second one driving expression of the gene of interest by the rtTA-responsive target 
promoter. The regulatory region with a bidirectional promoter pBi-1 consists of a heptamized 
tet-operator sequence flanked by two divergently orientated human CMV minimal promoters 
(Pmin-1 and Pmin-2). Pmin-1 controls expression of the luciferase gene luc* [292] followed by 
SV40 late poly(A) signal. Pmin-2 is followed by a multiple cloning site and the rabbit ß-globin
intron/poly(A) signal and would drive expression of a selected gene of choice upon induction 
with the tetracycline derivate doxicycline [293].
MLC promoter  IGF-1 isoform SV40 PolyA  MLC enhancer
EcoRI EcoRI
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For the purpose of driving tet-inducible IGF-1 transcription, all IGF-1 isoforms have been 
cloned into the pBi-2 vector by PCR-mediated generation of 5’-NheI and 3’-EcoRV restriction 
sites (Class 1 IGF-1: forward 5’-GCTAGCCTCGATAACTTTGCCAGAAG-3’; Class 2 IGF-1: 
forward 5’-GCTAGCAGTTTTGTGTTCACCTCGGCC-3’; 22-IGF-1: forward 5’-GCTAGCGAAAATC
AGCAGCCTTCCAAC-3’; Ea-coding: reverse 5’-GATATCCCTCCTACATTCTGTAGGTC-3’; Eb-
coding: reverse 5’-GATATCCCTGCACTTCCTCTACTTG-3’ (Figure 2.3A).
All primers were purchased from Invitrogen.
Fragments and pBi/IGF-1 isoform vectors were double-digested with NheI and EcoRV (NEB 
#R0131, #R0195), gel-purified, and ligated over night at 16°C. All constructs were 
sequenced by the EMBL sequencing service prior to use. For injection of pBi/Class 1 IGF-
1B, the plasmid was linearized by digestion with AseI (NEB #R0526). 
To generate the skeletal muscle-specific rtTA expression cassette, the rtTA sequence was 
amplified from the original pUHrtTA 62-1 vector by PCR. For cloning the rtTA2SM2 sequence 
into the pMex vector, primers were designed to include 5’-SacI and 3’-SalI restriction sites 
(forward 5’-GAGCTCATATGTCTAGACTGGACAAGAGC-3’; reverse 5’-GTCGACTTACTTAGTTAC
CCGGGGAGC-3’) (Figure 2.3B). The amplified insert was gel-purified and subsequently the 
different inserts and the pMex vector were sequentially digested with first SacI and then SalI.
After gel-purification, ligation was performed over night at 16°C. Integrity of the construct was 
confirmed by sequencing. For generation of transgenic rtTA mice, the construct was 
linearized by EcoRI digest.
A
B
Figure 2.3 Schematic representation of the skeletal muscle adapted “tet-on” system. Regulatory sequences 
of both constructs are shown in silver boxes. A Inducible pBi/IGF-1 isoform expression cassette. Upon binding of 
doxicycline activated rtTA molecules to the TetO sequence, transcription of luciferase (yellow box) is driven by 
Pmin-1, while Pmin-2 regulates transcription of a given IGF-1 isoform (red box). B By regulatory sequences of the 
MLC promoter and enhancer, rtTA (blue box) transcription is restricted to skeletal muscle. 
2.1.6 Cloning of an exon 4-5 splice variant-containing IGF-1 isoforms
In an attempt to clone the mouse IGF-1 isoform coding for the Eb-peptide described in 
humans (compare section 1.4.2.6), mouse liver total RNA was prepared as described in 
2.1.10. To exclusively isolate messenger RNA, the OLIGOTEX mRNA Midi Kit (QIAgen 
#70042) was used according to the instructions. Combined RT-PCR was carried out with 1µg 
of mRNA as described in section 2.1.12, using specific primers to amplify Class 1- and Class 
LuciferaseSV40 polyA ß-globin intron/poly(A) Pmin-1 7x(TetO) Pmin-2  IGF-1 isoform
 MLC promoter        rtTA SV40 PolyA  MLC enhancer
EcoRI EcoRI
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2-derived sequences on the 5’-end and two different reverse primers that bind to sequences 
5-25 bp and 118-136 bp downstream of the 5’-splice site normally used for generation of the 
exon 4-5-6 splice variant encoding for the rodent Eb-peptide (corresponds to the human Ec-
peptide). Primer sequences were: Class 1 IGF-1: forward 5’-CTCGATAACTTTGCCAGAAG-3’, 
Class 2 IGF-1: 5’-AGTTTTGTGTTCACCTCGGCC-3’, Exon 5 (5-25): reverse 5’-ATCCCTGTTC 
CCGCATGTC-3’, Exon 5 (118-136): reverse 5’-CCTTCTGGGTGTGTCTTTGG-3’. Expected 
fragment size for Class 1 IGF-1 mRNAs combined with the (5-25) exon 5 primer were 776 bp 
for mRNAs containing the full exon 1 5’-UTR and 590 bp for Class 1 IGF-1 mRNAs 
containing the spliced exon 1 5-UTR (compare section 1.4.2). Class 1 IGF-1 mRNAs 
amplified with the (118-136) exon 5 reverse primer were expected to yield fragments of 888 
bp for Class 1 mRNAs containing the full exon 1 sequence and 702 bp for those containing 
the spliced exon 1 5’-UTR. Amplification with Class 2 IGF-1 and (5-25) exon 5 primer was 
expected to yield a single fragment of 501 bp, while the combination of Class 2 IGF-1 primer 
and the further downstream (118-136) exon primer, was expected to amplify a fragment of 
613 bp.
2.1.7      Cloning of probes for Northern blots
Probes for endogenous IGF-1 isoform detection were generated by combined reverse 
transcription PCR (compare 2.1.12), using 1 µg of total RNA from mouse liver. Specific 
primers used were:
186-exon 1 probe (spans a 186bp region in exon 1 5’UTR, which is spliced in 20% of total 
IGF-1 mRNA population in mouse liver (compare 1.4.2.5), therefore detects all mRNAs 
generated from transcription start sites one, two, and three, but not the Class 1 transgenes, 
as they do not contain this region): forward 5’-GTGAGGATTTTCTCTAAATCC-3’, reverse 5’-
GAAATGAATTGGTGGGCAG-3’. Exon 2 probe (spans 81 bps of exon 2 sequence): forward 
5’-AGTTTTGTGTTCACCTCGGCC-3’, reverse 5’-GGTGCGGTCATTTTGGTAGG-3’. Eb-probe
(spans the entire 52 bps of exon 5): forward 5’-TCCCCGTCCCTATCGACAAAC-3’, reverse 
5’-CTTTCCTTCTCCTTTGCAGCTTC-3’. IGF-1R probe (spans 339 bps of IGF-1R mRNA): 
forward 5’-CTACTGGAAGATCCGCCATTC-3’, reverse 5’-GTGGTGGAGGTGAAACGGAG-
3’. SV40-probe (spans 185bp of the most 5’-end of the SV40 poly(A) signal sequence): 
forward 5’-GATCTTTGTGAAGGAACCTTAC-3’, reverse 5’-ATTCCACCACTGCTCCCATTC-3’. 
Gata-2 probe (spans 700 bps of Gata-2 mRNA): kindly provided by Antonio Musaro from the 
University of Rome, La Sapienza.
All probe fragments were cloned into pGEM-T Easy vectors. For probe generation, plasmids 
were EcoRI-digested, gel-purified and quantified by gel-electrophoresis using a quantitative 
DNA-Ladder (MassRulerTM DNA Ladder, Mix, ready-to-use; MBI Fermentas #SM0403). All 
primers were purchased from Invitrogen.
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2.1.8      Preparation of DNA for generation of transgenic mice
All constructs selected for generation of transgenic lines were linearized as indicated above. 
The digestion products were run on ethidium bromide-free gels, excised and gel-isolated. For 
further purification, isolated fragments were ethanol precipitated by adding 1/10 volume of 
5M sodium acetate and 2.5 volumes 100% ethanol, left for up to 1 hour at -20°C, washed in 
70% ethanol, dried and re-suspended in injection buffer (10mM Tris-HCl, pH 7.5; 0.25 mM 
EDTA, pH 8.0). All injections were performed by the transgenic service of the EMBL-
Monterotondo.
2.1.9      Genomic DNA isolation from mouse-tail biopsies and genotyping
Genomic DNA was isolated from mouse tail biopsies, taken from three-weeks-old pups. Tail 
biopsies were digested over night at 65°C proteinase K (PK) (Roche #11961799)-containing 
digestion buffer (0.5µg/µl PK, 10mM Tris-HCl pH 9.0, 50mM KCl, 0.1% Triston®X-100), 
followed by a 30 min incubation at 95°C to inactivate PK. Samples were centrifuged at high
speed for 15 min and without any further purification, 2 µl aliquots were used for all 
genotyping PCR reactions.
2.1.9.1 Genotyping of IGF-1 isoform transgenic mice
To ensure presence of the different IGF-1 transgenes, primers were designed to recognize
all IGF-1 isoforms by choosing a forward primer located in exon 4 and a reverse primer 
located in the SV40 Poly(A) signal sequence adjacent to the 3’-end of the IGF-1 coding 
sequence (forward: 5’-ACTGACATGCCCAAGACTC AG-3’; reverse: 5’-ATTCCACCACTGC
TCCCATTC-3’; Invitrogen). Band sizes were 283 bp for fragments containing the exon 4-6 
splice variant (coding for the Ea-peptide) and 335 for fragments containing the exon 4-5-6 
splice variant (coding for the Eb-peptide).
2.1.9.2 Genotyping of MLC/rtTA transgenic mice
Presence of the rtTA transgene was determined using primers amplifying a region within the 
SV40 poly(A) signal (forward 5’-GATCTTTGTGAAGGAACCTTAC-3’, reverse 5’-ATTCCA
CCACTGCTCCCATTC-3’; Invitrogen). A 185 bp fragment confirmed the transgenic 
background of the analyzed mice.
2.1.9.3 Genotyping of pBi/Class 1 IGF-1Eb transgenic mice
Presence of the inducible expression cassette was confirmed by PCR using primers specific 
for the luciferase gene (forward 5’-GCGAGAATCTGACGCAGGC-3’, reverse 5’-CCGC
TAGAGGATGGAACCG-3’), amplifying a fragment of 600 bp. Primers were purchased from 
Invitrogen.
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2.1.10 Total RNA isolation from mouse tissues
Total RNA was isolated from frozen tissue following the standard TRIzol protocol (Invitrogen 
#15596-026). All equipment used was previously treated with RNAse ZAP (Ambion 
#9780;0782). Tissues were homogenized (Biospec Products, Model 985379) in the 
appropriate amount of TRIzol (50-100 mg of tissue per 1 ml of TRIzol). RNA was separated 
using the appropriate amount of chloroform, precipitated with isopropanol, and washed in 
75% ethanol. RNA was dissolved in 20-50µl of sterile water and stored at -80°C until used. 
The concentration of the RNA samples was determined by spectrophotometric measurement 
of the absorbance (A) at 260 nm and 280 nm. 
2.1.11    Total RNA isolation from cultured cells
For RNA isolation, plates were washed twice with sterile phosphate-buffered saline (PBS)
and scraped in 1ml of sterile PBS. Scraped cells were centrifuged for 5 min at 4°C and 
1.100x g, washed in 5 ml of sterile PBS and the pellet was stored at -80°C if not processed 
immediately. For total RNA isolation the SV Total RNA Isolation System (Promega #Z3100) 
was used according to the manufacturer’s instructions.
2.1.12    Combined reverse transcription (RT) PCR
Combined reverse transcription PCR was performed using the Access RT-PCR System 
(Promega #A1260), according to the manufacturer’s instructions.
1µg of total RNA was used in each reaction and combined with specific primers. Other than 
suggested by the kit’s instructions, the mixture of RNA, primers, and water was incubated on 
94°C for 2 min to avoid any secondary mRNA structures. RT-PCR was performed (Reverse 
transcription:45 min 48°C, 94°C for 2 min, PCR: 40x (94°C for 30 sec; 57°C for 1 min; 68°C 
for 2 min), 68°C for 7 min, 4°C for ever), and reaction products were stored at –20°C.
2.1.13     Reverse Transcription
For reverse transcriptions, the Ready-To-Go T-primed First-Strand Kit was used according to 
the manufacturer’s instructions (Amersham, # 27-9263-01). 1µg of total RNA was used in 
every reaction and brought up to 33µl with sterile H2O. The samples were first incubated at 
65°C for 5 min and then left at 37°C for 5 min. The reaction tubes supplied by the kit were 
incubated at 37°C for the same time. Subsequently, the RNA/H2O mix was transferred to the 
Ready-To-Go reaction tube and left at 37°C. After 10 min of incubation, the tube content was 
mixed by flicking the tube mildly and left for 1 hour at 37°C. Every reaction was then brought 
up to 200µl with sterile H20 and cDNAs were stored at –20°C until needed.
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2.1.14 SYBR green/Taqman quantitative RT-PCR
1µg of RNA was used for reverse transcription using Ready-To-Go T-primed First-Strand Kit 
described in section 2.1.13. Taqman real time PCR was performed on 1µl of cDNA using 10 
µl of the Taqman Universal PCR Master Mix (Applied Biosystems #4304437), 1µl of each 
appropriate primer (10mM), and 2µl of the Taqman probe (2mM) in a total reaction volume of 
20 µl. When SYBR green quantitative PCR was performed the same reaction conditions 
were applied, but without adding a Taqman probe. Duplicated samples were incubated at 95º 
for 3 min, followed by 45 cycles of amplification (2 min 50°C, 10 sec 95°C, 20 sec 60ºC, 30 
sec 72º). Results for each molecule were normalized to ubiquitin expression (forward 5’-
TGGCTATTAATTATTCGGTCTGCAT-3’, reverse 5’-GCAAGTGGCTAGAGTGCAGAGTAA-
3’). Specific primers used for analysis of transgenic IGF-1 isoform expression levels were:
Endogenous IGF-1 isoform expression: 
Class 1 IGF-1Ea (recognize Class 1 IGF-1Ea AND Eb): forward 5’ATTTAAGATCTGCCTCT 
GTGACTTCTT-3’, reverse 5’-TCTTGTTTCCTGCACTTCCTCTACT-3’; probe: 5’TTTACTTCAAC 
AAGCCC-3’. This is an major groove binding (MGB) probe and was labeled with FAM. Class 
1 IGF-1 Eb (recognize Class 1 IGF-1Eb): forward 5’-ATTTAAGATCTGCCTCTGTGACTTCTT-3’, 
reverse 5’-TCTTGTTTCCTGCACTTCCTCTACT-3’; probe: 5’-TCTCCTTTGCAGCTTC-3’. This is a 
MGB probe and was labeled with VIC. VIC probes can be run with FAM probes in the same 
tube and with SYBR green. FAM probes can not be run with SYBR green in the same tube. 
Class 2 IGF-1Ea (recognize Class 2 Ea AND Eb): forward 5’-TGTGTAAACGACCCGGACCTA-
3’, reverse 5’-TCTTGTTTCCTGCACTTCCTCTACT-3’; probe: 5’-TTTACTTCAACAAGCCC-3’. This 
is an MGB probe and labeled with FAM. Class 2 IGF-1Eb (recognize Class 2 IGF-1Eb): 
forward 5’-ATTTAAGATCTGCCTCTGTGACTTCTT-3’, reverse 5’TCTTGTTTCCTGCACTTCCTCT 
ACT-3’; probe: 5’-TCTCCTTTGCAGCTTC-3’. This is a MGB probe and labeled with VIC. 
All primers can be used with SYBR green, which will recognize any double stranded DNA 
present. SYBR green is compatible with VIC but not FAM-labeled probes. All primers and 
probes were designed by Leanne Felkin (Harefield Heart Science Centre, Imperial College 
London, UK) and conditions set up by Leanne Felkin and Enrique Lara-Pezzi (HHSC, ICL, 
UK / EMBL-MR).
Since Class 1 and Class 2 IGF-1Ea primer and probe sets recognize both Class 1/2 IGF-1 
Ea and Eb, values for the IGF-1Eb versions were subtracted from values for IGF-1Ea 
expression to calculate expression levels for Class 1 or 2 IGF-1Ea.
Calcineurin isoform expression: 
?????(200): forward 5’-CAAGGCGATTGATCCCA-3’, reverse 5’-TCGAAGCACCCTCTGTTA-3’;
CnAß1 (229): forward 5’-AGAAGGTGAAGACCAGT-3’, reverse 5’-AGCAAGTTGCATAACAT
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ATT-3’; CnAß2 (300 bp): forward 5’-AGGCTATTGAGGCTGAAA-3’, reverse 5’- CGGATCTC 
AGAAAGCAC -3’. All RT-PCRs for calcineurin were done with SYBR green.
Primers used for regeneration analysis: 
Pro-Collagen 1: forward 5’-GTAACTTCGTCGCTAGCAACA-3’, reverse 5’-CCTTTGTCAGAAT
ACTGAGCAGC-3’; TGF-ß1: forward 5’-CCGAAGCGGACTACTAT-3’, reverse 5’-GTAACGCC
AGGAATTGT-3’; TNF-???forward 5’-GCAAGCTTCGCTCTTCTGTCTACTGAACTTCGG-3’, reverse 
5’-GCTCTAGAATGAGATAGCAAATCGGCTGACGG-3’; MCP-1: forward 5’-CACCAGCAAGATGA
TCC-3’, reverse 5’-ATAAAGTTGTAGGTTCTGATCTC-3’; Rantes: forward 5’-ACCATCATCCTCA
CTGC-3’, reverse 5’-GATGTATTCTTGAACCCACT-3’; IL-10: forward 5’-CCAAGCCTTATCGGA
AATG-3’, reverse 5’-TGGCCTTGTAGACACC-3’
2.1.15 Northern blot analysis
For separation of RNA samples a 1.3% agarose gel containing 1x MOPS and 7% 
formaldehyde (Sigma #F-8775) was prepared. 10-15 µg of RNA were brought to 5 µl with 
sterile water and mixed with 15 µl of freshly prepared RNA loading buffer (1 volume of 
bromophenol blue-xylene cyanole dye solution (Sigma B-3269), 4 volumes of formamide 
(Sigma #F-7508), and 1µl of ethidium bromide [10mg/ml] per 100 µl of solution). Samples 
were incubated at 65°C for 10 min, chilled on ice and loaded. Gels were run at 80 V and 
photographed under a UV lamp to ensure RNA integrity.
Gels were rinsed four times five min in sterile H2O, while the nylon membrane (GeneSceen 
Plus NEF976, NENTM Life Science Products) was hydrated in sterile H2O and incubated in 
10xSSC for 15 min. The Transfer Apparatus was built following standard protocols and 
performed over night. Membranes were rinsed in 2xSSC after transfer, UV-cross linked (UV-
Stratalinker 1800, Stratagene), and baked at 80°C for 1-2 hours.
For hybridization, Northern blots were re-hydrated in 2xSSC and pre-hybridized (50% 
formamide, 1M NaCl2, 10% dextran sulfate, 1%SDS) for at least 4 hours at 42°C.
Preparation of radiolabeled probes. All probes for Northern blots were labeled by using the 
Megaprime DNA labeling system (Amersham #RPN1604) according to the manufacturer’s 
instructions. This system is based on the use of random sequence hexanucleotides to prime 
DNA synthesis on denatured template DNA. 25-50ng of DNA and 5µl of radiolabeled [α32P] 
dGTP (3000Ci/mmol) (Amersham) were used in each labeling reaction. For isolation of the 
hot probe the G-50 Sephadex Quick Spin Columns for radiolabeled DNA purification (Roche 
#11273973001) were used following the manual’s instructions. 
Hybridization of Northern blots. Prior to use, the hot probe was mixed with 150 µl of 
salmon sperm DNA per 15 ml of hybridization solution, heated at 95°C for 5 min, and chilled 
on ice for 5 min. The mixture was then added directly to the pre-hybridization solution. 
Hybridization was carried out over night at 42°C.
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blots were rinsed once in 0.2M SSC, washed in washing buffer (0.2M SSC, 0.5% SDS) for 
10 min at RT, for 20 min at RT, and for 30 min at 60°C. The solution was changed after each 
washing step. The filters were then wrapped in saran wrap and exposed to a phosphoimager 
screen for 3 hours and if needed over night.
Removal of probes from Northern blots. To remove hybridization probes, the membrane 
was boiled in stripping solution (1% SDS, 0.1x SSC, 0.015M NaCl) for 10 min. To verify 
probe removal, the membrane was wrapped in plastic wrap and exposed to a 
phosphoimager screen for 3 hours.
2.1.16 GeneChip analysis
Two one-month-old male transgenic mice and two negative littermates from each transgenic 
line were sent for for Affymetrix GeneChip analysis performed by the EMBL Genomics Core 
Facility. Total RNA from the quadriceps muscle of each mouse was isolated following the 
TRIzol protocol described in section 2.1.10. Further purification was achieved by using the 
QIAgen RNeasy Midi Kit (QIAgen #75142) according to the manual’s instructions. To ensure 
integrity of the RNA, 2µg of each sample were run on a formaldehyde gel (1.3% agarose, 1x 
MOPS, 7% formaldehyde). Functionality of the RNA samples was determined by reverse 
transcribing 1µg of each sample (Ready-To-Go T-primed First-Strand Kit compare 2.1.13) 
and performing PCR with ß-tubulin-specific primers (forward 5’-CTGGGCTAAAGGCCAC-3’, 
reverse 5’-AGACACTTTGGGCGAG-3’).
Micro array analysis. Two transgenic and two control RNA samples from each animal 
model were hybridized to Affymetrix MO430-2 Mouse Genome Array chips. The screen 
returned 22626 probe set signals. With the great help of Tommaso Nastasi those data sets 
were then analyzed as follows. In order to reduce variances due to the background of each 
transgenic model, we calculated the average values and variability of the total eight control 
mice analyzed, and excluded the probe-sets that did not show consistent signal among the 
different wildtype controls. We also excluded probe-sets that showed a low signal or high 
variability in all of the sample groups analyzed, i.e. wildtype (WT) and the four IGF1 isoform 
transgenic samples. This initial filtering returned 15333 probe sets valid for analysis. For 
every transgenic model we selected all the probe sets that either showed an increase or 
decrease by 1.9 fold, compared to WT values. Within this pool of genes we then identified 
the probe sets that showed increase (or decrease) by 1.9 fold only in the model under focus 
and a signal ratio of 1.3 or less (or -1.3 or more) in the other 3 models (unique probe sets).
The distribution of the selected genes by cellular localization was performed by using the 
Gene Ontology database information available for the different probe sets at the Affymetrix 
website (www.affymetrix.com). Pathway analysis was performed using a trial account on the 
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Ingenuity Pathway Application server, based on the proprietary knowledge database of this 
company (www.ingenuity.com).
For the comparison of genes whose altered expression could be relevant for a Class- or E-
peptide-specific IGF1 function, the reduced filtered array of 15333 probe sets was analyzed 
as follows. We grouped the four samples by either Class or E-peptide feature (2 Class 
groups and 2 E-peptide groups); a cut off value of fold-induction of 1.3 was set for either up-
regulated or down-regulated genes; all the genes that resulted up-regulated in both samples 
of the analyzed group AND down-regulated or unchanged in the opposing group OR the 
genes that resulted down-regulated in the analyzed group AND up-regulated or unchanged 
in the opposing group were selected.
2.2 Cell Biology
2.2.1      Established myoblast cell cultures and transfection
L6E9 and C2C12 cells were plated and extended in growth medium (GM: 20% fetal bovine
serum (FBS) (Gibco #10270-106), 2mM L-glutamine (Gibco #25030-024), 1mM Na-pyrovate 
(Gibco #11360-039), 10mM HEPES (Gibco #15630-056), 1x penecillin/ streptomycin (Gibco
#15140-122) in Dulbecco’s Modified Eagel Medium (DMEM) (Gibco #41965-039)). L6E9 
cells were differentiated in differentiation medium (DM), containing 1% albumin (Sigma #A-
8806), 2mM L-glutamine, 1mM Na-pyrovate and 1x penicillin/ streptomycin. C2C12 cells 
were differentiated in DM containing 2% horse serum (Gibco #26050-088), 2mM L-
glutamine, 1mM Na-pyrovate, 10mM HEPES and 1x penicillin/ streptomycin.
Transient transfections of L6E9 cells were done with LipofectamineTM 2000 (Invitrogen 
#11668-019), using a modified protocol: the cells were plated at a concentration of 200.000 
cells/ml the day before the experiment. Prior to transfection, cells were washed three times in 
plain DMEM and incubated in DMEM containing 10% FBS, 2mM L-glutamine and 1mM Na-
pyrovate for at least 30 min before transfection. For transfection of one 10 cm plates a total 
of 24µg of DNA was used as suggested by the protocol and diluted in 1.5ml of DMEM only 
substituted with 1mM Na-pyrovate and 2mM L-glutamate. For the double-transfections with 
the two necessary plasmids of the tet-on system (compare section 2.1.5.2) a ratio of 1 
(pBi/IGF-1 isoform x): 3 (pUHrtTA) was used. For every 10 cm plate 60µl of LipofectamineTM
were diluted in DMEM containing 1mM Na-pyrovate and 2mM L-glutamine and both solutions 
were incubated for 5 min at RT. The solutions were then combined, incubated for another 20 
min at RT and added to the pre-incubated plates for at least 5 hours. After the transfection 
incubation, the medium was exchanged with DMEM containing 10% FBS, 2mM L-glutamine, 
1mM Na-pyrovate, 10mM HEPES and 1µ/ml doxicycline and the plates were incubated over 
night. After about 12 hours, the medium was exchanged with doxicycline-substituted (1µg/ml) 
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DM. The preparation of RNA and protein samples is described in sections 2.1.11 and 2.3.2
respectively. 
2.2.2      Skeletal muscle primary cell cultures
Whole legs from 2-5 days old pups were incubated in penicillin/ streptomycin/ gentamycin 
(400µg/ml) (GIBCO #15750-045) for 15 min. All skeletal muscle groups from 4-6 legs were 
removed carefully and chopped into small pieces. Enzymatic desegregation was achieved by 
30 min incubation at 37°C each in first collagenase (1mg/ml) (Sigma #C-5138) and then 
collagenase/ dispase (1mg/ml) (Sigma #C-3180) solutions. Enzymatic reactions were 
stopped by adding the appropriate amount of horse serum (GIBCO #26050-088). The 
solution was filtered twice to remove cell debris (70µm and 40µm cell strainer filters (Falcon 
#352350 and #352340)) and then centrifuged (10 min at 1100 rpm). The cell pellet was 
dissolved in the appropriate amount of GM (20% horse serum, 3% chicken embryo extract 
(ICN #2850145), 1mM Na-pyrovate, 2mM L-glutamine, XM HEPES, 1x penicillin/ 
streptomycin and 0.8µg/ml gentamycin (Gibco #15750-045) in DMEM) and pre-plated twice 
for 30 min each to reduce the number of fibroblasts. Cells were plated in 3cm petri dishes 
and left over night in GM. Medium was changed to DM (5% horse serum, 4mM L-glutamine, 
10mM HEPES and 1x penicillin/ streptomycin) after 24 hours to induce differentiation of the 
myoblasts.
2.3 Biochemistry
2.3.1      Preparation of protein lysates from mouse skeletal muscle
Frozen tissues were homogenized using a 2 ml tissue grinder (WHEATON #358003) at 4°C 
in the appropriate amount of  lysis buffer (20mM Tris pH 7.5, 5mM MgCl2, 150mM NaCl, 1% 
SDS, 1mM NaVO4, 1mM NaF, 1mM PMSF; for 5ml of final lysis buffer, one tablet of 
Complete Mini Protease Inhibitors (Roche #11836170001) was added). For 
immunoprecipitation, a milder lysis buffer was used (20mM Tris pH 7.5, 5mM MgCl2, 150mM 
NaCl, 1% NP40, 0.1% TritonX, 1mM NaVO4, 1mM NaF, 1mM PMSF; for 5ml of final lysis 
buffer, one tablet of Complete Mini Protease Inhibitors was added). Samples were sonicated 
for 20-30 sec, centrifuged (10 min at 4°, 14.000 rpm), and protein concentration of the 
supernatant was determined by Bradford assay (Bio-Rad Protein Assay Dye Reagent 
Concentrate #500-0006). All protein extracts were stored at -80°C until needed.
2.3.2      Preparation of protein lysates from cultured cells
Cultured cells were washed twice in sterile PBS and scraped in the appropriate volume of 
lysis buffer (20mM Tris pH 7.5, 5mM MgCl2, 150mM NaCl, 1% SDS, 1mM NaVO4, 1mM NaF, 
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1mM PMSF; for 5ml of final lysis buffer, one tablet of Complete Mini Protease Inhibitors was 
added). Lysates were sonicated for 20-30 sec, centrifuged for 10 min at 4°C and 14.000 rpm, 
and protein concentration of the supernatant was determined by Bradford assay. Protein 
extracts were stored at -80°C until needed. 
2.3.3.     Preparation of protein lysates from cultured cells for luciferase assay
For detection of luciferase in protein lysates the Promega Luciferase Assay System (#E1500) 
was used according to the manufacturer’s instructions. Cells were washed twice in sterile 
PBS, scraped in 300µl 1x lysis buffer (provided by the Assay System), and after transfer into 
a suitable tube incubated on ice for 12 min. Luciferase activity was measured immediately or 
samples were frozen at -20°C until needed. The measurements were done on 5µl of 1:500 
diluted protein lysates for 10 seconds.  
2.3.4      Immunoprecipitation
Protein extracts were prepared as described in section 2.3.1 and immediately used for 
immunoprecipitation. The appropriate amount of protein A (Sigma #P-3391) was left to swell 
in 1ml of PBS for 10 min at RT and centrifuged for 30 seconds at 4°C and maximum speed. 
Supernatant was removed and PBS was added for equal distribution of protein A to the 
desired number of tubes. 1 ml of lysis buffer stock solution (without inhibitors) was added and 
left for 10 min for equilibration. After centrifugation for 30 seconds, 4°C and maximum speed, 
the supernatant was removed and 150µl of lysis buffer stock solution substituted with the 
appropriate amount of antibody (diluted according to the manufacturer’s description) 
(compare table 1) were added and incubated rotating over night at 4°C. 2-4mg of protein 
sample were added to the pre-incubated tubes and left rotating for 1.5 hours at 4°C. Samples 
were washed four times with 1ml of lysis buffer stock solution. 30µl of 2x SDS-loading buffer 
(100mM Tris pH 6.8, 4% SDS, 20% glycerol, bromophenol blue) without DTT were added to 
each sample and specimens were frozen at -20°C until used for Western blot analysis.
Primary Antibody Description Company
Anti-IGF-1Receptor ß Rabbit polyclonal Cell Signaling #3027
Table 1 List of primary antibodies used for immunoprecipitation.
2.3.5      Western blot analysis
For SDS-page, proteins were diluted in 2xSDS sample buffer (100mM Tris pH 6.8, 4% SDS, 
20% glycerol, bromophenol blue), denatured by boiling for 5 min and subjected to gel-
electrophoresis. If immunoprecipitated samples were used, DTT to a final concentration of 
2mM was added to each sample prior to boiling. Proteins were electrophoretically transferred 
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onto a polyvenylidene difluoride (PVDF) membrane (Amersham), which has been activated 
for 10 seconds in methanol (Fluka #65542) and equilibrated in transfer buffer (14.45g Glycin, 
3g Tris-baze, 0.75g SDS, ad 800ml with H2O and 200 ml methanol) prior to transfer. 
Transfer was carried out in a wet transfer apparatus for 1.5 hours at 100V. After transfer 
membranes were left in methanol for 10 seconds, dried and incubated in blocking solution 
(5% non-fat powder milk (Roth #T145.2)) dissolved in TBST buffer (20mM Tris pH 7.5, 
140mM NaCl, 0.1% Tween20) for 1 hour up to over night. Primary and secondary antibodies 
were diluted in blocking solution to the dilutions indicated by the company if not otherwise 
specified (Tables 2 and 3). Membranes were washed 3 to 4 times in TBST buffer between 
primary and secondary antibody incubations. To detect specific bands the enhanced 
chemiluminescence system (ECLTM) Western Blotting Detection Reagent (Amersham 
#RPN2106) was used, followed by the exposure to HyperfilmTM ECL films (Amersham 
#RPN3103K).
Primary Antibody Description Company
Anti-IGF-1 Goat polyclonal R&D Systems
Anti-phospho histone H3 Rabbit polyclonal Cell Signaling
Anti-histone H3 Rabbit polyclonal Cell Signaling
Anti-phospho Akt Mouse monoclonal BD Pharmingen
Anti-???????? Mouse monoclonal BD Pharmingen
Anti-phospho SAPK/JNK Rabbit polyclonal Cell Signaling
Anti-JNK1 Rabbit polyclonal Santa Cruz
Anti-phospho p44/42 MAPK Mouse monoclonal Cell Signaling
Anti-p44/42 MAPK Rabbit polyclonal Cell Signaling
Anti-phospho p38 MAPK Rabbit polyclonal Cell Signaling
Anti-p38 (C-20) Rabbit polyclonal Santa Cruz
Anti-myogenin (Clone FD5) Mouse monoclonal Santa Cruz
Anti-MEF2C Rabbit polyclonal Cell Signaling
Anti-phospho S6 ribosomal protein Rabbit polyclonal Cell Signaling
S6 ribosomal protein Rabbit polyclonal Cell Signaling
Anti-mouse IGFBP-5 Rat monoclonal R&D Systems
Anti-?-tubulin Mouse monoclonal Sigma
Anti-Phosphotyrosine
Clone 4G10
Mouse monoclonal Upstate
Table 2 List of primary antibodies used in Western blot analysis
Secondary Antibody Description Company
Donkey-anti-rat IgG Polyclonal Jackson IR
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ECL Anti-rabbit IgG Polyclonal Amersham
ECL Anti-mouse IgG Polyclonal Amersham
Rabbit Anti-goat IgG HRP Polyclonal Chemicon
Table 3 List of secondary antibodies used in Western blot analysis
2.3.6      Generation of IGF-1 antibodies
Since IGF-1 isoform-specific antibodies are not available yet, we tried to raise Ea- and Eb-
peptide-specific antibodies. Antigenic peptide sequences were selected (pan-IGF-1 (to 
recognize mature IGF-1): VDECCFRSCDLRRLE; Ea-peptide: EVHLKNTSRGSAG; Eb-peptide: 
KKTKLQRRRKGSTFE) and synthetic peptides were produced by Sigma-Genosys. Generation 
of polyclonal rabbit antisera was also done by Sigma-Genosys. We received four bleedings 
for each injected rabbit (two rabbits per peptide) that were tested by ELISA (data not shown) 
and Western blot (data not shown). Pan-IGF-1 and Ea-specific antibodies failed to give a 
specific signal in western blot analysis, while Eb-specific antibodies detected Eb-peptide-
containing isoforms specifically (Figure 2.4). In a second attempt, the same synthetic 
peptides were used to raise monoclonal antibodies by the EMBL Monoclonal Antibodies 
Core facility. No positive clones were received for the Ea- and Eb-peptide injections, but two 
positive clones were obtained for pan-IGF-1 (Figure 2.4)
Figure 2.4 Generation of IGF-1 antibodies. 50µg of protein from IGF-1 isoform transfected cells were separated
by SDS-page and transferred for Western blot analysis. The upper panel shows one of two obtained positive 
clones of an antibody directed against mature IGF-1. This antibody therefore detects each IGF-1 isoform. The 
lower panel shows detection of only Eb-peptide containing isoforms with a polyclonal antibody directed against 
the Eb-peptide.
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Materials and Methods page 68
2.3.7      Immunoenzymometric assay (IEMA)
To determine circulating IGF-1 levels, the OCTEIA Rat/Mouse IGF-1 IEMA for the 
quantitative determination of IGF-1 in rat and mouse serum or plasma was used (iDS, AC-
18F1) according to the instructions. Sampling of blood and isolation of serum is described in 
2.5.1. Results were calculated by logarithmic plotting of the mean absorbance of each 
calibrator (provided by the kit) on the ordinate against concentration of rat IGF-1 on the 
abscissa. Values for controls (provided by the kit) and the unknown samples were read from 
the calibration curve in ng/ml.
2.4 Histochemistry
2.4.1 Processing of tissues for frozen and paraffin sections. 
Tissues collected for frozen sections were excised and frozen as described in section 2.5.1. 
Transverse sections of the mid belly region of the frozen muscle were cut on a cryostat, 
collected onto SuperFrost®Plus glass slides (Menzel-Glaeser), air-dried, and stored at -80°C 
until used.
Tissues sampled for paraffin sections were removed as described in section 2.5.1, fixed in 
4% paraformaldehyde (Sigma #P6148)) for 30 min, washed in 2 x 5 min in 1x PBS, and 
dehydrated by incubation in ethanol solutions of increasing percentage (2x30 min in 50%, 
2x30 in 70%, 1x30 min in 95%, and 2x30 min in 100% ethanol). Tissues were washed 3x15 
min in xylene (Riedel-de Haen #33817), incubated in a 1:1 paraffin wax/xylene mix at 60°C 
for 30 min, and after six changes of paraffin wax (1 hour per incubation), tissues were 
embedded in fresh paraffin wax and left over night to dry. Sections were cut at a thickness of 
8µm.
2.4.2 Double Immunohistochemistry
The VECTOR® M.O.M. Immunodetection Kit (VECTOR Laboratories #BMK-2202) was used 
according to the instruction manual. Frozen muscle sections (8µm) were equilibrated to room 
temperature, re-hydrated in PBS, and incubated for 1 hour in M.O.M Mouse Ig blocking 
reagent. Sections were washed twice for 2 min in PBS and incubated for 20 min in working 
solution of M.O.M diluent, which was removed afterwards. The primary type IIB myosin 
antibody was a kind gift from Miranda Grounds and applied as an undiluted supernatant over 
night at 4°C. Slides were equilibrated to room temperature and washed twice for 2 min in 
PBS. Pan-laminin (Sigma #L-9393), diluted 1:200 in M.O.M. diluent, was applied as the 
second primary antibody and incubated at 37°C for 1 hour, followed by two PBS washing 
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steps for 2 min each. The secondary antibody biotin-conjugated goat anti-mouse IgM (Sigma 
#B-9265) was diluted 1:250 in M.O.M. diluent, and incubated for 1 hour at RT. Sections were 
washed twice for 5 min in PBS. Anti-type IIB myosin antibody was detected by incubation 
with streptavidin ALEXA 488 (Molecular Probes #S-11223), diluted 1:3000 in 0.1% BSA, and 
Pan-laminin was visualized by incubation with goat anti-rabbit ALEXA 594 (Molecular Probes 
#A-11012), diluted 1:250 in 0.1% BSA. Incubation was carried out for 1 hour at RT, followed 
by two 5 min washing steps in PBS. Nuclei were stained with HOECHST for 2 min. Slides 
were washed twice for 5 min in PBS and mounted with Aqua-Mount (Lerner Laboratories 
#13800). 
2.4.3 Haematoxilin/Eosin Staining
Paraffin sections were incubated in xylene for 3 min, re-hydrated with 1 min ethanol washes 
of decreasing percentage (100%, 70%, 50%), washed in dH2O, and incubated in Harris 
Haematoxilin solution (Sigma-Aldrich #HHS16) for 1 min. Slides were washed in dH2O, 
treated with acidic alcohol (1% HCl, 70% ethanol) for 30 seconds, washed again in dH2O, 
and left in 1% eosin solution for 30 sec. After a dH2O wash, sections were transferred to 95% 
ethanol (30 seconds), 100% ethanol (1-2 min), an then left in xylene for at least 3 min until 
mounted (Eukitt quick hardening mounting medium, Fluka #03989).
2.4.4 Trichrome Staining
Paraffin sections were deparaffinized by three 5 min washes in xylene, followed by 3 min 
ethanol washes of decreasing percentage (100%, 95%, 80%, and 70%). Sections were then 
fixed for 15 min at 56°C in Bouin’s solution (Sigma-Aldrich #HT10-1-32) and washed in 
running tap water. Nuclear staining was achieved by 5 min incubation in Weighert’s iron 
haematoxilin solution (Sigma-Aldrich #HT 1079-1Set). Slides were washed in dH2O and 
stained 5 min in Biebrich scarlet-acid fucsin (Sigma-Aldrich #HT 1079-1Set) and washed 
again. After 10 min incubation in phosphotungstic/ phosphomolybdic acid solution, sections 
were stained for collagen (5 min) in aniline blue (Sigma-Aldrich #HT 1079-1Set), then treated 
with 1% acetic acid for 2 min, and washed in dH2O. Sections were then dehydrated by 
ethanol washes of increasing percentage (70%, 80%, 95%, and 100%), cleared in xylene for 
3min, and mounted (Eukitt quick hardening mounting medium).
2.4.5 Nicotinamide Adenine Dinucleotide Nitro-Blue Tetrazolium (NADH)-TR 
Staining
Histochemistry with NADH was used to differentiate fast, intermediate, and slow fibers [294]. 
Frozen muscle sections (8µm) were incubated in NADH-TR solution (1 volume NADH 
solution (Sigma #N-8129): 1 volume nitro blue tetrazolium (NBT) solution (Sigma #N-6876))  
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for 30 min at 37°C, followed by 3 washes in distilled deionized water (ddH2O) and 3 changes 
of increasing (30, 60, 90%) and decreasing acetone solutions (30 seconds each) to remove 
unbound NBT. Slides were rinsed with ddH2O and mounted with Aqua-Mount (Lerner 
Laboratories #13800).
Morphometric analysis was performed on digital images taken by a camera (Nikon DXM 
1200F) connected to a Leica PM RBE microscope. Non-overlapping images were taken of 
the entire cross-sectional area of the muscle using ImagePro Plus 4.0 (Microsoft) software 
and tiled to reconstitute the whole image of the muscle. CSA of fast, intermediate, and slow 
fibers was measured by tracing individual myofibers using ImagePro Plus 4.0 or 
MetaMorphTM (Universal Imaging Corporation). Fast, intermediate, and slow fibers were 
measured in the whole muscle section from four individual mice of each transgenic line and 
genotype.
2.5 Animals
Animals were housed in individual ventilated cages and maintained on a 12 hour light/dark 
regime with free access to standard chow and drinking water. All experiments were 
performed according to the EMBL ethical committee. In all cases the FVB strain of mice was 
used.
2.5.1 Experimental procedures
Dissection of mice. Animals were sacrificed by asphyxiation with CO2 and cervical 
dislocation. The body weight was determined and tissues were removed and weighted. 
For RNA and protein analysis, tissues were snap-frozen in liquid nitrogen, and then stored at 
-80°C until needed. For preparation of frozen sections, tissues were cut transversely in the 
central area, mounted onto tragacanth gum (Sigma #G-1128), and snap-frozen in liquid 
nitrogen-quenched isopentane (BDH #294526G). For paraffin sections, tissues were fixed in 
4% paraformaldehyde for 30 min. and processed as described in 2.4.1. If blood samples 
were taken, animals were sacrificed by asphyxiation with CO2. The chest was opened and 
blood samples were taken directly from the heart and kept at 4°C over night. Blood serum 
was separated by centrifugation of blood samples (4°C, 14.000rpm for 20 min.). Serum 
samples were stored at -80°C until needed. 
Cardiotoxin injections. Three-month-old mice were anesthetized by injecting the 
appropriate amount of 2.5% avertine (2,2,2-Tribromoethanol; Sigma-Aldrich #T48402), which 
was determined by the body weight of the animal. The left leg was shaved and 5µl of 10µM 
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cardiotoxin (Latoxan #L8102) was injected in five different points in the TA muscle (total of 
25µl) and in eight different points in the quadriceps muscle (total of 40µl). Cardiotoxin is a 
specific inhibitor of the protein kinase C isolated from Naja nigricollis snake venom and leads 
to depolarization of skeletal muscle fibers [295]. The right leg was used as a control. Animals 
were sacrificed after two, five, and ten days. The TA muscle was used for paraffin sections, 
while the quadriceps was removed for RNA and protein analysis.
2.5.2 Electrophysiology 
For the in vitro analysis of the mechanic properties of IGF-1 isoform transgenic skeletal 
muscle, an isometric protocol described below was applied. All experiments have been 
performed by Emanuele Rizzuto from the University of Rome, La Sapienza (Group of 
Antonio Musaro).
The muscle to be tested was vertically mounted in a temperature controlled chamber (30°C), 
where it was immersed in a continuously oxygenated Krebs-Ringer bicarbonate buffer 
solution. One end was linked to a fixed clamp while the other end was connected to the 
lever-arm of an ASI 300b Dual-Mode actuator/transducer with a non-compliant nylon wire.
The protocol is based on the appropriate electrical stimulation that is achieved by keeping 
the excised muscle in the bathing solution, which is connected to a couple of electrodes, and 
by the simultaneous acquisition of the evoked force. The muscle was initially stimulated with 
three 0.5ms single pulses (twitch) and subsequently with three trains of 0.1ms pulses 
performed at a typical summation frequency (120Hz pulses for 0.6s for the EDL muscles, 
30Hz pulses for 1s for the soleus muscles). To evoke tetanic force the muscle was then 
stimulated with two trains of 0.1ms pulses (180Hz pulses for 0.6s for the EDL muscles, 60Hz 
pulses for 1s for the soleus muscles). Finally the muscle was subjected to a series of closer 
trains of pulses to induce isometric fatigue (120Hz pulses for EDL and 60Hz pulses for 
soleus for 0.4s every just 1s).
During the first twitch we measured twitch force and contraction time (Figure 2.5 A), while 
during the first train of pulses at tetanic frequency the maximum force was acquired (Figure 
2.5 B). Dividing this value of force for the weight of each muscle we obtained the values for 
the specific force (N/g). Finally, during the fatigue stimulation we measured the skill of the 
muscle to resist to repeated stimulations measuring the time (fatigue time) it needs to half the 
value of its own maximum force (Figure 2.5 C).
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Figure 2.5 Electrophysiological analyses of skeletal muscle. A Measurement of maximal twitch force (red 
arrow) and contraction time (red parenthesis) by single pulse stimulation B Measurement of the maximal force 
(titanic force) by pulse train stimulation D Measurement of the fatigue time (time the muscle needs to half its 
maximum force) by pulse train stimulation 
2.6 Statistical analysis
Statistical analysis was performed using the student’s t test (tail 2, type 2) and differences 
were considered significant when p-value was <0.05.
A
C
C
B
Tetanic force
FatigueSingle twitch
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3 Results
3.1 A rodent IGF-1 isoform containing a third E-peptide
In rodents, two 3’ splice variants have been described, encoding different E-peptides. The 
rodent and human Ea-peptides share extensive homology, whereas the second rodent E-
peptide (Eb) corresponds to the Ec peptide in human nomenclature (discussed in section 
1.4.2.6). The possible existence of an exon 4-5 splice variant, which encodes a third E-
peptide in humans (confusingly named Eb-peptide), was also predicted in rats [176], but 
since it was not detected in rat liver using Northern blot analysis, it was assumed that the 
human Eb splice variant does not exist in rodents (compare section 1.4.2.6). This section 
describes the cloning of a mouse Class 2 IGF-1 isoform containing the exon 4-5 splice 
variant, which we term En-peptide.
Forward primers were designed to bind to exon 1 or 2, thereby amplifying Class 1 or Class 2 
isoforms, and reverse primers were designed to bind to two different regions in the intron
sequence downstream of the 52 bp region (bp 5-25 and 118-136) that until now was 
considered to represent rodent exon 5 (section 2.1.6). By choosing such primer pairs, Class 
1 and Class 2 isoforms containing the exon 4-5 splice variant were expected to be amplified. 
Since liver is the one tissue in the body that is known to express all IGF-1 isoforms, total 
RNA isolated from three-months-old mouse liver was chosen for RT-PCR (Figure 3.1A). RT-
PCR with the primer pair Class 1 and (5-25) did not yield any fragments, while primer pairs 
Class 1 and (118+136) amplified four fragments, but only one showed the expected size (702 
bp). RT-PCR performed with primers for Class 2 and (5-25) yielded two fragments with one 
being of the expected size (501 bp), and primers for Class 2 and (118-136) amplified one 
613 bp fragment (Figure 3.1 A). DNA fragments of expected sizes were sub-cloned and 
sequenced. Analysis of the sub-cloned sequences revealed that the 702 bp fragment 
obtained from RT-PCR with Class 1 and (5-25) and the 501 bp fragment from RT-PCR with 
Class 2 and (5-25) were unspecific, while the 613 bp fragment amplified with Class 2 and 
(118-136) primers represented a Class 2 IGF-1 isoform encoding the third E-peptide 
described in humans (human Eb-peptide). To avoid more confusion in the nomenclature of 
IGF-1 isoforms and E-peptides, we termed this third rodent version Enew-peptide (En-
peptide). The En-peptide could only be amplified together with the Class 2-specific primers, 
suggesting that no Class 1 IGF-1En isoforms are expressed in the liver. 
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Analysis of the mRNA sequence of the En-peptide revealed a TAG stop codon 141 bp 
downstream of the exon 5 start as well as four AATATA polyadenylation signals (458, 569, 
2888, and 5178 bp downstream of the exon 5 start respectively). No consensus AATAAA 
polyadenylation signals could be predicted. Further characterization is needed to identify the 
functional poly(A) addition sites of the exon 5-encoded 3’-UTR for this splice variant. 
The mouse exon 4-5 splice variant encodes a 63 amino acid En-peptide sequence (16 aa 
encoded by exon 4 and 47 aa encoded by exon 5), while the human counterpart (Eb-peptide 
in humans) encodes a 77 amino acid E-peptide (16 aa from exon 4 and 61 aa from exon 5) 
and there is only 57% homology between the common N-terminal 63 amino acids of those 
two sequences. Most importantly, the predicted amino acid sequence encoded by the mouse 
exon 4-5 splice variant does not contain a GKKK signal for proteolytic cleavage and peptidyl 
C-terminal amidation, which has been shown to be used in human Eb-peptides to generate 
the IGF-1B(103-124) E1amide (IBE1) [296]. Synthetic IBE1 has been shown to have 
mitogenic effects on normal and malignant human bronchial epithelial cells and to bind to 
specific high-affinity receptors [296]. In addition, the mouse exon 4-5 splice variant lacks a 
nuclear and nucleolar localization signal (KKGK), which has also been described for the 
human Eb-peptide and has been shown to direct this human IGF-1 isoform to the nucleolus 
[199] (Figure 3.1 B). Further analysis will therefore be necessary to determine whether the 
rodent En variant is functionally equivalent to the longer human Eb variant.
Figure 3.1 Cloning and preliminary characterization of the rodent En-peptide. A Cloning of an exon 4-5-
containing IGF-1 mRNA. 1µg of mRNA isolated from mouse liver was used for RT-PCR. Fragments of the 
expected size are indicated by a red arrow. B Comparison of IGF-1 exon 5 -encoded human, rat and mouse 
amino acid sequences. Peptide sequences shown to be important in the human Eb-sequence are indicated. C
Expression pattern of the Class 2 IGF-1En isoform in mouse tissues. 1µg of total RNA was used for RT-PCR.  
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Results page 75
To evaluate the expression of the mouse Class 2 IGF-1En isoform, RT-PCR was performed 
(Figure 3.1 C). Total RNA was isolated form mouse brain, liver, skin, kidney, testis, lung, 
heart, spleen, intestine, and stomach, as well as from the skeletal muscles quadriceps, 
gastrocnemius, pectoralis, and the diaphragm. Using this approach, no specific signals could 
be detected in any of the tissues analyzed for expression. In contrast to the RT-PCR 
performed for initial amplification of this isoform, where mRNA was used, expression analysis 
was performed with total RNA. Even in liver mRNA, expression of the Class 2 IGF-1En 
isoform was very weak, which might be the reason why amplification from total RNA gave a 
negative result.
Since identification of this isoform was not the focus of this thesis no further experiments 
were performed, which are clearly needed for deeper characterization of this isoform and its 
significance.  
3.2 Effects of IGF-1 isoform over-expression in vitro
In the past decades, numerous studies on the effects of IGF-1 on skeletal muscle cell 
proliferation and differentiation have been performed in tissue culture [215, 297]. Established 
cell lines that have been very useful fur such studies are C2C12 cells, a myoblast cell line 
isolated from mouse satellite cells, and L6E9 cells, a sub-clone of the parental rat neonatal 
myogenic line, which does not express endogenous IGF-1. The L6E9 cell line also lacks 
expression of other myogenic regulator proteins, such as MyoD, but does express the IGF-1 
receptor. The L6E9 cell line is therefore especially useful for studying the effects of single 
IGF-1 isoform over-expression. An earlier study described the stable transfection of L6E9 
cells with the Class 1 IGF-1Ea isoform (mIGF-1), which resulted in myotube hypertrophy, 
accompanied by the activation of the neonatal myosin heavy chain (MyHC) isoform (L6E9 
cells normally only express the embryonic MyHC isoform). Expression of the mIGF-1 isoform 
also increased expression of myogenin, muscle creatine kinase, ß-enolase, and IGFBP-5, 
and activated the MEF2C gene, which is normally silent in this cell line [278]. Stably 
transfected cells described in this study, expressed the mIGF-1 transgene under the control 
of the MLC promoter, which is only activated upon differentiation, thereby restricting the 
analysis to the post-mitotic effects of IGF-1. In contrast, the system applied in the present 
work drives transcript expression from an inducible hCMV promoter, which allows the 
analysis of the IGF-1 isoform actions at all stages of development. The effects of IGF-1 
isoforms on proliferation and differentiation of L6E9 cells are described in this section. 
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3.2.1     Transient transfection of L6E9 cells with inducible IGF-1 constructs
To test the differential function of IGF-1 isoforms in vitro, the “tet-on” system described in 
section 2.1.5.2 was applied. In an initial test experiment, cells were double-transfected with 
the original pBi-2 vector (only coding for luciferase) and the original pUHrtTA 62-1 plasmid to 
determine the induction efficiency of this inducible system (described in section 2.2.1). 
Results shown in Figure 3.2 A demonstrate the functionality of the system. Highest induction 
was achieved in growth medium (GM), where luciferase activity was increased 3152-fold. 
Throughout the four days of differentiation, luciferase activity decreased but was still 
sufficiently induced (464-fold at day 1, 138-fold at day 2, 70-fold at day 3, and 64-fold at day 
4). The decrease of luciferase signal in the subsequent days is most likely due to a dilution 
effect of the transfected plasmids. Since no genome-integration appears in transient 
transfections, the plasmids are not equally inherited by daughter cells and therefore become 
diluted with ongoing cell replication in GM.
In order to test the effect of inducible IGF-1isoforms on L6E9 proliferation and differentiation, 
cells were double-transfected with plasmids encoding the different IGF-1 isoforms and 
luciferase driven by the inducible tetO/ hCMV Pmin-1 and Pmin-2 promoter (pBi/IGF-1 isoform X) 
on the one hand, and the rtTA protein under control of the human CMV promoter (pUHrtTA) 
on the other hand (described in section 2.1.5.2). Control cells were transfected with the 
empty pBi-2 vector and pUHrtTA (mock control). Luciferase and IGF-1 isoform expression 
was induced five hours after transfection by addition of the tetracycline derivate doxicycline 
(1µg/ml) to the medium. Cells were kept in GM for 24 hours after doxicycline-induction and 
then shifted to differentiation medium (DM) for four days. Expression of the IGF-1 isoforms 
throughout the experiment was confirmed by RT-PCR (Figure 3.2 B). Further confirmation of 
IGF-1 transgene expression was achieved by monitoring luciferase expression throughout 
the experiment, which also allowed for a comparison if IGF-1 isoform expression levels. 
Results shown in Figure 3.2 C show that luciferase activity was strongest shortly after 
doxicycline induction in GM (4012-fold in mock controls, 1072-fold in Class 1 IGF-1Ea 
cultures, 2068-fold in Class 2 IGF-1Ea, 1823-fold in 22-IGF-1Ea, 903-fold in Class 1 IGF-
1Eb, 2589-fold in Class 2 IGF-1Eb, and 1435-fold in 22-IGF-1Eb transfected cells). Due to 
differences in transfection efficiency, a high variation has to be taken into account, but all of 
the differently transfected cultures continued to demonstrate a sufficiently high level of IGF-1 
transgene-induction, even though total values decreased after shift to DM (ranging from 139-
fold to 489-fold at day one, from 78-fold to 346-fold at day two, from 74-fold to 277-fold at day 
three, and from 59-fold to 746-fold at day four). However, induction levels at all time points 
were considered sufficient to study IGF-1 isoform induced differences.
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Figure 3.2 Expression analyses of transiently transfected L6E9 cells. A Pattern of luciferase activity in 
control transfected L6E9 cells. B RT-PCR analysis on 1µg of total RNA isolated from differently transfected cells 
at all time points. C Luciferase activity in IGF-1 isoform transfected L6E9 cells. Luciferase assay was performed 
on 5µl of 1:500 dilutions of protein lysates prepared for every time point. Measurements were done for 10 
seconds. D Western analysis of IGF-1 isoform expression. 50µg of protein were loaded for each sample. 
Molecular weights (kDa) of prepro IGF-1 isoforms are indicated above the appropriate band.
Results obtained by Western blot analysis show that in comparison to the mock control, 
where IGF-1 protein was not detectable, all transfected cultures over-expressed IGF-1 
protein at all time points surveyed (Figure 3.2 D). Interestingly IGF-1 protein was detected in 
unprocessed form during growth (GM) and appeared to be processes only upon shift to DM, 
shown by the appearance of multiple bands corresponding to the different processed forms 
of IGF-1 (with signal- and E-peptide, without signal-, but with E-peptide, and in case of Ea-
peptides containing isoforms, two additional bands are detected, most likely representing 
glycosylated versions of these isoforms). Notably, at no stage of proliferation and 
differentiation were the IGF-1 isoforms processed to the mature form of IGF-1 (7.6kDa), 
which was loaded as a positive control (Figure 3.1D last lane: recombinant mouse IGF-1 (Bio
Trend #C-25019-FC).
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In summary, doxicycline-induced expression of IGF-1 isoforms in double-transfected L6E9 
cells was confirmed by measuring luciferase activity, RT-PCR, and Western analysis and 
was considered sufficient to further analyze the phenotype of the IGF-1 transfected cells.
3.2.2      Morphology of IGF-1 isoform transfected cells
Morphology of IGF-1 isoform transfected cells was observed during all stages of proliferation 
and differentiation (Figure 3.3). In GM, cells did not show any differences in morphology 
(data not shown). Upon shift to DM, cell morphology was documented after 24 hours (day 
one), 48 hours (day two), and 72 hours (day three). At day one of differentiation, cells started 
to elongate as a first sign of differentiation. However, in comparison to the mock control cells, 
cells transfected with Class 1 IGF-1Ea showed an enhanced number of elongated cells, 
while cells transfected with the other five IGF-1 isoforms had less effect on the differentiation 
process, indicated by the overall appearance of only few elongated fibers (Figure 3.3 A). 
Most importantly, cultures transfected with IGF-1 isoforms containing the Eb-peptide 
appeared to be more confluent at day one in DM, suggesting a delay in cell-cycle exit (see 
section 3.2.3 below).
At day two of differentiation, all the differently transfected cultures displayed elongated 
myocytes (data not shown). At this point cells transfected with Class 1 IGF-1Ea already 
displayed small myofibers, indicating that myocytes started to fuse, again pointing towards 
an enhancement of the differentiation process (data not shown). 
Three days after shift to DM, myofibers were formed in all transfected cell cultures (Figure 
3.3 B). Control transfected cells showed very poor fusion and fibers were thin and small. 
Cultures transfected with IGF-1 isoforms containing the Ea-peptide, overall Class 1 IGF-1Ea 
and Class 2 IGF-1Ea, showed the formation of large myofibers, while fibers in cultures 
transfected with 22-IGF-1Ea and the three Eb-containing IGF-1 isoforms were rather thin and 
more comparable to the size of mock control fibers. 
Taken together, transient transfection of L6E9 cells with six different IGF-1 isoforms resulted 
in an enhanced differentiation of Class 1 IGF-1Ea-transfected cells that culminated in the 
formation of hypertrophied myofibers. Cells transfected with Class 2 IGF-1Ea showed normal 
differentiation kinetics but nevertheless showed an increased size of differentiated fibers after 
day three of differentiation. 22-IGF-1Ea-transfected cells instead showed fibers that were 
comparable to control fibers, indicating that this IGF-1 isoform does not induce a 
hypertrophic response. L6E9 cultures transfected with the Eb-peptide containing isoforms of 
IGF-1 showed a delay in the differentiation process and the formation of normally sized 
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muscle fibers, suggesting that IGF-1 isoforms containing the Eb-peptide do not play a role in 
mediating IGF-1 induced hypertrophy.
Figure 3.3 Morphology of IGF-1 isoform transfected L6E9 cells. Pictures were taken 24 hours (A) and 72 
hours (B) after shift to differentiation medium. A After 1 day in DM, cells transfected with the Class 1 IGF-1Ea 
isoform showed the enhanced elongation of cells (indicated by black arrows), while cells transfected with the 
other 5 isoforms were less efficient in starting the differentiative response. B At day 3 of differentiation cultures 
transfected with Class 1 IGF-1Ea and Class 2 IGF-1Ea showed enlarged fibers, while 22-IGF-1Ea as well as the 
three IGF-1 isoforms containing the Eb-peptide did not show an effect on fiber size.
3.2.3      Effects of IGF-1 isoforms on myoblast proliferation
To compare the proliferative state of IGF-1 isoform transfectants during growth, levels of 
phosphorylated histone H3 were analyzed (Figure 3.4 A). Phosphorylation of histone H3 is 
tightly correlated with chromosome condensation during mitosis and meiosis [298] and 
servers as a marker for cells undergoing mitosis. The mock control as well as the 22-IGF-
1Ea samples were slightly overloaded as shown by total levels of H3 protein and therefore 
showed a stronger signal for phospho H3. Taking this in account, transfection with Class 1 
IGF-1Ea and Class 2 IGF-1Ea samples resulted in decreased amounts of phosphorylated 
H3, while samples isolated from cultures over-expressing 22-IGF-1Ea, Class 1 IGF-1Eb, 
Class 2 IGF-1Eb, and 22-IGF-1Eb showed slightly higher levels of histone H3 
phosphorylation when compared to mock controls. These findings suggest that expression of 
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Class 1 IGF-1Ea and Class 2 IGF-1Ea had weaker effects on proliferation of L6E9 cells, 
while isoforms containing the Eb-peptide as well as 22-IGF-1Ea might stimulate proliferation.
Figure 3.4 Effects of IGF-1 isoforms during growth. 50µg of every protein sample were used for Western blot 
analysis. A Histone H3 phosphorylation was lower in Class 1IGF-1Ea and Class 2 IGF-1Ea cultures, while Eb-
containing IGF-1 isoforms and the 22-IGF-1Ea showed increased phosphorylation . B Activation level of MAP-
kinases JNK1, Erk1 and 2 and p38. Class 2 IGF-1Ea cultures showed lower levels of phsopho-JNK1 and Class 1 
IGf-1Ea cells up-regulated phosphorylation of ERk1 and 2. The other isoforms did not induce changes in MAP-
kinase phosphorylation. 
One of the major pathways that has been implicated in mediating the proliferative response 
to IGF-1 is the MAP-kinase pathway. A cascade of events can ultimately lead to 
phosphorylation-mediated activation of the MAP-kinases SAPK/JNK1, ERK 1 and 2, and p38 
(section1.4.5). To determine eventual differences in activation of these kinases in response 
to the different IGF-1 isoforms, their level of phosphorylation was analyzed by Western blot 
(Figure 3.4 B). Phosphorylation of SAPK/JNK1 was unchanged in samples from all
transfected cultures but Class 2 IGF-1Ea, where levels were slightly decreased. 
Phosphorylation levels of phospho-Erk1 and 2 were up-regulated in Class 2 IGF-1Ea 
samples, while samples from cultures transfected with the other five isoforms did not show 
any differences. Finally analysis of p38 phosphorylation showed no major differences among 
the IGF-1 isoform transfected samples and the mock control.
In summary, analysis of histone H3 phosphorylation revealed a weaker effect of Class 1 IGF-
1Ea and Class 2 IGF-1Ea on proliferation, while the level of phospho-H3 was slightly 
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increased in samples form 22-IGF-1Ea, Class 1 IGF-1Eb, Class 2 IGF-1Eb, and 22-IGF-1Eb 
transfected cells. Analysis of MAP-kinase activation revealed subtle changes for samples 
transfected with the Class 1 IGF-1Ea and the Class 2 IGF-1Ea isoforms, showing decreased 
phospho-JNK1 levels in Class 2 IGF-1Ea cultures and increased phospho-Erk1 and 2 levels 
in Class 1 IGF-1Ea cultures.  
3.2.4      Effects of IGF-1 isoforms on myoblast maturation and differentiation
To monitor effects of IGF-1 isoform expression on the differentiation process, cells were 
analyzed for the necessary expression of the myogenic determination factor myogenin, as 
well as the myocyte enhancing factor MEF2C (compare section 1.1.1) (Figure 3.5 A upper 
panel). While not detectable in GM (data not shown), myogenin was induced in all
transfected cultures after 24 hours in DM. Induction was stronger in all IGF-1 transfected 
cells compared to the mock control, an effect that is well described (reviewed in [297]). 
However, subtle differences in the degree of induction in response to different IGF-1 isoforms 
were noted. Class 1 IGF-1Ea showed the strongest up-regulation of myogenin protein, 
confirming the enhanced elongation of cells transfected with this isoform. Class 2 IGF-1Ea 
and Class 1 IGF-1Eb also showed increased up-regulation of myogenin when compared to 
the other IGF-1 isoforms, while 22-IGF-1Ea, Class 2 IGF-1Eb and 22-IGF-1Eb showed rather 
mild induction of myogenin. However, after two days of differentiation all IGF-1 isoform 
transfected cells showed similar levels of myogenin, which were still higher in comparison to 
the mock control. To further confirm normal progression of differentiation, protein levels of 
MEF2C were analyzed (Figure 3.5 lower panel). In comparison to the control cells, where 
MEF2C is not detectable at day one, all IGF-1 isoform transfected cells similarly induced 
MEF2C. With ongoing differentiation, levels further increased at day two, when also the 
control cells start expressing low levels of MEF2C. 
To efficiently promote growth, the level of protein translation must increase. One of the 
pathways implicated in IGF-1 mediated stimulation of growth is the PI(3)-kinase pathway 
(compare section 1.4.5.4). To investigate effects of IGF-1 isoform expression on induction of 
the PI(3)-kinase pathway, activation of the downstream target Akt was analyzed (Figure 5.5 
B upper panel). In comparison to the control cells, which activated Akt mildly, induction was
much stronger in cells transfected with the IGF-1 isoforms. Among the different IGF-1 
isoforms there was no difference in Akt activation, indicating that the six IGF-1 isoforms 
uniformly are capable of activating Akt. 
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Figure 3.5 Effects of IGF-1 isoforms during differentiation. 50µg of every sample were used for Western 
analysis. A upper panel: Induction of myogenin by IGF-1 isoforms. Lower panel: Induction of MEF2C by IGF-
1isoforms. B upper panel: Activation of Akt in IGF-1 isoform transfected cells. Lower panel: phosphorylation of S6 
ribosomal protein in IGF-1 isoform expressing cells.
One of the downstream effectors of the PI(3)-kinase/Akt pathway is the p70 S6-kinase 
(p70S6K), which phosphorylates the S6 ribosomal protein upon activation. Phosphorylation of 
the S6 ribosomal protein in turn is directly correlated with an increase in translation. To 
investigate if IGF-1 isoforms can lead to phosphorylation of S6 ribosomal protein similarly, 
levels of phospho-S6 ribosomal protein were determined (Figure 3.5 lower panel). As seen 
for Akt activation, all isoforms up-regulated induction of phosphorylation equally when 
compared to control cells. This further suggests that all of the isoforms similarly stimulate the 
PI(3)-kinase pathway.   
In summary, all IGF-1 isoforms uniformly induced expression of myogenin and MEF2C, even 
though subtle differences were seen for myogenin induction, where Class 1 IGF-1Ea showed 
the strongest induction, further implicating this isoform in enhancement of the differentiation 
process. Activation of the PI(3)-kinase pathway, determined by phosphorylation of the 
downstream targets Akt and S6 ribosomal protein, showed uniform up-regulation compared 
to the controls, but no differences among the different IGF-1 isoforms. 
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3.3 Effects of IGF-1 isoform over-expression in vivo
To gain insight into the role of the different IGF-1 isoforms in skeletal muscle in vivo, the six 
main IGF-1 isoforms were cloned into an expression vector containing the regulatory 
sequences from the MLC 1/3 promoter and enhancer (described in section 2.1.5.1). The 
MLC 1/3 promoter is exclusively activated in mouse skeletal muscle starting at embryonic 
day E9.5 and persisting into adulthood, thereby providing post-mitotic and skeletal muscle-
specific transgene expression throughout the life of the transgenic animal. 
A crucial aspect of this thesis is the ability to compare the effects of over-expression of IGF-1 
isoforms. Only by driving the transgene from the same regulatory sequences and in the 
same tissue, conclusions can be drawn about differential effects of IGF-1 isoforms. Three 
transgenic mouse lines over-expressing IGF-1 specifically in skeletal muscle have been 
generated in the past years (compare section 1.5), but since different regulatory sequences 
have been used to drive transgene expression, a profound comparison has been difficult 
(reviewed in [151]). In addition, the choice of the IGF-1 isoform used for over-expression has 
not always been clearly defined and adds another crucial parameter in understanding the 
phenotype of IGF-1 transgenic mice. 
The present work aimed to provide an overview of the phenotype seen in transgenic animals 
that over-express the main IGF-1 isoforms driven from the same regulatory elements. This 
approach allows the comparison of IGF-1 isoform effects in vivo for the first time.  
3.3.1 Generation of transgenic mouse lines
All expression constructs were generated as described in section 2.1.5.1 and sequenced 
before injection to ensure integrity of every IGF-1 isoform sequence. Vectors were digested 
to completion with EcoRI to linearize the expression cassette and eliminate plasmid 
sequences. All injections have been performed by the transgenic service of the EMBL-
Monterotondo.
One positive founder was born for the transgenic lines MLC/Class 1 IGF-1Ea (founder A) and 
MLC/22-IGF-1Ea (founder A). For the Line MLC/Class 2 IGF-1Ea (founders A-D) and 
MLC/Class 2 IGF-1Eb (founders A-D) four positive founders were obtained, three were 
generated for MLC/22-IGF-1Eb (founders A-C), and injection of MLC/Class 1 IGF-1Eb 
yielded two positive founder lines (founders A and B). Each positive founder was mated to 
WT mice and female and male offspring for each transgenic founder of every line were 
analyzed for transgene expression.
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3.3.2 Expression analysis of transgenic founder lines
Expression of IGF-1 isoform transgenes was surveyed by Northern blot analysis. Since the 
transgenic IGF-1 isoforms are of mouse origin, a probe specific for the most 5’-end of the 
SV40 poly(A) signal was used to exclusively detect the transgenic mRNAs (compare section 
2.1.5.1) Total RNA was isolated from three-months-old male and female quadriceps
muscles. 
Figure 3.6: Northern blot analysis of transgene expression of founder (Fo) lines. 10 µg of total RNA from 
female and male three-months-old quadriceps muscles were used for Northern analysis and probed with a SV40-
specific probe A MLC/Class 1 IGF-1Ea founder. A Lanes 1 and 2 are female; lanes 3 and 4 are male samples. B 
MLC/Class 2 IGF-1Ea. Lanes 1, 2, 5, 6, 9, 10, 13, and 14 are female, lanes 3, 4, 7, 8, 11, 12, 15, and 16 are male 
samples. C MLC/Class 1 IGF-1Eb founders A and B. Lanes 1, 2, 5, and 6 are female; lanes 3, 4, 7, and 8 are 
male samples. D MLC/Class 2 IGF-1Eb founders A-D. Lanes 3, 4, 7, 8, 11, and 12 are female; lanes 1, 2, 5, 6, 9, 
10, and 13 are male samples. E  MLC/22-IGF-1Ea founder A. Lane 1 is female; lanes 2 and 3 are male samples.
F MLC/22-IGF-1Eb founders A-C. Lanes 1, 6, and 7 are female; lanes 2, 3, 4, 5, and 8 are male samples.
For line MLC/Cass 1 IGF-1Ea only one founder was available for expression analysis (Figure 
3.6A) and therefore further analysis was performed on MLC/Class 1 IGF-1Ea founder A. Line 
MLC/Class 2 IGF-1Ea founders C and D showed the highest transgene expression, while 
founders A and B showed moderate to low expression (Figure 3.6B). Due to their high 
transgene expression level, founders C and D were kept for further analysis. The two 
founders obtained for line MLC/Class 1 IGF-1B expressed moderate (founder A) and high 
(founder B) levels of the transgene (Figure 3.6C) and both founders were further analyzed. 
Among founders A to D of line MLC/Class 2 IGF-1Eb founders C and D showed the
strongest transgene expression, while founder B expresses low levels of the transgene and 
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founder A showed only traces of a positive signal (Figure 3.6D). Founder C and D were 
therefore chosen for further analysis. The single founder A for line MLC/22-IGF-1Ea showed 
moderate to high expression of the transgene (Figure 3.6E) and was further analyzed. The 
three founders obtained for line MLC/22-IGF-1Eb showed high (founder A) and moderate 
(founders B and C) transgene expression (Figure 3.6F). Founder A was kept due to highest
transgene expression and since founder C gave a slightly stronger signal than founder B, it 
was kept as well. 
Figure 3.7: Northern comparison of transgenic founder line expression levels. 10µg of total RNA form 
quadriceps muscle of male mice were used and probed with a SV40-specific probe. A Northern comparison of all 
selected founder lines for each IGF-1 isoform transgenic line. B Density of IGF-1 isoform transgene bands 
detected with Northern analysis (A)
For a better comparison of the transgene expression level among the different founders of 
each line, total RNA isolated from three-month-old male quadriceps muscles of each 
selected founder was analyzed by Northern blot using the previously described SV40-
specific probe (Figure 3.7 A). The results were analyzed by using the Radames software to 
screen the density (pixel/area) of the bands detected by Northern blot (Figure 3.7 B). Highest 
expression was detected for line MLC/22-IGF-1Ea founder A (172476 pixel/area) and 
MLC/22-IGF-1Eb founder A (188542 pixel/area), followed by comparably high expression in 
lines MLC/Class 2 IGF-1Ea founder C (140161 pixel/area), MLC/Class 1 IGF-1Eb founder B 
(112511 pixel/area), founders C (120636 pixel/area) and D (137135 pixel/area) of line
MLC/Class 2 IGF-1Eb and MLC/22-IGF-1Eb founder C (123382 pixel/area). Expression of 
MLC/Class 2 IGF-1Ea founder D and MLC/Class 1 IGF-1Eb founder A was low compared to 
the other founders (30918 and 36675 pixel/area respectively). Based on this comparison, 
primary founders were selected for each line to perform further analysis. Primary founders of 
each line were: Founder A for line MLC/Class 1 IGF-1Ea, founder C for MLC/Class 2 IGF-
1Ea, founder A for line MLC/22-IGF-1Ea, founder B for line MLC/Class 1 IGF-1Eb, founder D 
for line MLC/Class 2 IGF-1Eb and founder A for line MLC/22-IGF-1Eb.
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Results page 86
3.3.3     Skeletal muscle-specific transgene expression of transgenic lines
The next crucial step in the analysis of the transgenic founder lines was to determine if the 
IGF-1 transgenes were expressed in a skeletal muscle-specific manner. For this purpose 
total RNA of distal organs (heart, brain, liver, kidney, and spleen), as well as different skeletal 
muscle groups (quadriceps, gastrocnemius, diaphragm, and tibialis anterior (TA)) of male 
and female (data not shown) WT and transgenic three-month-old mice of each selected 
founder was isolated and analyzed by Northern blot using the previously described SV40-
specific probe. Figure 3.8 A-F shows the results for the highest expressing founder of all six 
transgenic lines that were selected based on the expression analysis described in section 
3.3.2. Results obtained for the second selected founders were similar (data not shown). No 
signal was detectable in any WT tissue and non-muscle transgenic tissue. Specific bands 
were exclusively found in the skeletal muscle groups of all transgenic lines, confirming
expected expression of the transgenic IGF-1 isoforms. Due to the expression pattern of the 
MLC promoter, transgene expression was highest in the fast IIB fibers, although lower levels 
are also expressed in fast IIX and IIA fibers. Therefore fast muscles like the quadriceps, 
gastrocnemius, and TA, showed higher IGF-1 isoform transgene expression than the 
diaphragm that does not express IIB fibers and consequently only expressed the transgene 
at low levels.
Figure 3.8: Skeletal muscle-specific transgene expression. 10µg of total RNA were run for every sample and 
probed with a SV40-specific probe. Transgenic tissues of different lines were compared to WT littermates. A 
MLC/Class 1 IGF-1Ea founder A. B MLC/Class 2 IGF-1Ea founder C. C MLC/Class 1 IGF-1Eb founder B. D 
MLC/Class 2 IGF-1Eb founder D E MLC/22-IGF-1Ea founder A. F MLC/22-IGF-1Eb founder A.
For deeper phenotypic analysis of the IGF-1 isoform transgenic mouse lines, priority was 
given to the founder that expressed highest levels of the transgene and to the four isoforms 
mainly expressed in WT animals, namely MLC/Class 1 IGF-1Ea, MLC/Class 2 IGF-1Ea, 
MLC/Class 1 IGF-1Eb, MLC/Class 2 IGF-1Eb.
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During preliminary analysis it became clear though that the MLC/Class 1 IGF-1Ea line was 
problematic. The mice were aggressive and didn’t breed well, which led to loss of this line. 
Since no second founder was available, the previously well described MLC/mIGF-1 line, 
generated by Antonio Musaro [77] was used for further comparative work. This line carries 
the same transgene as used for generating the MLC/Class 1 IGF-1Ea line (Class 1 IGF-
1Ea), but of rat and not of mouse origin, and contains the same MLC 1/3-derived regulatory 
sequences to drive transgene expression. From now on this line will be referred to as 
MLC/mIGF-1.
3.3.4       Comparison of expression levels to MLC/mIGF-1 transgenic line
For further work including the MLC/mIGF-1 transgenic line, the expression level of each of 
the selected founders for every line chosen had to be compared again. 
Final comparison was done by Northern blot, quantitative real time RT-PCR, and Western 
blot (Figures 3.9 and 3.10). Results obtained by Northern blot experiments using of 10µg of 
total RNA form one-month-old quadriceps probed with the previously described SV40 probe 
(Figure 3.9 A) were analyzed with the Radames software to determine the density of bands 
detected by Northern analysis (Figure 3.9 B ). This analysis revealed highest expression for 
MLC/Class 2 IGF-1Ea (125627 pixel/area) and MLC/Class 2 IGF-1Eb (171052 pixel/area),
followed by MLC/mIGF-1 (92482 pixel/area). Lowest transgene expression levels were 
detected for line MLC/Class 1 IGF-1Eb (57838 pixel/area).  
Figure 3.9 Comparison of selected lines to MLC/mIGF-1 transgenic line. 10µg of total quadriceps RNA from 
male one-month-old animals was used for Northern analysis and probed with a SV40-specific probe. A
Comparison of selected founder lines to MLC/mIGF-1. B Density of IGF-1 isoform transgene bands detected with 
Northern analysis (A).
For quantification in relation to WT total IGF-1 levels and specific IGF-1 isoform levels, 
quantitative real time RT-PCR was performed on RNA isolated from three-months-old 
quadriceps muscle of three WT mice and three transgenic mice of each line. To determine 
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total IGF-1 levels in WT quadriceps muscle, the WT values obtained by quantitative RT-PCR 
for every isoform were added (3301.2 molecules/ng). Values for the specific isoform over-
expressed were then related to this value to gain the total fold-increase over the WT (Figure 
3.10 A). With this type of analysis MLC/mIGF-1 animals (181-fold) and MLC/Class 2 IGF-1Ea 
(52-fold) showed the highest increase, while MLC/Class 1 IGF-1Eb (8-fold) and MLC/Class 2 
IGF-1Eb (2-fold) instead, showed a rather mild increase. However, if values obtained for the 
different over-expressed IGF-1 isoforms were related to the WT expression level of the 
corresponding endogenous isoform, the level of induction was more comparable (Figure 3.10 
B). Line MLC/mIGF-1 showed a 227-fold increase, MLC/Class 1 IGF-1Eb a 190-fold 
increase, and MLC/Class 2 IGF-1Ea displayed a 364-fold increase. Since the Class 2 IGF-
1Eb isoform was not detectable in WT quadriceps muscles, the fold-increase over the WT 
was much higher for this transgene (6280-fold) (Figure 3.10 C). The discrepancies in the 
expression levels of the IGF-1 transgenes observed with the different methods are most
likely due to naturally occurring differences in expression level between different animals of 
the same transgenic line. 
Figure 3.10 Over-expression of IGF-1 isoform transgenes. The level of IGF-1 isoform over-expression was 
compared by quantitative RT-PCR. A Fold over-expression of IGF-1 isoforms in relation to WT total IGF-1 level. B 
Fold over-expression of isoforms with the wt expression level of the same isoform as a reference. For a better 
overview the graph was prepared without MLC/Class 2 IGF-1Eb. C Fold over-expression over wt levels of the 
same isoform with MLC/Class 2 IGF-1Eb
To relate the mRNA expression level to the protein levels detected in the transgenic muscles, 
as well as to confirm proper protein expression of the transgenic IGF-1 isoforms, Western 
blot analysis was done on quadriceps protein lysates of one-month-old and six-months-old 
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WT and transgenic animals for each IGF-1 isoform (Figure 3.11). The antibody used for both 
experiments was directed against the mature IGF-1 sequence and therefore detected all the
differently processed forms of IGF-1, represented by the multiple bands detected. As 
observed in vitro, isoforms containing the Ea-peptide showed two additional bands, most 
likely reflecting glycosylated forms of those IGF-1 variants. Most importantly, all isoforms 
were processed to the mature IGF-1 in vivo. Due to detection of multiple bands, 
quantification was performed by combining the densities of each detected band for every 
sample. These values are not absolutely accurate, since the Radames software used for 
detection and quantification of the single bands, did not detect bands of very low intensity. 
However, this analysis is still accurate enough to allow the determination of expression 
levels.
Figure 3.11 Protein expression of IGF-1 isoform transgenes. 50µg of protein from male quadriceps muscle 
from one-month (A) and six-months-old mice (C) were used for Western analysis with an antibody to detect all 
IGF-1 isoforms. Band density was determined using the Radames software for one-month-old (B) and six-month-
old samples (D).
At one month of age, no IGF-1 was detected in the WT sample, while MLC/mIGF-1 (521705 
pixel/area), MLC/Class 1 IGF-1Eb (579348 pixel/area), and MLC/Class 2 IGF-1Eb (773249 
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pixel/area) showed comparable high levels of IGF-1 protein expression. The signal detected 
for MLC/Class 2 IGF-1Ea (75805 pixel/area) instead, was quite low (Figure 3.11 A and B).
However, the different IGF-1 isoform transgenic lines showed comparable levels of IGF-1 
protein expression at six months of age (Figure 3.11 C and D), while no IGF-1 was
detectable in the WT sample. These results confirm that all IGF-1 isoform transgenic lines 
express the IGF-1 protein to a comparable extent. Variations seen in one-month and six-
months-old animals most likely reflect normally occurring differences in expression between 
different animals of the same line, since these differences were also seen by analysis of 
transgenic mRNA. Notably, the quite dramatic differences seen in the fold-increase of 
transgenic mRNA in reference to total WT levels in the different mouse lines are not reflected 
in the IGF-1 protein expression of these animals. This observation raises the question if there 
is a limit or threshold for IGF-1 protein translation that is not overcome by higher transcription 
levels. 
In summary, comparison of IGF-1 isoform transgene expression on the transcriptional level 
revealed variable differences among the lines, depending on which method was used. 
However, despite these differences, expression of IGF-1 protein determined by quantification 
of results obtained by Western blot analysis showed comparable expression of the different 
IGF-1 isoforms.
3.3.5 Influence of IGF-1 isoforms on endogenous IGF-1 isoform expression 
To investigate if the over-expression of IGF-1 isoforms influenced the endogenous IGF-1 
isoform expression levels, primers were designed for quantitative RT-PCR, allowing 
amplification of the full-length isoforms, thereby providing reliable evidence for endogenous 
IGF-1 isoform expression levels. The screening for endogenous IGF-1 isoform expression in 
each transgenic mouse line was carried out on total RNA from three-months-old quadriceps 
muscle, isolated from three WT and three transgenic mice from each line. While MLC/Class 
2 IGF-1Ea and MLC/Class 2 IGF-1Eb did not have any influence on the expression of 
endogenous IGF-1 isoforms (Figure 3.12 C and D), the over-expression of rat Class 1 IGF-
1Ea in MLC/mIGF-1 animals up-regulated endogenous Class 2 IGF-1Ea 6.7-fold (p=0.04) 
without affecting other endogenous IGF-1 isoforms (Figure 3.12 A). MLC/Class 1 IGF-1Eb 
transgenic samples showed a 7.7-fold induction of endogenous Class 1 IGF-1Ea (p=0.03), 
while other IGF-1 isoforms were unchanged (Figure 3.12 B). The values of each isoform
were always compared to the WT expression levels of the corresponding isoform.
To confirm these results, Northern blot analysis was performed with probes designed to bind 
to specific sequences of the differentially spliced exons (section 2.1.7). Transgenic lines 
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over-expressing Class 1 isoforms (derived from exon 1) were analyzed with a probe directed 
against exon 2 sequences, while lines over-expressing Class 2 isoform (derived from exon 2) 
were analyzed with a probe recognizing the 186 bp 5’-UTR exon 1 sequence, which is 
subject to a splicing event in 20% of the total IGF-1 mRNA in the liver. By choosing the probe 
in this region, the majority of endogenous exon 1-derived Class 1 transcripts were detected. 
Over-expressed isoforms containing the Ea-peptide (exon 4-6 splice variant) were analyzed 
with a probe derived from exon 5 (giving rise to the specific part of the Eb-encoding 
sequence). Generation of a probe allowing the detection of the exon 4-6 sequence was not 
possible, since the sequences giving rise to the Ea-peptide are also contained in the exon 4-
5-6 splice variant giving rise to the Eb-peptide.
Figure 3.12 Expression of endogenous isoforms (1). Quantitative RT-PCR was used to assess if the over-
expression of IGF-1 isoforms had an effect on the expression of endogenous isoforms. The transgenic line 
analyzed is indicated on top of the graph. A Results for line MLC/mIGF-1 show significant up-regulation of 
endogenous Class 2 IGF-1Ea transcripts (p=0.04), while other isoforms were not affected. B Line MLC/Class 1 
IGF-1Eb samples showed significantly more Class 1 IGF-1Ea transcripts (p=0.03), but no changes for other 
isoforms. No effect on endogenous isoform expression was seen in lines MLC/Class 2 IGF-1Ea and Class 2 IGF-
1Eb (C and D). The values of each isoform were always compared to the WT levels of the same isoform.
Results obtained with an exon 2-specific probe confirmed the slight skeletal muscle-specific 
up-regulation of a Class 2 isoform in response to the Class 1 IGF-1Ea (mIGF-1) transgene 
(Figure 3.13 A), while Northern blot analysis with an exon 5-specific probe to detect exon 4-
5-6 splice variants giving rise to the Eb-peptide, confirmed no changes for Eb-encoding 
mRNAs (Figure 3.13 B). To monitor endogenous Class 1 isoform transcription in MLC/Class 
2 IGF-1Ea animals, the 186 exon 1-, and the exon 5-specific probes were used. Both 
experiments confirmed no changes for those isoforms (Figure 3.13 C and D). Since the exon 
4-6 splice variant that gives rise to the Ea-peptide cannot be specifically detected, Northern 
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analysis for MLC/Class 1 IGF-1Eb was restricted to the exon 2-specific probe for Class 2 
mRNA detection. Results shown in Figure 3.13 E confirm no changes for Class 1 IGF-1Eb
transcripts. MLC/Class 2 IGF-1Eb analysis instead was restricted to detection of class 1 IGF-
1 mRNAs and showed no changes in comparison to the WT samples (Figure 3.13 F), again 
confirming results obtained by quantitative RT-PCR.
Taken together, these results revealed that the Class 1 IGF-1Ea transgene present in 
MLC/mIGF-1 animals up-regulated endogenous Class 2 IGF-1Ea transcripts without 
affecting the expression of other endogenous isoforms. In contrast, the MLC/Class 1 IGF-
1Eb transgene up-regulated endogenous Class 1 IGF-1Ea, even though this could not be 
confirmed by Northern blot analysis due to lack of a suitable probe. No effects on 
endogenous IGF-1 isoforms were seen in lines MLC/Class 2 IGF-1Ea and MLC/Class 2 IGF-
1Eb. 
Figure 3.13 Expression of endogenous IGF-1 isoforms (2). 10µg of total RNA from three-month-old male 
quadriceps muscle from WT and transgenic mice were analyzed with the specific probes indicated. A MLC/mIGF-
1 samples probed with an exon 2-specific probe showed mild induction of exon 2-containing transcripts 
specifically in the transgenic skeletal muscle groups (indicated with an arrow). B MLC/mIGF-1 samples probed 
hybridized with an exon 5-specific probe revealed no changes. C No changes in MLC/Class 2 IGF-1Ea samples 
probed with the 186 exon 1-specific probe. D MLC/Class 2 IGF-1Ea derived samples screened with the exon 5-
specific probe were also unchanged.  E MLC/Class 2 IGF-1Eb samples analyzed with an exon 2-specific probe 
were negative. F MLC/Class 2 IGF-1Eb samples probed with the 186 exon 1-specific probe showed similar levels 
to WT samples.
3.3.6     Effects IGF-1 isoform on body weight and weight of visceral organs
A previous study on a transgenic mouse line over-expressing IGF-1 in skeletal muscle (SIS2) 
reported an increase in body weight and an effect on the size of visceral organs such as the 
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spleen [299]. This IGF-1 transgenic line over-expressed a human Class 1 IGF-1Ea isoform 
?????? ???? ???????? ??? ???? ?????? ????????? ?-actin promoter (SIS2 mice), which restricted the 
transgene expression to skeletal muscle and heart. In contrast, the primary characterization 
of the MLC/mIGF-1 transgenic mouse line, also over-expressing the Class 1 IGF-1Ea 
isoform, but exclusively in skeletal muscle, did not show an effect on the total body weight, 
and the weight of distal organs was not assessed in these animals [77]. Since the transgene 
expression in these animals is controlled by different promoters and therefore the expression 
pattern is different, a direct comparison is difficult. In addition the first, but not the second 
study reported the presence of transgenic human IGF-1 in the circulation, which might cause 
the increased weight of the spleen. It is therefore crucial to determine if these parameters are 
influenced in the IGF-1 isoform transgenic mice described here. 
Figure 3.14 Effect of IGF-1 isoform over-expression on body weight. Number of animals is indicated at the 
bottom of the columns. All measurements were performed on male animals. A MLC/mIGF-1 animals show 
significantly elevated body weight by 1 (p=0.01) and 2-3 months of age (p=0.0001). B MLC/Class 2 IGF-1Ea mice 
are significantly heavier at all ages analyzed (p=0.01 for all). C MLC/Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb 
(D) do not have an effect on body weight.
On the bases of over-expressing the different IGF-1 isoforms under the same conditions, the 
effect of IGF-1 isoform over-expression on the over all body weight and the weight of visceral 
organs of the transgenic animals was monitored throughout life of the transgenic mice and 
their WT littermates. Results shown in Figure 3.14 demonstrate a significant (p<0.05) effect 
on the overall body weight for lines MLC/mIGF-1 and MLC/Class 2 IGF-1Ea. MLC/mIGF-1 
body weight was increased by 8% at one month of age (p=0.01), 11% at two-three months 
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(p=0.0001), and by 6% at six months of age, even though at six months, values no longer 
reached significance (p=0.3) (Figure 3.14A). MLC/Class 2 IGF-1Ea animals showed a similar
increase up to two-three months of age (9% at one month (p=0.01), 11% at two-three months 
(p=0.01)), but in contrast to MLC/mIGF-1 mice, the 14% increase measured at six months of 
age for MLC/Class 2 IGF-1Ea animals was still significant (p=0.01) (Figure 3.14B). 
MLC/Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb instead, did not show any significant 
changes in body weight throughout all ages analyzed (p>0.05) (Figure 3.14C and D).
To exclude an effect of IGF-1 isoform over-expression on visceral organs, also the weight of 
visceral organs (heart, brain, liver, kidney, and spleen) was monitored throughout life of the 
transgenic animals. All weight values were normalized for body weight and results are shown 
in Figure 3.15 A-D. None of the transgenic lines showed a significant increase in any of the 
organs monitored (p>0.05).
Figure 3.15 Effect of IGF-1 isoform over-expression on the weight of visceral organs. Tissue weights were 
taken from male transgenic mice (1, 3, and 6 months of age) and their negative littermates. The number of 
animals is indicated in every diagram. All organ values were normalized for bodyweight. A MLC/mIGF-1 animals 
did not show any effect on the weight of visceral organs. Only the weight of the EDP was significantly increased at 
3 (p=0.006) and 6 months of age (p=0.03). MLC/Class 2 IGF-1Ea (B), MLC/Class 1 IGF-1Eb (C), and MLC/Class 
2 IGF-1Eb animals (D) did not show an effect of the weight of distal organs.
To determine whether IGF-1 isoform over-expression had an effect on fat deposition, as 
reported for male SIS2 mice, which deposited less fat between five and ten weeks of age  
[299], measurements of the epididymis fat pat (EFP) of male mice were included. The EFP is 
the only well defined fat pat in the organism and is therefore well suited for comparison. 
However, these measurements do not necessarily reflect the total fat content of the animal. 
Only MLC/mIGF-1 animals (over-expressing the same Class 1 IGF-1Ea isoform as the SIS2 
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mice, but of rat and not of human origin) showed significant changes, reflected in a 26% 
decrease (p=0.006) at three months of age and a 15% decrease (p=0.03) at six months of 
age. None of the other transgenic lines showed an influence on fat deposition in the EFP 
(p>0.05).
In summary, both IGF-1 isoforms that contain the Ea-peptide showed an effect on overall 
bodyweight, which was significant for MLC/mIGF-1 up until three months, while MLC/Class 2 
IGF-1Ea showed a significant increase at all ages surveyed. IGF-1 isoforms containing the 
Eb-peptide in contrast, did not show any changes in bodyweight. None of the transgenic lines 
showed an influence on the weight of visceral organs, and only MLC/mIGF-1 showed a 
significant decrease of fat deposition in the EFP. 
3.3.7     Effects of IGF-1 isoform over-expression on serum IGF-1 levels
A next crucial step in defining the phenotype of the different IGF-1 isoform over-expressing 
mice was to determine if the IGF-1 transgenes influenced the levels of circulating IGF-1. 
Previously generated transgenic mice over-expressing IGF-1 have been reported to secrete 
IGF-1 transgenes to the circulation (reviewed in [300]), a side effect that ideally should be 
avoided in a therapeutic setting, since it could lead to metabolic changes and/or effects on 
other organ systems in the body. This is especially important considering IGF-1 as a 
potential drug for curing muscle diseases.
None of the assays to determine serum concentrations of IGF-1 available to date distinguish 
between IGF-1 isoforms or between rat and mouse IGF-1. Since all transgenic lines 
analyzed in this work over-express transgenes of rat (MLC/mIGF-1) or mouse origin 
(MLC/Class 2 IGF-1Ea, MLC/Class 1 IGF-1Eb, and MLC/Class 2 IGF-1Eb), total IGF-1 
concentrations in the blood serum of male transgenic mice of three and six months of age 
were compared to total IGF-1 concentrations in the blood serum of age-matched WT animals 
of the same gender (Figure 3.16). At the age of three months, MLC/mIGF-1 and MLC/Class 
2 IGF-1Ea mice showed modest, but still significantly elevated serum IGF-1 levels (16% 
increase in MLC/mIGF-1 serum samples (p=0,02) and 19% in MLC/Class 2 IGF-1Ea 
samples (p=0,005)). Total serum levels of IGF-1 were unchanged in lines MLC/Class 1 IGF-
1Eb and MLC/Class 2 IGF-1Eb (Figure 3.16 A). At the age of six months MLC/mIGF-1 serum 
samples showed a 7.4% increase in total circulating IGF-1 concentrations, which is not 
significant (p>0.05), while total circulating IGF-1 levels of MLC/Class 2 IGF-1Ea mice showed 
a similar increase noticed in three-months-old animals (24% increase (p=0.0001))(Figure 
3.16 B). MLC/ Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb showed no effect on serum IGF-1 
levels (Figure 3.16 B).
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Figure 3.16 Effect of IGF-1 isoform expression on total circulating IGF-1 levels. All blood samples were 
taken from male transgenic mice and age matched WT animals (the number of animals is indicated on the bottom 
of the columns). A At 3 month of age MLC/mIGF-1 and MLC/Class 2 IGF-1Ea showed significantly elevated IGF-
1 levels in the serum (p=0.02 and p=0.005 respectively), while serum levels of MLC/Class 1 IGF-1Eb and 
MLC/Class 2 IGF-1Eb levels were unchanged. B By the age of six months, only MLC/Class 2 IGF-1Ea levels 
were significantly increased (p=0.0001) and MLC/mIGF-1 total circulating IGF-1 levels were still elevated (7.4%). 
MLC/Class 1 IGF-1Ea and MLC/Class 2 IGF-1Eb showed no change.
In summary, over-expression of both Eb-peptide-containing versions of IGF-1 did not show 
any effect on total levels of IGF-1 in the blood serum, while the two isoforms including the 
Ea-peptide induced an increase of total serum IGF-1: MLC/Class 2 IGF-1Ea mice showed
consistently significant increases at three and six months of age, while MLC/mIGF-1 IGF-1 
serum levels were only significantly increased by the age on three months, even though still 
elevated by six months of age.
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3.3.8 Skeletal muscle weight of IGF-1 isoform transgenic lines
The first step in analyzing the skeletal muscle phenotype of the different IGF-1 isoform 
transgenic mouse lines was to determine changes in the weight of different skeletal muscle 
groups. The weight of the quadriceps (abbreviated “quad”), gastrocnemius (abbreviated 
“gas”), tibialis anterior (TA), extensor digitorum longus (EDL), and soleus (abbreviated “sol”) 
muscles was measured in male mice of one, three, and six months of age and compared to 
age-matched WT animals of the same gender. All values were normalized for body weight 
and are shown in Figure 3.17.
Figure 3.17 Skeletal muscle weights of IGF-1 isoform transgenic lines. One-, three-, and six-months-old male 
mice were used for skeletal muscle weight measurements. The number of mice is indicated on the top right 
corner of every graph. All values were normalized for bodyweight. A MLC/mIGF-1 fast skeletal muscle groups 
showed a significant weight increase (p<0.0002 for all) at three and six months, soleus weight was not changed. 
B MLC/Class 2 IGF-1Ea fast muscle groups were increased in weight at three months and six months of age 
(p<0.007 for all), while values at one months were elevated, but apart from gastrocnemius not significant. The 
weight of the slow soleus muscle was not influenced. C MLC/Class 1 IGF-1Eb one-month-old samples did not 
show any changes, while the weight of quad and TA showed a significant increase (p<0.03) at three months. By 
the age of six months, all fast muscles but the EDL were significantly increased in weight (p=0.01). D Line 
MLC/Class 2 IGF-1Eb samples showed elevated skeletal muscle weight at one and six months of age, while 
three-month-old samples were unchanged. None of the values reached significance.
MLC/mIGF-1 animals showed a significant increase of all fast muscles at three months of 
age (quad 16%, gas 9%, TA 22%, EDL 30% (p<0.0002 for all)), which was maintained at 
similar levels at six months of age (quad 18%, gas 12%, TA 26%, EDL 32% (p<0.02 for all)), 
while the weight of the soleus, a slow muscle, was unchanged at all times (Figure 3.17A). At 
one month of age, MLC/Class 2 IGF-1Ea mice displayed a modest increase of the fast 
muscles quadriceps (5%) and gastrocnemius (7%), which was only significant for the 
gastrocnemius muscle (p=0.03). The weight of TA, diaphragm, and soleus were not 
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significantly changed (Figure 3.17B). At three months of age the skeletal muscle weight was 
significantly increased in all fast muscle groups (quad 13%, gas 12%, TA 19%, EDL 24% 
(p<0.007 for all)), reaching even higher levels at six months of age (quad 32%, gas 23%, TA 
32%, EDL 33% (p<0.007 for all)). The soleus muscle weight did not significantly change at 
any age, but showed a tendency for a modest weight gain (Figure 3.17B).
The increase of skeletal muscle weight in MLC/Class 1 IGF-1Eb animals was rather mild at 
all ages surveyed. At one month of age, no significant changes were found for the analyzed 
skeletal muscle groups (Figure 3.17C). By the age of three months, quadriceps (11%) and 
TA (9%) weights are significant in their weight increase (p<0.03), while gastrocnemius (4%) 
and EDL (7%), values did not reach significance. The weight of the soleus muscle was 
unchanged (Figure 3.17C). At six months of age, all fast skeletal muscle groups but the EDL 
showed a significant but modest weight increase (quad 14%, gas 12%, and TA 12% 
(p<0.01). Weights of EDL and soleus were not significantly altered.
Results for the MLC/Class 2 IGF-1Eb transgenic animals revealed increased but not 
significant weights for fast skeletal muscle groups at one month of age (quad 20%, gas 11%, 
TA 15%), while measurements of three-months-old mice showed no significant differences 
for any of the muscles measured (Figure 3.17D). By the age of six months, fast muscle 
weights were increased (quad 13%, gas 8%, TA 20%, and EDL 7%), but again did not reach 
significance. Soleus muscle weight was not influenced at any age.
Taken together, lines MLC/mIGF-1 and MLC/Class 2 IGF-1Ea showed the most prominent 
increase of skeletal muscle mass, which was consistently significant at three and six months 
of age. Lines MLC/Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb instead showed only modest 
and highly variable changes in muscle weight, many which fall below the level of statistical 
significance. 
3.3.9 Histological analysis of IGF-1 isoform transgenic skeletal muscle 
To determine whether the increase in skeletal muscle weight of IGF-1 isoform transgenic 
mice can be correlated to an increase of muscle fiber size, histological analysis of the 
skeletal muscle of IGF-1 isoform transgenic lines was carried out on four six-months-old 
male animals for each line and compared to age-matched WT mice of the same sex. As a 
measurement of increased muscle fiber size, the cross-sectional area (CSA) of slow, 
intermediate, and fast fibers was determined for the entire TA, EDL, and soleus muscles. 
12µm frozen sections were stained for NADH-TR (section 2.4.5), which allows the 
differentiation between fast, intermediate, and slow fibers based on the intensity of the
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Results page 99
staining (slow fibers stain dark blue due to a higher content of mitochondria, fast fibers stain 
very light blue due to a low content of mitochondria, and intermediate fibers stain light blue 
due to a higher mitochondria content than fast fibers but a lower content than slow fibers) 
(Figures 3.18 A, 3.19 A, and 3.20 A, upper panel). To confirm identity of the fast type IIB 
fibers, double-immunohistochemistry was performed with antibodies against type IIB myosin 
and laminin (Figures 3.18 A and 3.20 A, lower panel). MLC/mIGF-1 animals were not
analyzed for CSA in the present work, since the CSA phenotype has already been analyzed
elsewhere [77]. The data published by Musaro et al. demonstrated an overall increase in the
CSA of fibers in the quadriceps but not the soleus muscle, with an increased diameter 
specifically of the fast fibers. The composition of fibers of the fast EDL muscle showed a 
significant decrease in the fast IIA fibers, while the percentage of type IIB fibers was 
modestly, but not significantly increased.  
Figure 3.18 Histological analysis of MLC/Class 2IGF-1 Ea muscles. Six-month-old transgenic mice were 
compared to littermates of the same sex (n=4 for both). A Representative pictures of EDL and TA sections 
stained with NADH-TR (upper panel). Identity of fast IIB fibers was confirmed with antibodies against type IIB 
myosin and laminin (lower panel). B CSA analysis of EDL and TA fast, intermediate, and slow fibers. C Size 
distribution of different fiber types of the TA muscle. D Fiber type composition of the EDL muscle. E Analysis of 
the total number of fibers in the EDL muscle.
Analysis of the MLC/Class 2 IGF-1Ea transgenic line revealed a significant increase of fast, 
intermediate, and slow fibers in both fast muscles analyzed, the EDL (fast: 44%, p=0.003, 
intermediate: 40%, p=0.004, and slow: 41%, p=0.02) and the TA (fast: 39%, p=0.0002, 
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intermediate: 20%, p=0.02, and slow: 20%, p=0.02). The slow soleus muscle showed a mild 
increase in CSA (13.5% for intermediate and 10% for slow fibers), which was not significant 
(Figure 3.18 B). Analyzing the data for the distribution of fibers of a certain CSA range as 
shown in figure 3.18 C for the TA as an example, clearly shows that the normal size 
distribution of fibers in the muscle was maintained, but in presence of the MLC/Class 2 IGF-
1Ea transgene, the curve was dramatically shifted towards bigger fibers. This effect was 
most pronounced in the fast fibers, where the transgene is predominantly expressed, but 
also visible for intermediate and slow fibers. The same shift was seen for the EDL muscle 
(data not shown). These findings indicate that the transgene affects not only the fast fibers, 
where the MLC promoter is most active, but also the intermediate and the slow fibers, where 
it is less active or not active at all. This paracrine effect of IGF-1 over-expression was not
described for the MLC/mIGF transgene [282], which is most likely due to a different type of 
analysis.
To determine if the presence of the Class 2 IGF-1Ea transgene influenced the composition of 
fibers within the muscle, the number of fast, intermediate, and slow fibers was counted in the 
EDL muscle and did not show a significant change (fast fibers: 47±6% in the WT, 43±6% in 
the transgenic; intermediate fibers: 20±2% in the WT, 19±4% in the transgenic; slow fibers: 
31±6% in the WT, 37±6% in the transgenic) (Figure 3.18 D), indicating that the transgene did 
not induce any changes in fiber composition, which was reported for the MLC/mIGF-1 
transgenic line [282]. 
To rule out the possibility that the increase of skeletal muscle weight could also be due to an 
increase in fiber number (hyperplasia), the total number of fibers was counted in the EDL 
muscle of WT and transgenic animals. Results shown in Figure 3.18 E did not show a 
significant difference in the total number (695±101 in the WT and 892±156 in the transgenic 
EDL), providing the definite evidence that the increase of the wet weight in MLC/Class 2 IGF-
1Ea transgenic animals (section 3.3.8) was due to hypertrophy of the muscle fibers.
In contrast to line MLC/Class 2 IGF-1Ea, the CSA was not significantly changed in any of the 
muscles analyzed for line MLC/Class 1 IGF-1Eb (Figure 3.19 B). However, a modest 
increase was noted for all fiber types in the EDL muscle (fast: 4.5%, intermediate: 4.8%, and 
slow: 12%) and for the fast fibers in the TA muscle (6%). When analyzed for size distribution, 
the TA muscle (Figure 3.19 C), as well as the EDL muscle (data not shown) showed a 
modest shift towards a higher percentage of bigger fibers.
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Figure 3.19 Histological analysis of MLC/Class 1 IGF-1Eb muscles. Six-months-old mice were compared to 
littermates of the same sex (n=4 for both). A Representative pictures of EDL and TA sections stained with NADH-
TR. B CSA analysis of EDL and TA fast, intermediate, and slow fibers. C Size distribution of different fiber types 
of the TA muscle. D Total number of fibers of the EDL muscle. E Whole muscle CSA of TA, EDL, and soleus. F 
Fiber type composition of the EDL muscle.
Since the analysis of wet skeletal muscle weight described in section 3.3.8 demonstrated a 
significant increase for both the EDL and TA muscle, the total number of fibers was counted 
in the EDL muscle to determine if a higher number of fibers could account for this weight 
increase. Results shown in Figure 3.19 D, demonstrate that there was no change between 
the total number of fibers between the WT and transgenic EDL muscle (771±101 in the WT 
and 694±260 in the transgenic). Thus, the weight increase could not be correlated to a higher 
amount of fibers in the muscle.
To determine whether the shift towards a higher percentage of big fibers in the EDL and TA 
was sufficient to account for the CSA increase of the whole muscle, this parameter was 
determined as well and showed a 19% increase for the TA CSA, a 36.5% increase for the 
EDL and no change for the soleus (Figure 3.19 E). None of these changes reached
significance, but generally indicate that a small increase in individual fiber size can account 
for an increase of the whole muscle CSA, without affecting the mean values for fiber-specific 
CSA.
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Finally, the analysis of fiber composition in the EDL of the MLC/Class 1 IGF-1Eb transgenic 
animals showed no changes (fast: 47±6% in the WT, 51±8% in the transgenic; intermediate:  
20±2% in the WT, 19±2% in the transgenic; slow: 31±6% in the WT, and 29±6% in the 
transgenic) (Figure 3.19 F).
A similar analysis of the MLC/Class 2 IGF-1Eb transgenic muscles revealed that the CSA of 
EDL fast and slow fibers was significantly increased (fast 32%, p=0.04 and slow 19%, 
p=0.01), while intermediate fibers were not affected. The TA instead did not show a 
significant increase in any of the fiber types, even though a very moderate elevation was 
detectable (fast: 8.4%, intermediate: 4%, and slow: 4.4%) (Figure 3.20 B). A slight increase 
of the CSA was also seen in the soleus muscle, with intermediate fibers being 10% and slow 
fibers being 25% increased, but due to a high standard deviation, values did not reach 
significance (intermediate: 1933±264 µm2 in the WT, 2129±178 µm2 in the transgenic; slow: 
1550±250 µm2 in the WT and 1928±206 µm2 in the transgenic) (Figure 3.20 B). The analysis 
of the fiber size distribution revealed that despite of the non-significant increase of fiber CSA 
in the TA muscle, a shift towards a higher percentage of bigger fibers was induced in 
presence of the Class 2 IGF-1Eb transgene (Figure 3.20 C). A similar shift was noted for
fibers of the EDL muscle (data not shown). The shift was much less pronounced than seen 
for MLC/Class 2 IGF-1Ea fibers and more comparable to line MLC/Class 1 IGF-1Eb. 
Measurements of skeletal muscle weight of MLC/Class 2 IGF-1Eb mice described in section 
3.3.8, did not show a significant increase of skeletal muscle wet weight, even though the TA 
and EDL muscle weights were elevated (20% TA and 7% EDL at six months of age). 
To exclude a hyperplastic response to Class 2 IGF-1Eb over-expression, the total number of 
EDL fibers was determined and as seen for the other transgenic lines, did not show a 
significant change (695±101 in the WT and 703±129 in the transgenic) (Figure 3.20 D). Thus,
the increased amount of big fibers in the TA and EDL, which at least in the EDL muscle also 
resulted in a significant increase of CSA, accounts for the elevation of muscle weight. The 
investigation of changes in the distribution of fibers in the EDL muscle did not show any 
significant changes (fast: 47±6% in the WT, 36±5%, in the transgenic, intermediate: 20±2% 
in the WT, 22±4% in the transgenic, slow: 32±6% in the WT and 40±2% in the transgenic).
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Figure 3.20 Histological analysis of MLC/Class 2IGF-1 Eb muscles. Six-month-old transgenic mice were 
compared to littermates of the same sex (n=4 for both). A Representative pictures of EDL and TA sections 
stained with NADH-TR (upper panel). Identity of fast IIB fibers was confirmed with antibodies against type IIB 
myosin and laminin (lower panel). B CSA analysis of EDL and TA fast, intermediate, and slow fibers. C Size 
distribution of different fiber types of the TA muscle. D Fiber type composition of the EDL muscle. E Analysis of 
the total number of fibers in the EDL muscle.
In summary, the histological and morphometric analysis of three of the transgenic lines, 
showed a consistent increase in the CSA of all skeletal muscle fiber types in the EDL and TA 
muscle of MLC/Class 2 IGF-1Ea animals. The CSA of soleus fibers was unchanged. In 
contrast to these findings, MLC/Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb showed a milder 
phenotype, with a modest shift towards a higher percentage of bigger fibers, which did not 
reach significance in the MLC/Class 1 IGF-1Eb animals, and were only just significant for 
MLC/Class 2 IGF-1Eb EDL fast and slow muscle fibers. The CSA of the soleus muscle was
also not significantly changed in these animals. None of the transgenic lines analyzed 
showed an effect on the total number of fibers in the EDL muscle and no changes were seen 
in the fiber distribution of this muscle.
3.3.10     Skeletal muscle physiology of IGF-1 isoform transgenic skeletal muscle
In order to translate the changes seen in the skeletal muscle phenotype of the different IGF-1 
transgenic lines into functional performance of these muscles, the EDL and soleus muscles 
were analyzed for their physiological properties. This work was done in collaboration with 
Antonio Musaro (University of Rome, La Sapienza). The protocol used is described in detail 
in section 2.5.2. Male WT animals (n=4) were compared to transgenic animals at 2.5 months
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of age (MLC/Class 2 IGF-1Ea n=5, MLC/Class 1 IGF-1Eb n=3, MLC/Class 2 IGF-1Eb n=4). 
Analysis of MLC/mIGF-1 animals (n=4 for WT and transgenic animals) was done separately 
on six-months-old mice and the results were kindly provided by Antonio Musaro for 
comparison. Measurement of the single twitch force (Ftwitch), the tetanic force (Fmax), and the 
specific force (Fspec) allow conclusions about the muscle strength and force generation. The 
measurements of the time the muscle needs to reach the peak of Ftwitch (Tresponse) reflects the 
contraction speed and is related to the muscle fiber composition, which also determines the 
time the muscle needs to reach half the tetanic force (Tfatigue). The analysis of these 
parameters was analyzed in the EDL muscle as an example of a predominantly fast muscle, 
and in the soleus, as an example for a slow muscle.
Figure 3.21 Functional analyses of IGF-1 isoform transgenic muscles (1). Two and a half months-old animals 
of male sex were analyzed for EDL and soleus electrophysiological properties. MLC/mIGF-1 animals were 
analyzed at six month of age and are therefore shown separately. The number of animals from each line is 
indicated at the bottom of each column. A EDL single twitch force generation (Ftwitch) is shown in the left panel and 
was only significant for MLC/Class 2 IGF-1Ea (p=0.01). Soleus Ftwitch is shown in the left panel and was 
significantly increased in MLC/Class 1 IGF-1Eb (p=0.04). Data for MLC/mIGF-1 was not available. B EDL 
contraction speed (Fresp) is shown in the left panel and showed a significant change for MLC/Class 2 IGF-1Ea 
(p=0.04), while soleus Fresp shown in the right panel, was unchanged.
Analysis of the single twitch force Ftwitch in the EDL muscle revealed a significant increase for  
MLC/Class 2 IGF-1Ea animals (76%, p=0.01), while MLC/Class 1 IGF-1Eb (12%) and 
MLC/Class 2 IGF-1Eb (23%) showed an increase that was not significant (Figure 3.21 A left 
panel). Data to determine this parameter for MLC/mIGF-1 was unfortunately not available. 
The EDL contraction speed (Tresponse) was slightly decreased in MLC/Class 2 IGF-1Ea (9%) 
and Class 1 IGF-1Eb (9%) animals, while unchanged in MLC/mIGF-1 (12±1.2 ms in the WT 
and 12±1.2 ms in the transgenic) and MLC/Class 2 IGF-1Eb animals (12±0.9 ms in the WT 
and 12±0.9 ms in the transgenic) (Figure 3.21 B left panel). Measurements of the maximal 
force (tetanic force) Fmax of the EDL muscle showed the most dramatic increase for line 
MLC/Class 2 IGF-1Ea (101% (p=0.003)). MLC/mIGF-1 transgenic EDL muscles also showed
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a significant increase of 54% (p=0.01), while values for MLC/Class 1 IGF-1Eb and 
MLC/Class 2 IGF-1Eb were not significant due to high variability of the measurements. 
However, the tetanic force was increased by 43% and 24% respectively (Figure 3.22 A left 
panel). The time the different muscles needed to reach half their EDL tetanic force Fmax
(Tfatigue) was decreased by 30% in MLC/Class 2 IGF-1Ea muscles, MLC/Class 1 IGF-1Eb 
Tfatigue was decreased by 39% and a decrease of 23% was measured in MLC/Class 2 IGF-
1Eb EDL muscles. The high variability of the WT samples makes this decrease very 
unreliable and therefore none of the values were significant (Figure 3.22 B left panel). Values 
measured for line MLC/mIGF-1 were not changed at all (WT: 18.1±1.6 ms, transgene: 
17.1±1.7 ms). Finally, the specific force Fspec for every muscle was calculated by dividing the 
tetanic force Fmax by the weight of the muscle measured. EDL specific force was increased by 
43% in MLC/Class 2 IGF-1Ea samples and both MLC/Class 1 IGF-1Eb and MLC/Class 2 
IGF-1Eb showed an increase of 25%, without being significant in any of these animals. 
MLC/mIGF-1 did not show any changes in EDL specific force (WT: 15.5±6 N/g, transgenic: 
15.4±2.4 N/g) (Figure 3.22 C left panel).
Figure 3.22 Functional analyses of IGF-1 isoform transgenic muscles (2). Two and a half months-old animals 
of male sex were analyzed for EDL and soleus electrophysiological properties. MLC/mIGF-1 animals were 
analyzed at six month of age and are therefore shown separately. The number of animals from each line is 
indicated at the bottom of each column. A EDL tetanic force (Fmax) is shown in the left panel and was significant 
for MLC/Class 2 IGF-1Ea (p=0.003) and MLC/mIGF-1 (p=0.01). Soleus Fmax is shown in the right panel and was 
unchanged in all transgenic lines. B The time the EDL muscle needed to half Fmax (Tfatigue) is shown in the left 
panel and was not significantly changed in any of the samples. Results for the soleus muscle are shown in the 
right panel and were unchanged as well. C The specific force Fspec was calculated by dividing Fmax by the weight 
of each analyzed muscle. Results for EDL (left panel) and soleus (right panel) were not significantly influenced by 
the presence of different IGF-1 isoform transgenes.
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The same measurements were performed on the soleus to evaluate the effect of IGF-1 
isoform over-expression on the overall physiological performance of a slow muscle. The 
single twitch force Ftwitch of the soleus muscle of the different IGF-1 isoform transgenic lines 
showed a non-significant increase of 37% in Line MLC/Class 2 IGF-1Ea and 27% in 
MLC/Class 2 IGF-1Eb, while the 57% increase observed in MLC/Class 1 IGF-1Eb soleus 
was significant (p=0.04) (Figure 3.21 A right panel). The soleus contraction speed (Tresponse) 
did not show any transgene-induced changes (MLC/mIGF-1: WT 34±5 ms, transgenic 33±1.6 
ms; MLC/Class 2 IGF-1Ea: WT 28±5 ms, transgenic 29±4 ms; MLC/Class1 IGF-1B: WT 
28±5 ms, transgenic 27.1±1.4 ms; MLC/Class 2 IGF-1Eb: WT 28±5 ms, transgenic 30.6±1.9 
ms) (Figure 3.21 B right panel). The assessment of the maximal force (tetanic force) Fmax in 
the soleus muscle revealed no changes for MLC/Class 2 IGF-1Ea (WT: 65±24 mN 
transgenic: 64±19 mN), MLC/Class 1 IGF-1Eb (WT: 65±24 mN transgenic: 73±33 mN), and 
MLC/Class 2 IGF-1Eb (WT: 65±24 mN transgenic: 75±33 mN). MLC/mIGF-1 samples 
instead showed a 40% increase, but due to a very high variability, this value did not reach 
significance (86±31 mN in the WT and 122±47 mN in the transgenic) (Figure 3.22 right 
panel). The time the different muscles needed to reach half the tetanic force Fmax (Tfatigue) was 
not significantly changed for MLC/Class 2 IGF-1Ea (WT: 65±21 ms, transgenic: 75±18 ms), 
MLC/Class 1 IGF-1Eb (WT: 65±21 ms, transgenic: 69±20 ms), and MLC/Class 2 IGF-1Eb 
(WT: 65±21 ms, transgenic: 81±18 ms). MLC/mIGF-1 animals showed a 27% increase, but 
the variability was too high to reach significance (Figure 3.22 B right panel). Finally, the 
specific force Fspec, calculated by dividing the tetanic force Fmax by the weight of the muscle, 
did not show any differences in any of the transgenic mice analyzed (MLC/mIGF-1: WT 9.4±3 
N/g, transgenic 69.2±1.8 N/g; MLC/Class 2 IGF-1Ea: WT 7±3 N/g, transgenic 6.9±2; 
MLC/Class 1 IGF-1Eb: WT 7±3 N/g, transgenic 8.5±3.5; MLC/Class 2 IGF-1Eb: WT 7±3 N/g, 
transgenic 9.4±2.8 N/g) (Figure 3.22.C right panel).
In summary, the electrophysiological analysis of the different IGF-1 isoform transgenic lines 
for the parameters related to force generation and strength (single twitch force (Ftwitch), tetanic 
force (Fmax), and specific force (Fspec)), revealed a significant increase for the EDL muscle of 
MLC/Class 2 IGF-1Ea animals, and at least the maximal force generation was significantly 
increased in the EDL muscle of MLC/mIGF-1. These findings correlate to the increased 
muscle mass and fiber CSA of these two transgenic lines (described in section 3.3.8 and 
3.3.9) and establish a functional hypertrophy for MLC/Class 2 IGF-1Ea, that is even more 
pronounced than previously described for line MLC/mIGF-1 [77]. In contrast, force-related 
parameters were not significantly changed in lines MLC/Class 1 IGF-1Eb and MLC/Class 2 
IGF-1Eb, which correlates to the much milder increase in muscle mass and fiber CSA in 
these two transgenic lines (sections 3.3.8 and 3.3.9). Parameters correlated to the fiber
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composition, Tresponse and Tfatigue in the EDL muscle were not significantly changed in any of 
the transgenic lines, confirming that the overall fiber composition was not affected by any of 
the transgenes. Analysis of these parameters in the soleus muscle of the IGF-1 isoform 
transgenic lines did not reveal any significant changes for none of the lines, but MLC/Class 1 
IGF-1Eb, which showed a significant increase of the single twitch force Ftwitch. 
3.3.11 IGF-1 isoform-mediated signaling
In the past years at least three different pathways have been shown to be activated by IGF-1 
(compare section 1.4.5). In the present work, several routes were taken to gain an overview 
of the signal transduction pathways that might mediate the different phenotypes seen in the 
distinct IGF-1 isoform transgenic lines. A first step in this analysis was to determine the 
activation level of the IGF-1 receptor (section 3.3.11a). In a next step, two high throughput 
screens were applied to gain a broad overview of candidate molecules involved in the IGF-1 
isoform mediated response: Affymetrix GeneChip analysis (section 3.3.11b), and the 
KinetworksTM Phospho-site screen done by Kinexus (section 3.3.11c). While Affymetrix 
analysis yielded some insight on the genes that might be differentially regulated by IGF-1, 
the Kinexus analysis provided an overview of the IGF-1 isoform-induced and 
phosphorylation-mediated activation of key kinases involved in IGF-1 signaling. Note, that 
the Affymetrix analysis and the KinetworksTM Phospho-site screen were performed on mice 
from Line MLC/Class 1 IGF-1 Ea and not MLC/mIGF-1, since this analysis was performed 
early in the characterization of the transgenic lines. Finally, the involvement of the calcineurin 
pathway was investigated, since this pathway has been implicated in mediating the 
hypertrophic phenotype induced by the mIGF-1 (Class 1 IGF-1Ea) transgene [77, 282]
(section 3.3.11d).
3.3.11a Activation of the IGF-1 receptor in IGF-1 isoform transgenic lines
To date it is well established that IGF-1 exerts its function by binding to the IGF-1 receptor 
(IGF-1R). To determine if all IGF-1 isoforms had an effect on the expression level of IGF-1R 
mRNA, Northern blot analysis was performed with total RNA isolated from the gastrocnemius 
muscle of one-month-old male WT and transgenic mice (Figure 3.23 A). No changes were 
seen between expression levels of WT and transgenic samples, indicating that transcriptional 
regulation was not affected by over-expression of the different IGF-1 isoforms.
To determine if the IGF-1R was regulated by phosphorylation, immunoprecipitations (IP) 
were performed with an antibody against the ß-subunit of the IGF-R. Protein samples were 
prepared from six-months-old male mice of WT and transgenic background and 1.3 mg of 
protein were used for immunoprecipitations. For Western blot analysis the whole IP reaction 
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was used for SDS-page and transfer and phosphorylation of the IGF-1R ß-subunit was 
detected with an anti-phosphotyrosine antibody (for details see section 2.3.4). Results 
presented in Figure 2.23 B clearly show the activation of the IGF-1R in all of the transgenic 
samples when compared to WT samples. Density analysis of the specific bands (Radames 
software) revealed that the strongest phosphorylation was seen in response to both Class 2 
IGF-1 isoforms, Class 2 IGF-1Ea and Class 2 IGF-1Eb (Figure 3.23 C).
Figure 3.23 mRNA expression and activation of IGF-1R. A  Northern blot analysis of IGF-1R expression.10µg 
of total RNA from one-months-old male quadriceps muscle from WT and transgenic mice were used and the IGF-
1R mRNA was detected with an IGF-1R-specific probe. Levels of expression did not show any changes induced 
by any of the transgenes. B Immunoprecipitation of the ß-subunit of the IGF-1R. 1.3mg of protein per sample was 
immunoprecipitated with an IGF-1Rß-specific antibody. Western blot analysis was performed with an anti-
phosphotyrosine antibody to detect the phosphorylation of the intracellular IGF-1R ß-subunit. All transgenes 
activated the IGF-1R. C Density graph for phospho-IGF-1R-specific bands. Activation of IGF-1R was strongest in 
Class 2 IGF-1 transgenes.
Taken together, these results show that IGF-1R mRNA not influenced by over-expression of 
different IGF-1 isoforms, while activation of the IGF-1R ß-subunit was seen in all IGF-1
isoform transgenic lines. These findings proof that over-expressed IGF-1 isoforms are all 
capable of activating the receptor, even though the extent of activation is variable, with Class 
2 IGF-1 isoforms showing the strongest effect.
3.3.11b   Affymetrix GeneChip analysis of IGF-1 isoform transgenic muscles
Gene array analysis represents a powerful tool for gaining an overview of changes in the 
transcriptional regulation in response to a certain stimulus. Affymetrix GeneChip analysis 
was applied in this work in an attempt to understand IGF-1 isoform-induced alterations in 
RNA expression patterns. 
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Affymetrix analysis has been performed on the quadriceps muscle of WT and transgenic 
mice for each IGF-1 transgenic line (n=2 for each) and a large set of data was obtained. A 
crucial aspect of analyzing the Affymetrix data is to choose a reliable way of finding 
interesting candidate genes among the 22626 probe sets that returned a positive signal. The 
strategy for reducing the data sets is described in section 2.1.16. To further decrease the 
number of genes to an acceptable amount of candidates we chose a cut off of 1.9-fold up- or 
down-regulated. Notably, this excludes genes that are not regulated to such an extent, but 
nevertheless might have an important role. But this drawback has to be accepted to allow 
evaluation the data. However, it might be useful in the future to re-evaluate the data under 
different conditions. 
Using such a cut off, the filtered genes can be grouped under several criteria, such as the 
sub-cellular localization, the molecular function, the involvement in disease states and many 
more, depending on the interest of research. We chose to group by sub-cellular localization 
to gain an overview of regulated genes with a function in a certain compartment of the cell. 
This can provide an idea about the nature of IGF-1 isoform-mediated effects. Figure 3.24 A-
D shows the pooled up-or down-regulated genes for each IGF-1 isoform transgenic line.
This kind of sorting of genes demonstrates that almost half of the genes regulated by each 
IGF-1 isoforms can be correlated to organelle function, while only a very small percentage of 
those genes can be connected to a function in the mitochondria. An almost equal amount of 
genes is related to a function in the extracellular matrix and the cytosol, while IGF-1 isoforms
regulated only a very small percentage of genes with a nuclear function. Class 1 IGF-1Eb did 
not regulate any nuclear genes. Between the different isoforms, no major differences were 
seen when analyzing the data in this way. A selection of genes that were found to be up- or 
down-regulated in this analysis is listed in tables B1-B4 in the appendix of this thesis 
(page145-148). These gene lists identify genes that were up-or down-regulated in response 
to one specific isoform (highlighted with bold font) and represent those candidate genes, 
which might play an important role in the IGF-1 isoform-mediated response. The regulation of 
these genes has not been confirmed in the present thesis, but an involvement of these 
candidates as downstream targets of an IGF-1-mediated response is planned for the future. 
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Figure 3.24 Distribution of regulated genes by cellular localization. The genes that were regulated (either up-
or down-regulated) in each IGF1-isoform transgenic were pooled and classified by cellular localization according 
to their Gene Ontology annotations (available at www.Affymetrix.com). The values in each pie chart therefore 
represent the total number of regulated genes scored as belonging to each compartment. A MLC/Class 1 IGF-
1Ea B MLC/Class 1 IGF-1Eb C MLC/Class 2 IGF-1Ea D MLC/Class 2 IGF-1Eb
To just name some examples, an interesting candidate identified as being unique to 
MLC/Class 1 IGF-1 Ea transgenic samples is forkhead box O3a (FOXO3A), which is a 
downstream target of Insulin/IGF1-Akt pathway and has been shown to impede muscle
growth both in cardiac and skeletal muscle [62, 301]. Foxo3A can also stimulate expression 
of IGFBP1 in response to insulin signaling [302] and was found 2.8-fold down-regulated 
specifically in the MLC/Class 1 IGF-1 Ea transgenic samples. An interesting candidate gene 
found to be 2.74-fold up-regulated in MLC/Class 1 IGF-1Eb animals is the matrix 
metalloproteinase 7 (MMP7), which has been associated with processing of an important 
regulator of IGF1 function, i.e. IGFBP5 [303]. In MLC/Class 2 IGF-1Ea animals the Bcl2-like 
2 mRNA, which was 2.05-fold down-regulated, represents an attractive candidate belonging 
to the family of Bcl-proteins that regulate cell death and that could play a key role in disease 
states [304, 305]. Although we could identify genes showing altered expression solely in the 
MLC/Class 2 IGF-1Eb, they did not appear as solid candidate of interest. However, a 
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stringent analysis of up- or down-regulated genes can offer the opportunity to explore 
molecular players previously unnoted to the current view of IGF1 isoform function. Therefore, 
consolidation of our analysis by thorough confirmation of identified targets should be a 
prerequisite for further speculation on the potential underlying mechanisms.
A general observation was that more genes were down-regulated in the different IGF-1 
transgenic samples and that there was little overlap of differentially expressed genes among 
the different IGF-1 isoforms. In order to have a preliminary overview of potentially common 
mediators of IGF1-isoform-specific functions, we lowered the cut off of the filtered genes and 
analyzed the lists of only those genes that presented opposing trends of expression in Class 
1 vs. Class 2, or in Ea vs. Eb isoforms. The list of such genes (see table B5 and B6) is less 
stringent, but highlights a group of genes that in both IGF1Ea isoform transgenic models 
show a trend opposed to the one of the IGF1Eb isoform transgenic models. These genes 
include putative candidates involved in regulating signal transduction, such as endothelin 
converting enzyme and proteins associated to Rho and G-protein activity, as well as proteins 
relevant for muscle function, such as a cardiac myosin isoform, integrin subunits and cGMP-
dependent protein kinase. Due to the intrinsic significance of gene profiling analysis, and to 
the lower cut off value chosen for this analysis, these genes are potentially useful to 
elaborate a working hypothesis able to explain at least some of the phenotypes common to 
the IGF1Ea transgenic models; however, further validation of the candidates will be 
necessary before formulating such hypothesis.
The analysis described above, although only valid as initial assessment of the data, is useful 
to identify solid targets to confirm and possibly link to the different phenotypes. However, one 
could take an alternative approach. With increasing demand from researchers for tools that 
allow to analyze large sets of data (coming from gene expression analyses or other means of 
high throughput screenings), more sophisticated network analysis tools have been 
developed. These software platforms rely on an underlying knowledge database in which 
every node (gene of interest) is connected to any other node by either direct or indirect 
relationships (such as being a downstream/upstream regulator, a phosphorylating enzyme, a 
binding partner and so on). By screening the filtered array of probe sets through these 
network interaction repositories, it is possible to identify groups of genes that, although being 
differentially regulated outside of specific stringency criteria, nevertheless belong to a 
coherent biochemical/molecular pathway. By identifying and grouping genes with altered 
expression in this way, we can gain a consistent overview of the significance of those 
candidate genes. Of course, the more comprehensive the database of knowledge, the more 
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solid the analysis can be. Ingenuity Inc. (www.ingenuity.com) offers such a tool and we had 
the possibility to run these data via a trial account. 
In order to validate our approach we selected a network related to IGF1R function, included 
additional elements (such as NF-kB related genes) and compared the results by overlapping 
the expression ratios relative to each of the four transgenic models (Figure C1 in the 
appendix). The results were impressively promising. Targets such as the IGFBPs, which are 
important regulators of IGF1 function and which were not highlighted in our previous analysis 
because of their lower level of expression changes (below 1.9-fold up- or down-regulated), 
are now embedded in a coherent network and appear to be selectively and differentially 
deregulated in the four animal models. At the same time this view highlights other genes with 
different levels of regulation, which could be interesting targets for further studies, such as 
IGF-2, GH or the IGFBP-related gene Cyr61 (Figures C2-C5 in the appendix)
3.3.11c KinetworksTM Phospho-site screen 
The KinetworksTM Phospho-site screen provides both qualitative and semi-quantitative 
analysis of the expression and phosphorylation states of protein kinases. For analysis of the 
IGF-1 isoform transgenic muscles, the KinetworksTM Phospho-site screen KPSS 4.1 was 
chosen, because it provides a broad overview of the phosphorylation of a set of kinases 
known to be downstream of the IGF-1R (Table 4). This tool was used to gain a broad
overview of the protein kinases that might be involved in the signal transduction pathways 
mediated by different IGF-1 isoform. 
Whole quadriceps samples, isolated in duplicates from two transgenic mice per transgenic 
line were sent for analysis. The quadriceps muscles from one negative littermate for each 
line were pooled for comparison (total n=4). The complete processing of the samples was 
performed by the KinetworksTM service (further information is available on the Kinexus
webpage:  www.kinexus.ca and more specifically on http://www.kinexus.ca/KPSS.htm).
Results obtained by this high throughput screen are shown in Figure 3.25 A-F. The first 
pathway of interest was the PI(3)-kinase/Akt pathway (Figure 3.25 A), where GSK-???????-
3ß, mTOR, PDK1, and Akt1 were analyzed for their phosphorylation state. In addition, 
members of the S6-kinase family, p85S6K, p70 S6K and ribosomal S6 protein-serine kinase 
(RSK1/2/3) were part of the screen (Figure 3.25 B). Notably, most of the values were not 
significantly changed, thus only tendencies can be described for this pathway. In the 
presence of both Class 1 isoforms protein phosphorylation was consistently down-regulated 
or did not change (MLC/Class 1 IGF-1Ea: GSK-????-8%, GSK-3ß: -29%, PDK1: -28%, Akt1: -
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26%; MLC/Class 1 IGF-1Eb: GSK-????-6%, GSK-3ß: 2%, PDK1: -35%, Akt1: -19%). Class 2 
isoforms in contrast up-regulated the phosphorylation of these protein-kinases (ML/Class 2 
IGF-1Ea:  GSK-???? ????? ???-3ß: -35%, PDK1: 4%, Akt1: 12%; MLC/Class 2 IGF-1Eb: 
GSK-???? ????? ???-3ß: 55%, PDK1: 18%, Akt1: 50%). The only exception was mTOR 
phosphorylation, which was up-regulated by both Ea-containing isoforms (MLC/Class 1 IGF-
1Ea: 32% and MLC/Class 2 IGF-1Ea: 18%), while unchanged in samples over-expressing 
the two Eb-containing isoforms (MLC/Class 1 IGF-1Eb: 2% and MLC/Class 2 IGF-1Eb: 2%). 
These results point towards a preferential activation of the PI(3)-kinase/Akt pathway by 
isoforms containing a Class 2 signal peptide, while Class 1 isoforms do not seem to activate 
those molecules. 
Interestingly this trend does not apply to the S6-kinases, which are also downstream of the 
PI(3)-kinase (Figure 3.25 B). p85 S6K (S6K2) phosphorylation of residues T444 and S447 was 
significantly down-regulated by MLC/Class 1 IGF-1Ea (-64%, p=0.01), MLC/Class 2 IGF-1Ea 
(-58%, p=0.01), and MLC/Class 1 IGF-1Eb (-71%, p=0.003), while the 17% decrease in 
MLC/Class 2 IGF-1Eb samples was not significant. Phosphorylation of residue T412 of S6K2 
instead was unchanged in presence of MLC/Class 2 IGF-1Ea (-1%) and increased by the 
other three IGF-1 isoforms (MLC/Class 1 IGF-1Ea: 30%, MLC/Class 1 IGF-1Eb: 121%, 
MLC/Class 2 IGF-1Eb: 218%). Even though these results were not significant, our findings 
suggest a preferential phosphorylation of residue T412 in these latter three transgenic lines. 
Analysis of p70S6K (S6K1) phosphorylation showed a strong induction in presence of IGF-1 
isoforms MLC/Class 1 IGF-1Ea (299%), MLC/Class 2 IGF-1Ea (635%), and MLC/Class 2 
IGF-1Eb (606%), while p70S6K was not present in WT and MLC/Class 1 IGF-1Eb samples. 
The induction seen in the first three transgenic lines again did not reach significance, but 
allows speculations about a preferential activation of p70S6K over p85S6K.
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Results page 114
Table 4 List of kinases screened by the KinetworksTM Phospho-site screen
Finally, phosphorylation of RSK1/2/3 revealed a significant increase for both Ea-containing 
isoforms (MLC/Class 1 IGF-1Ea: 91%, p=0.02 and MLC/Class 2 IGF-1Ea: 60%, p=0.02), 
while the induction by both Eb-containing isoforms was not significant (MLC/Class 1 IGF-
1Eb: 42% and MLC/Class 2 IGF-1Eb: 21%). The significant results obtained for both Ea-
containing isoforms do raise the possibility that these IGF-1 variants might transmit part of 
their hypertrophic signal via RSK1/2/3.
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Figure 3.25 KinetworksTM Phospho-site screen. The entire processing of samples was performed by the 
KinetworksTM service: Transgenic quadriceps samples from two one-month-old animals per genotype have been 
sent for analysis together with one negative littermate from each line (total n=4). A Results for members of the Akt 
pathway. No significant changes were observed. B Screening results for members of the S6-kinase family. 
Significant changes were only seen for specific residues of S6K p85. C Members of the MAP-kinase pathway 
were not significantly influenced by IGF-1 isoform over-expression. D Phosphorylation level of IKK? and ß. 
MLC/Class 1 IGF-????????????????????????????????-phosphorylation (p=0.01).
The other major pathway downstream of the IGF-1R is the MAP-kinase pathway. Raf-1, as 
the most upstream kinase, MAPK-Erk protein-serine kinase (MEK) 3/6 and MEK1/2, Erk1, 
and Erk2 were analyzed for their phosphorylation state by the KinetworksTM Phospho-site 
screen (Figure 3.25 C). None of the results obtained for this part of the screen were 
significant and most of the results displayed enormous variations and therefore did not show
major phosphorylation-mediated changes. However, phosphorylation of Raf1 was increased 
only in response to Class 1 IGF-1 isoforms (MLC/Class 1 IGF-1Ea: 55% and MLC/Class 1 
IGF-1Eb: 48%), while both Class 2 IGF-1Ea isoforms showed a decrease (MLC/Class 2 IGF-
1Ea: -19% and MLC/Class 2 IGF-1Eb: -42%). MEK3/6 displayed minor differences 
(MLC/Class 1 IGF-1Ea: -3%; MLC/Class 2 IGF-1Ea: -1%; MLC/Class 1 IGF-1Eb: 6%; 
MLC/Class 2 IGF-1Eb: -12%), MEK1/2 levels were highly variable and no pattern of Class or 
E-peptide-specificity could be noted (MLC/Class 1 IGF-1Ea: -9%; MLC/Class 2 IGF-1Ea: -
8%; MLC/Class 1 IGF-1Eb: -31%; MLC/Class 2 IGF-1Eb: 55%). Erk1 phosphorylation was 
down-regulated in all different IGF-1 isoform transgenic samples (MLC/Class 1 IGF-1Ea: -
23%; MLC/Class 2 IGF-1Ea: -31%; MLC/Class 1 IGF-1Eb: -23%; MLC/Class 2 IGF-1Eb: -
3%), while Erk2 activation was decreased in MLC/Class 1 IGF-1Ea (-23%), MLC/Class 2 
IGF-1Ea (-12%), and MLC/Class 1 IGF-1Eb (-5%) transgenic lines, but was slightly up-
regulated in MLC/Class 2 IGF-1Eb (12%). Although the lack of significance in these changes 
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precludes any definitive involvement of this pathway, the data exclude a pronounced up-
regulation of Erk1 and Erk 2 in response to any of the IGF-1 isoforms. 
Other kinases screened by using the KinetworksTM approach, that were not part of the major 
pathways described for IGF-1 are not described within this work, since they were not 
significantly changed. The only remaining significant result to be described here was 
obt????????????????????????????????????????????????????????????????????????????????????-
1Ea (-11%), MLC/Class 2 IGF-1Ea (14%), and MLC/Class 2 IGF-1Eb (-0.5%), while 
MLC/Class 1 IGF-1Eb significantly up-?????????? ????-phosphorylation by 51% (Figure 3.25 
D). IKKß phosphorylation was not significantly affected by any of the IGF-1 isoform 
transgenes, but was slightly decreased (MLC/Class 1 IGF-1Ea: -18%, MLC/Class 2 IGF-1Ea: 
-42%) or unchanged (MLC/Class 2 IGF-1Eb: 0.6%).
In summary, results described above point towards Class 2 IGF-1 isoforms signaling through 
the classical PI(3)-kinase pathway, since they showed an increase in Akt1, PDK-1, and GSK-
??????? -3ß phosphorylation, while Class 1 IGF-1 isoforms did not. The analysis of the S6-
kinases as further downstream targets of this pathway, revealed an induction of p70S6K –
phosphorylation in MLC/Class 1 IGF-1Ea, MLC/Class 2 IGF-1Ea, and MLC/Class2 IGF-1Eb 
samples, while p70S6K was absent in MLC/Class 1 IGF-1Eb samples. RSK1/2/3 S6-kinases-
phosphorylation was increased in response to all IGF-1 isoforms, but only Ea-peptide 
containing isoforms (MLC/Class 1 IGF-1Ea and MLC/Class 2 IGF-1Ea) values reached 
significance. The MAP-kinase pathway was not regulated to a significant extent, but showed 
increased levels of Raf1-phosphorylation for both Class 1 IGF-1 isoform transgenic lines 
(MLC/Class 1 IGF-1Ea and MLC/Class 1 IGF-??????????????????????????????????????? ?????
was significantly increased in MLC/Class 1 IGF-1Eb samples, an effect that was not 
previously described as being regulated by IGF-1 in resting skeletal muscle previously.
Taken together, a high variation was observed, which makes interpretation of these results 
difficult. It should be noted that due to the high cost of different lines to be screened, only 
duplicates could be sent for each transgenic line, which makes the significance of these 
findings statistically questionable. Especially when interpreting results for MLC/Class 1 IGF-
1Ea and comparing them to a previously performed KinetworksTM analysis on MLC/mIGF-1 
animals [261], the different nature of the transgenic line has to be taken in account for the 
experiments described in this chapter.
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3.3.11d The calcineurin pathway
In the last few years the calcineurin (Cn) pathway has been controversially implicated in the 
mediation of the hypertrophic response in skeletal muscle (compare section 1.4.5.5). 
Especially because previous work on the mIGF-1 (= rat Class 1 IGF-1Ea) transgene 
implicated Cn in mediating skeletal muscle hypertrophy [77, 282], the role of Cn isoforms in 
the different IGF-1 isoform transgenic mice was investigated.
To discover changes in expression of the three calcineurin A-??????????????????????ß1, and 
Aß2, quantitative RT-PCR was performed on quadriceps RNA (n=3) of male WT and each 
IGF-?? ???????? ??????????? ?????? ????????? ???? ?????????? ????? ??? ???? ????????? ???? ??????
CnAß1, and CnAß2 (section 2.1.14). Results shown in Figure 3.26 A-C demonstrated that 
none of these isoforms was changed significantly in any of the IGF-1 isoform transgenic 
mice. On the contrary, a tendency towards a down-???????????????????????????????????????
CnAß2 (Figure 3.26 C) was noticed, while the expression of CnAß1 was slightly up-regulated 
in the presence of both Class 1 IGF-1 isoforms (MLC/mIGF-1: 16% and MLC/Class 1 IGF-
1Eb: 6%). MLC/Class 2 IGF-1Ea showed a 32% decrease of CnAß1 mRNA and MLC/Class 
2 IGF-1Eb showed a 162% increase. This strong increase was accompanied by a very high 
standard deviation (51±44 molecules/ng), which has to be taken in account for final 
conclusions (Figure 3.26 B).
To further confirm these results, the expression of the Cn downstream target Gata-2 was 
assessed by Northern blot analysis. Gata-2 has been shown to be up-regulated in response 
to IGF-1 in the MLC/mIGF-1 mice [77] and to be involved in mediation of cardiac hypertrophy 
[275]. Northern blot analysis was performed on RNA of the quadriceps muscle from six-
months-old male WT and transgenic mice from every IGF-1 isoform transgenic line. No 
differences were detected in Gata-2 mRNA expression levels between two WT and the 
transgenic samples (Figure 3.26 D and E), further suggesting that other pathways are 
involved in IGF-1-mediated hypertrophy. 
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Figure 3.26 The calcineurin pathway in IGF-1 isoform transgenic skeletal muscle. A-C RNA from three-
months-old male quadriceps muscle of transgenic mice from every line and from age-matched WT animals of the 
same sex (n=3 for all) was used for quantitative RT-PCR to determine changes of CnA isoforms in response to 
IGF-1 isoform over-expression. None of the IGF-1 isoform transgenic lines induced changes in CnAa (A), CnAß1 
(B) or CnAß2 (C) expression. D Northern blot analysis of GATA-2 expression in six-months-old WT (n=2) and 
transgenic mice (n=1). 10µg of total RNA were isolated from the quadriceps muscle and GATA-2 was detected 
with a specific probe. E Density of bands detected by Northern blot. No major differences could be detected for 
any of the transgenic IGF-1 isoform lines.
3.4 Regeneration of IGF-1 isoform transgenic muscle
Skeletal muscle is one of the tissues in the body that has the intrinsic capacity to regenerate 
and adapt to environmental changes. With the onset of age and/or disease, this capacity 
decreases or is even lost, leading to atrophy and paralysis of skeletal muscle (described in 
detail in section 1.2.1 and 1.2.2). Based on recent findings showing that mIGF-1 had 
beneficial effects on many disease states associated with skeletal muscle (compare section 
1.2), the obvious question of how other IGF-1 isoforms would affect regeneration of skeletal 
muscle arose and was addressed in this chapter. Since such investigations represent only a 
portion of the work for this thesis, the results presented in the following chapter have to be 
considered preliminary. Thus, we aimed to provide preliminary evidence of IGF-1 isoform 
regenerative capacities. The MLC/mIGF-1 transgenic animals have not been included in the 
histological analysis of cardiotoxin (CTX)-injured muscle, since the regenerative capacities of 
this line are well described (see above). However, for comparative reasons, MLC/mIGF-1 
samples were analyzed on the molecular level with the other lines.
Skeletal muscle injury was achieved by CTX injections into the TA and quadriceps muscle of 
male three-months-old WT and transgenic animals (n=4 for each genotype and time point). 
CTX is a snake venom, which leads to depolarization of muscle fibers resulting in necrosis of 
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those cells. Skeletal muscle samples were taken two, five, and ten days after injections. The 
TA muscle was used for histological analysis, while quadriceps samples were kept for RNA 
and protein analysis. Only injuries of similar size were chosen for comparative analysis.
3.4.1 Histological analysis of regeneration in IGF-1 isoform transgenic mice 
To evaluate changes in the regenerative capacity of the different IGF-1 isoform transgenic 
lines after CTX-induced injury, the TA muscle sections of WT and transgenic mice were 
stained by trichrome staining, which allows the visualization of skeletal muscle fibers, nuclei, 
as well as fibrotic tissue, by staining collagen. Representative pictures are shown in Figure 
3.27. After two days of CTX injection muscle fibers underwent massive necrosis, indicated by 
the comparable damaged structures and the invasion of mononuclear cells at the site of 
injury that marks the initiation of the inflammation process. The comparison of the muscle 
phenotype between the different IGF-1 isoform transgenic lines and the WT did not show any 
differences at two days after injury.  
After five days of CTX injury, the WT muscle showed a strong inflammatory response, 
reflected in the dense population of intracellular spaces by mononuclear cells (Figure 3.27 
middle panel). At this stage of regeneration, new muscle fibers start forming and can be 
identified by centrally localized nuclei. The WT muscle displayed a considerable amount of 
regenerating fibers that were still quite small and closely surrounded by mononuclear cells. In 
contrast, TA muscles of MLC/Class 2 IGF-1Ea transgenic animals showed newly forming 
fibers of much bigger size and less mononuclear cells, determined by more intracellular 
space. In addition, many newly formed fibers contained up to three nuclei already, while the
majority of WT fibers only contained one central nucleus. This indicates that the regeneration 
process in MLC/Class 2 IGF-1Ea proceeded faster. Overall, the morphology of the 
regenerating muscle appeared to be improved by the presence of this IGF-1 isoform 
transgene. Similarly, MLC/Class 1 IGF-1Eb muscle sections displayed a more ordered 
morphology with more free intracellular space. In comparison to the WT and also to 
MLC/Class 2 IGF-1Ea samples, muscles of MLC/Class 1 IGF-1Eb animals had more smaller 
new fibers, rather than bigger new fibers as seen in MLC/Class 2 IGF-1Ea animals. The 
regenerating fibers did not have more than two nuclei and were only slightly increased in size 
when compared to WT controls. MLC/Class 2 IGF-1Eb samples instead had a similar or 
even slightly stronger inflammatory response when compared to the WT, but nevertheless 
displayed a visible increase in the amount of fibers present in the injured area. The size of 
the new myofibers showed a mild increase but did not reach the size of MLC/Class 2 IGF-
1Ea fibers and the majority of those fibers contained only one central nucleus.
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Figure 3.27 Histological analysis of CTX-injected skeletal muscle. Three-month-old male WT and transgenic 
mice (n=4 for each genotype and time point) were subjected to CTX injury. Samples were taken at two, five, and 
ten days after injury. 8µm transverse sections of the TA muscle were cut and stained with trichrome staining. The 
mid region of the injury was identified for each injury and pictures were taken at a 20x magnification (corresponds 
to 200x, considering a 10x magnification of the camera). Representative pictures of samples for two days after 
injection are shown in the upper panel, five day samples are represented in the middle panel, and the lower panel 
shows the muscle morphology ten days after CTX injection.
Finally, all muscles were analyzed ten days after CTX injection to evaluate the capacity of 
the different IGF-1 isoforms to restore the muscle phenotype (Figure 3.27 lower panel). In the
WT samples, many fibers had reached almost normal size, but other regions of the 
regenerated area displayed large islands of inflammatory cells, many small fibers, and 
accumulation of fibrotic tissue. In comparison to the WT regenerated muscle, the three IGF-1 
isoform transgenic lines uniformly displayed a more normal morphology: fibers reached 
normal size without leaving much space between the fibers. Only a very small amount of 
mononuclear cells was observed and there was no accumulation of these cells as seen in 
the WT samples.  
Taken together, this preliminary analysis of tissue morphology after CTX injury revealed an 
improved regeneration process in every transgenic line analyzed. MLC/Class 2 IGF-1Ea 
displayed larger fibers containing between one and three nuclei at day five after injury, 
MLC/Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb showed more fibers when compared to WT 
and also to MLC/Class 2 IGF-1Ea. After ten days of regeneration, all transgenic lines 
displayed similar improvements in muscle morphology that appeared to be closer to the 
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normal muscle morphology when compared to the WT, indicating that the presence of the 
different IGF-1 isoforms each resulted in enhanced regeneration.
3.4.2 Changes in endogenous IGF-1 isoform expression in response to injury
IGF-1 isoforms have been implicated in the regenerative response to exercise- and stretch-
induced injury previously [209-211] and have therefore been included in the present 
regeneration study for several reasons. First, this allowed the comprehensive analysis of WT 
IGF-1 isoform expression in response to muscle injury, which previously has been focused 
on Class 1 IGF-1Ea and Class 1 IGF-1Eb expression analysis. Second, endogenous IGF-1 
levels of IGF-1 isoform transgenic lines were monitored and compared to the WT expression 
of the same isoform and time point after injury to evaluate if over-expression of certain IGF-1 
isoforms had a feedback effect on the endogenous IGF-1 isoform expression pattern after 
CTX injury. 
This analysis was performed by quantitative RT-PCR on RNA samples isolated from the 
quadriceps muscle of injured WT and transgenic animals (n=3 for all genotypes and time 
points). Three uninjured controls were included for every genotype. Analysis of endogenous 
Class 1 IGF-1Ea in the WT background revealed a non-significant increase of 111% at day 
two after injury, and a significant and pronounced increase of this isoform at day five and day 
ten after injection (209% at day five (p=0.003) and 664% at day ten (p=0.001) when 
compared to uninjured controls (Figure 3.28 A). Class 2 IGF-1Ea molecules displayed a 
similar but less pronounced pattern of increased expression, culminating in a significant 
induction after ten days of regeneration (604%, p=0.005). Notably, expression of this isoform 
was generally lower than Class 1 IGF-1Ea expression (Figure 3.28 B).
Class 1 IGF-1Eb and Class 2 IGF-1Eb isoforms instead showed very high variability with 
generally low expression profiles and were therefore not significantly changed throughout the 
process of regeneration. The only exception was a transient and significant up-regulation of 
Class 2 IGF-1Eb molecules at day five after injury (111%, p=0.02) (Figure 3.28 C and D). 
Despite the high variability, a mild induction of the two Eb-containing isoforms that was 
comparable throughout the different time points was observed.
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Figure 3.28 Expression of endogenous IGF-1 isoforms in WT CTX-injected muscle. Three-months-old male 
quadriceps RNA from WT and transgenic mice (n=3 for all) was used for quantitative RT-PCR analysis of CTX-
injury induced changes in endogenous IGF-1 isoform expression. A Class 1 IGF-1Ea RNA was significantly 
induced at day five (p=0.003) and day ten (p=0.001) after CTX-injection. B Class 2 IGF-1Ea RNA showed a 
similar trend as seen for Class 1 IGF-1Ea RNA, but was only significantly increased after ten days of regeneration 
(p=0.005). C Class 1 IGF-1Eb did not show significant changes in response to injury, but a tendentious increase 
was noted. D Class 2 IGF-1Eb was transiently and significantly induced at day five after injury (p=0.02).
In summary, the analysis of the WT expression pattern of IGF-1 isoforms upon injury 
revealed a pronounced up-regulation of both Ea-peptide-containing isoforms throughout the 
process of regeneration, reaching highest induction levels at day ten after injury. The two Eb-
containing isoforms instead, showed mild induction upon injury without being significant. The 
only exception was a transient up-regulation of Class 2 IGF-1Eb at day five after injury.
The WT expression pattern of IGF-1 isoforms was then compared to the expression pattern 
of endogenous isoforms in the different IGF-1 isoform transgenic animals. The line over-
expressing the analyzed isoform of interest was not included in the analysis, as endogenous 
isoform levels were masked by the over-expression of the transgene. Results for 
endogenous Class 1 IGF-1Ea expression revealed no significant changes for line MLC/Class 
2 IGF-1Ea throughout the regeneration process (Figure 3.29 A). Analysis of line MLC/Class 1 
IGF-1Ea showed a significant (p=0.03) up-regulation of this isoform in uninjured MLC/Class 1 
IGF-1Eb animals, an effect that was described in section 3.3.5. At day two after injury, when 
many myofibers are destroyed this up-regulation is decreased, but an elevation of Class 1 
IGF-1Ea mRNA was still visible (123%), but not significant anymore. Five days after injection, 
MLC/Class 1 IGF-1Eb samples were again significantly increased by 154% (p=0.001), while 
at day ten the 9% increase of Class 1 IGF-1Ea mRNA was no longer significant (Figure 3.29 
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A), due to up-regulation of this isoform in the WT upon injury. Since values were compared to 
the WT expression of the same day, where Class 1 IGF-1Ea transcripts are increased by 
664%, this increase is not significant.
MLC/Class 2 IGF-1Eb samples showed no significant changes at day two and ten after 
injury, but significantly up-regulated Class 1 IGF-1Ea mRNA at day five when compared to 
the WT sample of the same time point (77%, p=0.04) (Figure 3.29 A).
Taken together, endogenous Class 1 IGF-1Ea expression patterns observed in the WT were 
not influenced by over-expression of Class 2 IGF-1Ea, but showed a significant increase at 
day five after injury for Lines MLC/Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb.
Figure 3.29 Influence of IGF-1 isoform transgenes on endogenous isoform expression after CTX-injury.
Three-months-old male quadriceps RNA from WT and transgenic mice (n=3 for all) was used for quantitative RT-
PCR analysis of injury-induced changes in endogenous IGF-1 isoform expression in the background of IGF-1 
isoform over-expression. All values were compared to WT values of the same time point to evaluate if IGF-1 
isoform over-expression influenced the normal WT expression pattern of IGF-1 isoforms after injury. A Analysis of 
endogenous Class 1 IGF-1Ea molecules revealed significant changes at day five after injury for Lines MLC/Class 
1 IGF-1Eb (p=0.001) and MLC/Class 2 IGF-1Eb (p=0.04). B Endogenous Class 2 IGF-1Ea expression was not 
influenced in MLC/mIGF-1 and MLC/Class 1 IGF-1Eb animals after injury. C Endogenous levels of Class 1 IGF-1 
Ea were not significantly changed. D Endogenous Class 2 IGF-1Eb mRNA was also not altered in the background 
of any of the transgenes. 
The expression analysis of endogenous Class 2 IGF-1Ea revealed a significant increase in 
MLC/mIGF-1 animals, an effect that was described in section 3.3.5. During the time-course
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of regeneration neither line MLC/mIGF-1 nor line MLC/Class 1 IGF-1Eb had a significant 
influence of the endogenous expression pattern of Class 2 IGF-1Ea (Figure 3.29 B).
However, an increase was noticed at day five  post-injury (169% in MLC/mIGF-1 animals and 
152% in MLC/Class 1 IGF-1Eb animals) and a decrease was observed for both transgenic 
lines at day ten, where MLC/mIGF-1 decreased Class 2 IGF-1Ea mRNA levels by 59% and 
MLC/Class 1 IGF-1Ea by 73%. MLC/Class 2 IGF-1Eb values displayed a standard deviation 
that was too high and therefore was not considered here. 
In summary, no significant alterations of endogenous Class 2 IGF-1Ea expression was 
observed in response to the MLC/mIGF-1 and MLC/Class 1 IGF-1Eb transgenes.
The evaluation of endogenous expression of Class 1 IGF-1Eb and Class 2 IGF-1Eb (Figure 
3.29 C and D) showed no significant changes in response to the Class 1 IGF-1Ea transgene 
(mIGF-1) and the Class 2 IGF-1Ea transgene. In the background of MLC/Class 2 IGF-1Eb a 
non-significant increase of Class 1 IGF-1Eb RNA was observed throughout the regeneration 
process(Figure 3.29 C), while in the background of MLC/Class 1 IGF-1Eb endogenous Class 
2 IGF-1Eb was elevated upon injury (Figure 3.29 D), but again not reaching significance. 
3.4.3 Expression of calcineurin isoforms in response to injury
Recently the catalytic subunit CnAß1 isoform of CnAß, which lacks the auto-inhibitory 
domain (compare section 1.4.5.5), has been implicated in regeneration of skeletal muscle 
(Enrique Lara-Pezzi, manuscript submitted). This isoform was shown to be up-regulated in
response to injury and over-expression of this isoform in skeletal muscle of transgenic mice 
led to enhanced regeneration and reduced fibrosis in response to CTX-injury (Enrique Lara-
Pezzi, manuscript submitted). This same isoform of CnAß has also been shown to be 
induced in the regenerating muscle tissues of a mouse model of ALS, when crossed to the 
MLC/mIGF-1 transgenic line, indicating a role for CnAß1 in regeneration [78]. To determine if 
the different IGF-?????????????????????????????????????????????????????????????????????????
CnAß1 and ß2 isoforms were analyzed at all time points after injury.
This analysis was performed by quantitative RT-PCR on RNA samples isolated from the 
quadriceps muscle of injured WT and transgenic animals (n=3) for all genotypes and time 
points). Three uninjured controls were included for every genotype.
??? ?????????????????????????????????????????????????????????????????????? ??????? ????????
3.30 A) and no changes to the WT expression were significant in the background of the
different IGF-1 isoform transgenes. Alanysis of CnAß1 RT-PCRs confirmed the previously 
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established up-regulation of CnAß1 upon injury in the WT background (54% at day two, 93% 
at day five, and 116% at day 10 after CTX-injection) compared to the uninjured control 
animals, even though these values were not significant due to high standard variations 
(Figure 3.30 B). Interestingly, this trend was not observed for the IGF-1 isoform transgenic
lines MLC/mIGF-1, MLC/Class 2 IGF-1Ea and MLC/Class 1 IGF-1Eb, where CnAß1 levels 
actually decreased in comparison to WT levels of the same time point, without reaching 
significance. The only exception was line MLC/Class 2 IGF-1Eb, which up-regulated CnAß1 
mRNA at all time points after CTX injury when compare to WT levels of the same time points 
(240% at day two, 230% at day five, and 120% at day 10 after injury). Only the 240% 
increase at day two reached significance (p=0.02), since the standard error was very high for 
five day and 10 day samples of this IGF-1 transgenic line (day five WT: 38±20 molecules/ng, 
transgene: 124±67 molecules/ng; day 10 WT molecules/ng: 42±26molecules/ng, transgene: 
93±84 molecules/ng).
Figure 3.30 Expression of calcineurin isoforms in CTX-injured transgenic muscles. Quantitative RT-PCR 
was performed on three-month-old CTX-injected male mice of WT and transgenic origin. RNA was isolated from 
the quadriceps muscle of uninjured mice, as well as injured mice two, five, and ten days after injection (n=3 per 
genotype and time point). A RT-PCR for CnAa showed no differences between WT and transgenic animals. B
Analysis of CnAß1 expression revealed a significant increase at day two of regeneration for line MLC/Class 2 
IGF-1Eb, while other IGF-1 isoform transgenic lines did not show significant changes. C CnAß2 expression was 
also not changed in the background of IGF-1 isoform over-expression.
RT-PCR analysis of CnAß2 revealed a non-significant decrease of this isoform upon injury in 
the WT situation (day two: -65%, day five:-67%, and day ten: -60) when compared to non-
injured controls (Figure 3.30 C). In the presence of the different IGF-1 isoforms this situation
was unchanged, leading to a similar decrease of this isoform upon injury as seen in the WT 
background. 
??? ????????? ????? ???? ???ß2 WT expression levels decreased upon injury and this 
situation was unchanged in the background of the different IGF-1 isoform transgenes. CnAß1 
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expression was induced in the WT upon injury, an effect that was even more pronounced in 
the background of the MLC/Class 2 IGF-1Eb transgene, even though this increase was only 
significant at day two post-injury. The other IGF-1 isoforms did not significantly change in 
comparison to the WT situation, but showed a tendency towards a mild down-regulation. 
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4 Discussion
Much research and effort has been invested to evaluate the enormous variety of effects that 
IGF-1 has on different cells types and tissues of the body at all stages of pre-and postnatal 
development. An impressive body of knowledge has been accumulated in the last two 
decades, but surprisingly the existence of many isoforms that are generated from the IGF-1 
gene was not taken into account for the majority of the studies on IGF-1 function, even 
though their transcription was already reported 20 years ago. Only recently has the field 
begun to appreciate that the different IGF-1 isoforms have specialized functions, which might 
explain the pleiotropic effects of IGF-1 on proliferation, differentiation and survival. In the last 
couple of years, research has focused on the potential therapeutic application of IGF-1 in 
treating many skeletal muscle diseases and therefore the need for evaluating IGF-1 isoform 
function has become a crucial prerequisite for developing IGF-1 based therapies. A 
comprehensive comparison of IGF-1 isoform function is long overdue and is described in the 
present thesis. The work presented here documents the diverse effects of IGF-1 isoforms on 
skeletal muscle, and will have major implications on therapy-oriented research. This study 
also provides a comprehensive basis for further investigations into mechanisms that underlie 
these differential effects. In addition, we succeeded in cloning an IGF-1 isoform variant that 
was thought to be absent from mouse tissues.
4.1 The rodent En-peptide
Section 3.1 described the cloning of a Class 2 IGF-1 isoform containing an E-peptide splice 
variant that has previously not been reported to be present in rodents. Although the possible 
existence of this isoform was predicted from the sequence, transcripts could not be detected 
by Northern blot analysis, which led to the assumption that this isoform was not transcribed 
in rat liver {Shimatsu, 1987 #29}. With the availability of more sensitive methods to detect 
mRNA transcripts (amplification by RT-PCR from mouse liver mRNA), we succeeded in 
cloning a Class 2 IGF-1 isoform that contained an exon 4-5 splice variant, which has been 
described to give rise to the Eb-peptide in humans. Since the Eb-peptide in rodents 
corresponds to the Ec-peptide in humans, we termed this version En-peptide, to avoid further 
confusion.
Until now the rodent exon 5 has been considered to be a 52 bp cassette exon (in contrast to 
a terminal exon giving rise to a functional 3’-UTR), while the human exon 5 represents a 
terminal exon, encoding a stop codon and a 3’-UTR. With the description of the Ec-peptide in 
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humans, where exon 5 is spliced to exon 4 and 6, it became clear that also the human exon 
5 can becomes a cassette exon, if a cryptic 5’-donor splice site is used [208].  With the 
cloning of the exon 4-5 splice variant in mice, this model will need to be revised for rodents 
as well.
In humans, splicing of the exon 4-5-6 variant (encoding the Ec-peptide in humans) occurs by 
use of a cryptic IGF633 donor splice site located 49 bp downstream from the 5’ end of exon 5. 
The sequence of this donor splice site deviates from the vertebrate 5’-donor splice site 
consensus and failure to use this cryptic IGF633 donor splice site results in the exon 4-5 splice 
variant (corresponds to the human Eb-peptide) [208]. A possible reason for the low 
expression of the exon 4-5 splice variants in rodents might be the strength of the 5’-splice 
donor site. When comparing the 3’exon5:5’intron boundary to the vertebrate 5’-donor splice 
site consensus AG:AGTAAGT, the rat sequence matches by five out of six bases, the mouse 
sequence matches by four out of six bases, and the human sequence matches only by three 
out of six bases (Figure 4.1). These polymorphisms might alter the strength of the donor 
splice site and influence the splicing machinery. Because the rat donor splice site shows the 
highest match to the vertebrate 5’-donor splice site consensus, it is less likely to be overseen 
by the splicing machinery.  In addition, the rat intron sequence following the 52 bp cassette 
exon contains 4 purine-rich repeats (GGAAG) within 300 bp downstream of the 5’-donor 
splice site, which have been shown to enhance splicing in the bovine GH gene [306]. Finally, 
the sequence downstream of the 5’-donor splice site contains only one AATATA 
polyadenylation signal, which might not be strong enough to compete with the stronger 5’-
donor splice site.
Figure 4.1 Vertebrate 5’-donor splice site comparison. Red marks the bases that are differ from the 
consensus sequence.
The observation that the En-peptide variant could only be detected in Class 2 IGF-1 mRNAs 
and showed weak expression only in mouse liver suggests a specialized, possibly endocrine 
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function for this isoform, which might need specific stimuli to be induced. However, since the 
rodent En-peptide lacks sequences that have been demonstrated to be important for human 
Eb-peptide function (compare section 3.1) [199, 296], further analysis will be necessary to 
evaluate the function of this splice variant in rodents. 
4.2 The effects of IGF-1 on myoblast proliferation
Numerous studies have described IGF-1 as a mitogen, a function that is well established 
(reviewed extensively in [215, 297]). Since the majority of studies described in the literature 
applied commercially available mature IGF-1 to treat cells exogenously, the present in vitro
study was designed to define if the mitogenic effect of IGF-1 were specific to a certain 
isoform or if they can be observed in response to all the six different isoforms analyzed here. 
The in vitro experiments were performed using a doxicycline-inducible system of IGF-1 
isoform expression in L6E9 cells, a rat myogenic cell line that does not express endogenous 
IGF-1 (described in section 3.2). The analysis suggests that Class 1 and Class 2 IGF-1Ea
isoforms do not stimulate proliferation of myoblasts as efficiently as IGF-1 isoforms that 
contain the Eb-peptide. This conclusion was drawn from observations of the transfected cells 
upon shift from growth medium (GM) to differentiation medium (DM), where IGF-1 isoforms 
containing the Eb-peptide displayed a delayed exit from the cell cycle and underwent an 
additional round of replication as has been reported using recombinant, fully processed IGF-
1 [307]. In addition, IGF-1 isoforms that contain the Ea-peptide, especially Class 1 and Class 
2 IGF-1Ea, displayed weak levels of histone H3 phosphorylation as a maker of mitotic 
activity, while Eb-peptide containing isoforms showed higher levels of phospho-H3. These 
findings suggest a link between IGF-1Eb isoforms and proliferation and IGF-1Ea isoforms 
and differentiation (discussed in detail below). A possible role for an Eb-peptide-containing 
isoform in stimulating proliferation of myoblasts was reported previously [308], but was 
accompanied by a block in differentiation, which was not seen in the present study 
(discussed below). 
Notably, none of the over-expressed prepro-variants of IGF-1 were processed to pro-IGF-
1Ea/Eb or mature IGF-1 during proliferation. This observation makes it difficult to link the 
present findings to previous studies, where mature IGF-1 was used to determine IGF-1 
mediated effects on proliferation. However, it suggests that the entire prepro-peptide, 
including signal- and Eb-peptide, influenced proliferation of myoblasts in this system. The 
possibility that L6E9 cells are not equipped to process IGF-1 due to the lack of endogenous 
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IGF-1 expression can be excluded, since processing was observed at later stages during 
differentiation (discussed below). 
These findings also shed light on the outstanding question of whether the IGF-1 isoforms are 
active or properly localized without cleavage of the signal or E-peptides. Since the transgenic 
mice in the present study were designed for post-mitotic expression of IGF-1, the relevance 
of these results in cell culture to the role of specific pro-peptides on myoblast proliferation in 
vivo remains to be determined. Nevertheless, the data presented here strongly indicate that 
the entire IGF-1 prepro-peptide does not need processing to be active, and raise the 
possibility that specificity of IGF-1 function might be determined by processing status, or by 
the presence of isolated E-peptide once the prepro-peptide is cleaved.
4.3 Effects of IGF-1 isoforms on myoblast differentiation 
and muscle growth 
4.3.1 In vitro effects of IGF-1 isoforms  
IGF-1 effects on the differentiation of skeletal myoblasts are well described and largely 
attributed to the fact that IGF-1 can activate the myogenin gene, one of the MDFs that is 
most directly associated with terminal differentiation of skeletal muscle [309]. In addition, in 
vitro and in vivo studies have described increased myofiber size upon IGF-1 treatment or 
over-expression. In one such case recombinant IGF-1 (corresponding to mature IGF-1) was 
administered exogenously to L6E9 cells, which resulted in an increased size of differentiated 
fibers [307]. Also C2C12 cells showed a hypertrophic phenotype when stably transfected 
with IGF-1 (isoform was not indicated) or treated with IGF-1 [310]. Other groups employed 
specific isoforms, overall the Class 1 IGF-1 Ea isoform of either human [287] or rat origin [77, 
278] in vitro and in vivo. Colemen et al. demonstrated enhanced fusion in stably transfected 
C2C12 cells, while Musaro et al. showed hypertrophic growth of stably transfected cells in 
vitro and of transgenic skeletal muscle in vivo. On the other hand, an unpublished study on 
transgenic mice over-expressing the mature version of IGF-1 in skeletal muscle did not show 
hypertrophy of myofibers (reviewed in [300]). Yet another group applied the IGF-1Eb isoform 
(Class was not indicated) or a synthetic Eb-peptide alone, to demonstrate that this isoform 
actually blocked differentiation in C2C12 cells and might act through another receptor [308]. 
Finally, a very recent report described the viral-mediated expression of Class 1 IGF-1Ea and 
Class 1 IGF-1Eb and showed that viral injection of both IGF-1 isoforms in young (two-weeks-
old) animals resulted in hypertrophic muscles, while injection of older animals (six-months-
old) only resulted in hypertrophy of Class 1 IGF-1Ea injected muscles [311]. This report 
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concluded that Class 1 IGF-1Eb was effective in promoting hypertrophy only in young 
muscles.
The present study described a comprehensive comparison of the different effects of the four 
main IGF-1 isoforms in vitro and in vivo. The approach is unprecedented in that in provides 
comparable transgene expression form the same regulatory elements that drive expression 
specifically in skeletal muscle of transgenic mice and provide expression throughout the life 
of the animals from embryonic day E9.5. The selection of isoforms used in this study (defined 
combination of signal peptide and E-peptide) provides valuable information and distinguishes 
it from many previous studies that lacked information of the precise isoform employed.
The in vitro data described in section 3.2 revealed an enhancement of differentiation for cells
transfected with Class 1 IGF-1Ea that culminated in the formation of hypertrophied 
myofibers. Interestingly, cells transfected with Class 2 IGF-1Ea showed normal differentiation 
kinetics but nevertheless showed an increased size of differentiated fibers after day three of 
differentiation. L6E9 cultures transfected with the Eb-peptide containing isoforms of IGF-1 
showed a delay in the differentiation process and the formation of normally sized muscle 
fibers, suggesting that IGF-1 isoforms containing the Eb-peptide do not play a role in 
mediating IGF-1 induced hypertrophy. Moreover, cells transfected with 22-IGF-1Ea revealed 
a third phenotype, since they showed fibers that were comparable to control fibers although 
an early initiation of the differentiation process was indicated by a stronger up-regulation of 
myogenin in comparison to the mock control cells and cells transfected with other IGF-1 
isoforms after one day of differentiation. Notably, after two days of differentiation all isoforms 
uniformly up-regulated myogenin and MEF2C in comparison to mock controls, indicating that 
the myogenic program was efficiently induced by all of the IGF-1 isoforms.
These findings confirm earlier publications that demonstrated a hypertrophic response to the 
Class 1 IGF-1Ea isoforms, but contradict a study mentioned above, which claimed that IGF-
1Eb or the Eb-peptide alone could block differentiation [308], since in the present study all 
the different isoforms containing the Eb-peptide up-regulated markers of myocyte maturation 
and differentiated into myotubes. A possible reason for this observation is that Yang et al. 
used an IGF-1Eb peptide that presumable did not contain a signal peptide and a synthetic 
Eb-peptide. The signal peptide most likely plays an important role in directing IGF-1 isoforms 
to the desired compartment of the cell and thereby also determines IGF-1 processing and 
IGF-1 function. This possibility is supported by two observations: first, IGF-1 isoform 
processing in the system described here only occurred upon shift to DM, indicating that 
initially the entire prepro-peptide has a function (as mentioned above), and second, that the 
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induction of IGF-1 isoform processing upon early differentiation might determine their 
function during differentiation. Thus, the availability of IGF-1Eb (without signal peptide) or the 
Eb-peptide alone might influence the cells differently. However, since it cannot be excluded
that the IGF-1Eb peptide used by Yang et al. contained a signal peptide, differences seen 
might also be due to the different cell lines used. The significance of a synthetic Eb-peptide is 
also questionable, since alone it is apparently very unstable, and in that study was stabilized 
by amino acids substitutions and polyethylene glycol addition, therefore side effects from 
these modifications cannot be excluded.
The in vitro findings presented here also show for the first time that Class 2 IGF-1Ea is also 
capable of inducing cell hypertrophy. In contrast, the three different IGF-1Eb isoforms do not 
display enlarged fiber sizes. These findings implicate that the Ea-peptide is important for 
mediating a hypertrophic response, while the presence of the Eb-peptide is not involved in 
mediating such an effect. Clearly, context is critical, since the 22-IGF-1Ea isoform, with a 
truncated signal peptide, did not lead to a hypertrophic phenotype of transfected cells. At this 
point further research is needed to evaluate why this isoform behaves differently. It is 
possible that the 22 amino acid signal peptide directs this isoform to a different sub-cellular 
localization, which might result in less efficient secretion or differential binding of this isoform 
to the different IGFBPs.  
4.3.2 In vivo effects of IGF-1 isoforms 
In order to comprehensively compare IGF-1 isoform function in vivo, six transgenic mouse 
lines over-expressing the six main IGF-1 isoforms have been generated. Selected founders 
from different transgenic lines were chosen on the bases of high and comparable expression. 
High to moderate skeletal muscle-specific expression was seen for each transgene, 
depending on the specific skeletal muscle group analyzed: fast muscles showed higher 
transgene expression levels due to the fast fiber restriction of the MLC regulatory elements.
For further analysis, priority was given to the main IGF-1 isoforms expressed in mouse liver:
MLC/Class 2 IGF-1Ea, MLC/Class 1 IGF-1Eb, and MLC/Class 2 IGF-1Eb. Since line 
MLC/Class 1 IGF-1Ea was lost due to breeding problems early in this study, the well-
characterized MLC/mIGF-1 line, generated by Antonio Musaro [77] was used for further 
comparative work. This line carries the same transgene as used for generating the 
MLC/Class 1 IGF-1Ea line (Class 1 IGF-1Ea), but of rat rather than mouse origin, and 
contains the same MLC 1/3-derived regulatory sequences to drive transgene expression. 
Further, comparative expression analysis between the different transgenic lines revealed 
variable differences in IGF-1 transgene expression on the transcriptional level, which were 
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nevertheless translated into comparable protein levels. This observation implies a threshold 
for IGF-1 protein translation that is not dependent on absolute transcription levels.
In correlation with the in vitro findings described in section 4.3.1, detailed analysis of skeletal 
muscle phenotype and physiological performance revealed striking muscle hypertrophy in 
line MLC/Class 2 IGF-1Ea. This was reflected by an increase in CSA of fast, intermediate, 
and slow fibers in the TA and EDL muscle. The increase of skeletal muscle fiber CSA was 
accompanied by a significant increase of skeletal muscle wet weight and a pronounced 
increase in force generation of fast but not slow skeletal muscle groups, confirming functional 
hypertrophy. The transgenic MLC/Class 2 IGF-1Ea animals also showed increased body 
weight at all ages studied, which can be correlated to the pronounced increase of fast 
skeletal muscle wet weight, since distal organs were not affected in their weight. 
Interestingly, the phenotype observed in these animals was more pronounced compared to 
the MLC/mIGF-1 line, reflected in a stronger increase of skeletal muscle weight and 
physiological performance, as well as in a consistent, but small relative increase in overall 
bodyweight. These results highlight a strong connection between IGF-1Ea isoforms and 
induction of hypertrophy in skeletal muscle.
The fact that the MLC/Class 1 IGF-1Ea transgene increased endogenous levels of Class 2 
IGF-1Ea raises the possibility that hypertrophy in these animals is predominately due to the 
Class 2 IGF-1Ea isoform. This is supported by the fact that the increase in endogenous 
Class 1 IGF-1Ea induced by the MLC/Class 1 IGF-1Eb transgene did not result in a 
hypertrophic response. It also appears that only Class 1 isoforms can influence endogenous 
IGF-1 expression, since endogenous IGF-1 levels were unaffected in transgenic lines over-
expressing Class 2 IGF-1 isoforms. Thus the crosstalk between exogenous and endogenous 
IGF-1 isoforms must be taken into consideration when interpreting the results of any over-
expression studies. 
The two lines over-expressing the Ea-peptide-containing isoforms Class 1 IGF-1Ea (mIGF-1) 
and Class 2 IGF-1Ea also showed a modest, but significant up-regulation of total circulating 
levels of IGF-1, which was not the case for transgenic lines over-expressing IGF-1 isoforms 
containing the Eb-peptide. Notably, the increase of total serum IGF-1 remained significant in 
MLC/Class 2 IGF-1Ea mice at the age of six months, while levels were still elevated, but no 
longer significant in MLC/mIGF-1 mice. In either case, the total IGF-1 elevation did not lead 
to an increase in the weight of visceral organs, such as heart, brain, liver, kidney or spleen at 
all ages analyzed for both lines, indicating that the mild increase of serum IGF-1 did not 
disturb other organ systems. The assay used for these experiments included a step to strip 
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off IGF-binding proteins and therefore does not reflect levels of free, bioavailable IGF-1. An 
attempt to analyze the level of free IGF-1 in control and transgenic animals using the same 
assay failed to give conclusive results. Thus, is it difficult to determine at this point whether 
the modest elevation of total serum IGF-1 in these animals has any biological significance. A 
recent study on the SIS2 mice (over-expressing human Class 1 IGF-1Ea) demonstrated that 
hIGF-1 was detectable in the circulation, without changing total levels of IGF-1. An 
unpublished study on MLC/mIGF-1 serum levels (Shavlakadze et al., unpublished) 
demonstrated no changes at three months of age, contradicting the results presented here. 
Finally, another unpubl??????????????? ????????-actin/hIGF-1 mice (over-expressing mature 
IGF-1 of human origin), revealed a strong increase of total serum IGF-1, which resulted in an 
increase of seminal vesicles in 24-months-old male mice (Shavlakadze et al., unpublished). 
However, in the last case mature IGF-1 was fused to the signal peptide of somatostatin, 
which is normally found in the circulation (compare section 1.5) and therefore most likely 
directs this version of IGF-1 to the circulation as well. Controversial claims in the literature 
and a large discrepancy of circulating IGF-1 levels in different mouse strains (reviewed in 
detail in [151]) underscore the need for caution in interpreting the relevance of these 
measurements.  When using sensitive assays such as ELISA, which are routinely used to 
determine serum IGF-1 levels, it is crucial to consider that results can only be compared in a 
reliable way, if the samples have been screened using the same calibrators and controls in 
the same assay. Most importantly, different assays using different antibodies for IGF-1 
detection can give different results and should not be compared. For this reason only relative 
changes were considered in the present study. They suggest that IGF-1 isoforms containing 
the Ea-peptide could enter the circulation, since this has been observed for the SIS2, the 
MLC/Class 2 IGF-1Ea, and the MLC/mIGF-1 mice, at least in the present study. Since no 
correlation with the signal peptide was seen (Class 1 versus Class 2), the Ea-peptide might 
therefore determine if an isoform is secreted to the circulation or not. This could be mediated 
by the binding to certain IGFBPs, an issue that has not been addressed in the present study, 
but will be necessary in the future. Notably, this approach could not determine whether the 
over-expressed transgene itself was secreted or led to the induction of endogenous IGF-1 
secretion.
In contrast to the phenotype seen in MLC/mIGF-1 and MLC/Class 2 IGF-1Ea mice, both 
transgenic lines that over-express Eb-containing isoforms (MLC/Class 1 IGF-1Eb and 
MLC/Class 2 IGF-1Eb) displayed only a mild increase of skeletal muscle mass, accompanied 
by a small shift towards a higher proportion of larger fibers in the fast muscles that did not 
result in a consistent increase of fiber CSA. These modest changes did not result in 
physiological improvements of muscle performance and did not affect the overall bodyweight 
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of these animals. The in vitro and in vivo results presented for both Eb-peptide-containing 
isoforms demonstrate for the first time that these versions of IGF-1 do not play a role in 
mediating IGF-1 induced functional hypertrophy of skeletal muscle in vivo. 
These findings stand in contrast to a very recent report that analyzed the differential effects 
of Class 1 IGF-1Ea versus Class 1 IGF-1Eb in skeletal muscle, using rAAV viral injection of 
these isoforms under the control of the same MLC1/3 regulatory elements applied in the 
present study [311]. Viral-mediated expression of both Class 1 IGF-1Ea and Class 1 IGF-
1Eb resulted in a mild increase of muscle mass (12±2% for Class 1 IGF-1Ea and 7±2% for 
Class 1 IGF-1Eb) after two months of injection of the viruses into the TA and EDL muscles of 
two-weeks-old mice and was maintained up until four months post-injection. The author 
concluded a hypertrophic phenotype in response to both isoforms, without an increase of 
force-related physiological parameters. Critical evaluation of this report reveals that the 
hypertrophic phenotype was only determined by measuring the muscle weight. No 
histological analysis was performed to prove an increase of the CSA of fibers in the injected 
muscles and no correlation was seen with an increase in muscle strength. Injections of the 
same viral constructs in six-months-old animals resulted in a 5% increase of muscle mass in 
animals injected with Class 1 IGF-1Ea viruses at four months post-injury, while no 
differences were seen at this age in muscles injected with Class 1 IGF-1Eb viruses. Thus, 
the mild increase in muscle mass most likely reflected a modest shift towards a higher 
content of bigger fibers, as observed for MLC/Class 1 IGF-1Eb animals in the present study, 
and did not represent a hypertrophic phenotype. Although discrepancies in the experimental 
design of the two studies must be considered (C57B1/6 versus FVB backgrounds, different 
mode of delivery and time-line of transgene expression) the conclusion that Class 1 IGF-1Eb 
promotes hypertrophy in growing animals is unlikely to hold in light of the present study, 
where the Class 1 IGF-1Eb transgene produced from embryonic cay E9.5 onwards did not 
lead to a significant increase in fiber size, even though a modest weight increase was 
observed. This is supported by the comparable phenotype of MLC/Class 1 IGF-1Eb and 
MLC/Class 2 IGF-1Eb transgenic mice, neither of which display a consistent significant 
weight increase or a consistent increase in fiber CSA.
4.4 IGF-1 signaling in response to different IGF-1 isoforms
The detailed description of IGF-1-mediated intracellular signaling in section 1.4.5 
underscores the complex and inter-connected nature of these interactions, as well as the 
confusion that still exists in the literature. Three main pathways have been implicated for 
different functions of IGF-1: first, the MAP-kinase pathway, which has mainly been connected 
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to the proliferative response to IGF-1 [242] and reviewed in [297], second, the PI(3)-kinase 
pathway, which has been linked to myoblast differentiation (reviewed in [215]), hypertrophy 
of skeletal muscle [61], survival (reviewed in [257]), and prevention of atrophy [60, 61], and 
third, the calcineurin pathway, which is also connected to myoblast differentiation [39, 278]
and controversially suggested to mediate the hypertrophic response to IGF-1 [39, 61, 282, 
310]. 
Results presented here demonstrated that over-expression of the four main IGF-1 isoforms 
in skeletal muscle in vivo similarly resulted in activation of the IGF-1R, without influencing the 
transcription of the IGF-1R gene. However, the efficiency of IGF-1R activation varied 
amongst the IGF-1 isoforms, with MLC/Class 2 IGF-1Ea samples providing the strongest 
signal. Even though MLC/Class 2 IGF-1Ea displayed the most pronounced phenotype in 
skeletal muscle, the stronger activation of the IGF-1R cannot be correlated to the stronger 
phenotype, since also MLC/Class 2 IGF-1Eb animals, which do not show such a strong 
phenotype, also demonstrated an increased phosphorylation of IGF-1R. Thus, other 
components downstream of the IGF-1R are likely to govern the hypertrophic response.
Analysis of differential activation of MAP-kinase family members during growth in vitro
revealed subtle changes for samples transfected with the Class 1 IGF-1Ea and the Class 
2IGF-1Ea isoforms: Class 2 IGF-1Ea transfected cultures decreased phospho-JNK1 levels, 
while increased phospho-Erk1 and 2 levels were observed in cultures transfected with Class 
1 IGF-1Ea. The significance of these changes in not clear, since they cannot be correlated to 
the phenotype of the cells discussed in section 4.2. Since the Eb-containing isoforms showed
prolonged proliferation it is perhaps surprising that Class 1 IGF-1Ea, which actually showed 
less effect of proliferation, was the only isoform up-regulating Erk 1 and 2. A broader screen 
of molecules implicated in the proliferative response to IGF-1 will be needed in the future to 
further dissect the mechanism, whereby IGF-1 isoforms control the proliferative response.
The cellular response to the post-mitotic over-expression of IGF-1 isoforms in vivo did not 
involve the MAP-kinase pathway, as revealed by the KinetworksTM Phospho-site screen. This 
is in agreement with previous studies on skeletal muscle-specific IGF-1 transgenic animals, 
and a recent publication describing a down-regulation of MAP-kinase kinase (MEK) 1 and 2 
and MEK 3 and 6 in response to the MLC/mIGF-1 transgene [261], also supports the results 
presented here. Interestingly, the KinetworksTM analysis presented here and previously [261]
revealed a trend towards Raf-1 phosphorylation for both Class 1 transgenic lines. In light of 
recent findings linking p21 activated kinase (PAK1)-mediated Raf-1 phosphorylation to 
mitochondrial translocation of Raf-1 and phosphorylation of BAD [274], this phosphorylation 
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of Raf-1 might be connected to an activation of survival pathways, although its relevance in 
healthy and unchallenged mice used here remains to be determined. 
Analysis of the PI(3)-kinase pathway in vitro demonstrated a similar increase in 
phosphorylated Akt and its downstream target S6 ribosomal protein in response to each IGF-
1 isoform. Ubiquitous activation of Akt in the cell transfection experiments may be an artifact 
of doxicycline induction, which is stressful for the cells. Thus, activation of Akt in cell culture 
could be attributed to the fortuitous induction of survival pathways, which are not implicated 
in the analysis of transgenic animals that were not challenged in any way. Indeed, analysis of 
this pathway in vivo revealed up-regulation of PI(3)-kinase pathway members such as Akt1, 
PDK1, and GSK-???????ß only in Class 2 IGF-1 transgenic mice.  This is corroborated by a 
recent study demonstrating that Akt was not regulated in response to the mIGF-1 transgene 
in MLC/mIGF-1 mice [261], supporting the conclusion that Class 1 isoforms did not influence 
Akt activity. Similar evidence comes from analysis of cardiac-specific mIGF-1 transgenic 
mice, where no activation of Akt was detected (Santini at al., manuscript submitted). 
Not all aspects of IGF-1 intracellular signaling are as consistent between studies. Activation 
of the known downstream effectors of the PI(3)-pathway, such as the induction of p70S6K, 
was documented in MLC/Class 1 IGF-1Ea, MLC/Class 2 IGF-1Ea and MLC/Class 2 IGF-1Eb 
transgenic animals, confirming previous analysis for the mIGF-1 transgene [261]. However, 
phosphorylation of PDK-1 in mIGF-1 transgenic mice [261] was not observed in the present 
study, where Class 2 but not Class 1 IGF-1Ea isoforms led to up-regulation of PDK-1. 
Conversely, significant induction of RSK1/2/3 in MLC/Class 1 IGF-1Ea and MLC/Class 2 
IGF-1Ea transgenic animals was not seen in MLC/mIGF-1 animals [261]. These 
discrepancies may stem from variables in experimental design such as the number and ages 
of animals analyzed, potential subtle differences in rat versus mouse transgenes, and the 
reliability of the KinetworksTM screen results, which were not always confirmed by Western 
blot (data not shown). In addition, signaling analysis in vivo is biased by the variety of cell 
types present in skeletal muscle. It will also be of interest to repeat these analyses on mice 
that have been challenged with exercise, injury or disease such as the mdx mouse model for 
DMD, which may enhance differences of IGF-1 isoform-mediated signaling. For example, Akt 
phosphorylation absent in steady state conditions of MLC/mIGF-1 animals [261], could be 
induced in the background of muscular dystrophy in mdx/mIGF-1 animals [90], and in 
conditions of cardiac cachexia following myocardial infarction [46].  
Notably, analysis of the calcineurin pathway clearly demonstrated that none of the transgenic 
lines activated any of the calcineurin isoforms and no changes in GATA-2, a downstream 
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target of calcineurin, was observed. Although involvement of calcineurin in mediating the 
hypertrophic response to the MLC/mIGF-1 transgene has been suggested in vitro [282] and 
in vivo [77], subsequent studies suggested that calcineurin was not implicated in mediating 
an IGF-1 mediated hypertrophic response in skeletal muscle [39, 61]. The latter two reports 
employed recombinant (fully processed) IGF-1; the present study further documents that 
calcineurin is not implicated in mediating the hypertrophic response of IGF-1Ea isoforms.
In summary, the present study serves to emphasize the complexity of the IGF-1 signaling 
system and to provide a firm base for deeper analysis. One issue that merits further study is 
the regulation of the different IGF-1 isoforms by the different IGFBPs and the effect this might 
have on phenotype and signaling. The structure of different E-peptides may direct the 
binding of IGF-1 protein to different IGFBPs, a likely mechanism whereby IGF-1 isoforms 
might achieve their target specificity and influence downstream intracellular signaling. From 
the Ingenuity pathway analysis performed on the Affymetrix data, it is clear that the IGF-1 
isoforms themselves differentially regulate IGFBP availability (up- or down-regulation), further 
highlighting the importance of these IGF-1 regulator proteins and the presence of feedback 
loops in the system. The two different approaches described in section 3.3.11b are extremely 
valuable, since they highlight that fact that analysis using only one approach with a certain 
cut off of regulated genes might miss important connections between a differential stimulus 
(in our case different IGF-1 isoforms) and the downstream transcriptional regulation in an 
overall connected network of genes.  Candidate genes identified with both approaches may 
serve as potential candidates involved in the IGF-1 isoform-induced response in the future. In 
this respect the Affymetrix analysis provides a different approach, as it reflects a genomic 
response to IGF-1 isoform over-expression. Taken together with snap-shots of protein 
activation provided by the KinetworksTM Phospho-site screen, the steady-state status of gene 
expression afforded by transcriptional profiling provides valuable information about the basic 
regulatory units that can govern IGF-1 isoform-induced phenotypes.
Another area of future research will be the control of IGF-1 prepro-peptide processing as well 
as the glycosylation of the Ea-peptide, which as the present study demonstrates, is highly 
regulated in skeletal muscle. An early in vitro study on the relation between the length of the 
signal peptide and the glycosylation of the Ea-peptide [186] demonstrated that IGF-1Ea 
isoforms containing the longest (48 amino acids) signal peptide, did not undergo post-
translational glycosylation. However, in the present work, a band-shift presumably reflecting 
the molecular weight increase caused by glycosylation was observed for all Ea-containing 
isoforms, providing the first evidence that IGF-1Ea isoform-glycosylation is differently 
regulated in vivo. These distinct and separable phenotypic variations described for the IGF-1 
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isoform transgenic mice will inform the future design of better tools, more specific 
experiments and new approaches to tackle these outstanding questions in IGF-1 research.
4.5 Effects of IGF-1 isoforms on regeneration of skeletal 
muscle
Although skeletal muscle maintains an intrinsic capacity to regenerate after work-induced 
damage and injury, it gradually loses this capacity in many disease states, but also in 
unavoidable conditions like aging. Endogenous IGF-1 levels decrease with age, which is 
considered one of the reasons for the reduced capacity of skeletal muscle regeneration. 
Supplemental administration of Class 1 IGF-1Ea (mIGF-1) by muscle-specific transgenesis 
or muscle-specific viral-mediated delivery has enhanced regenerative capacity of aged 
skeletal muscle, providing evidence for the beneficial effect of IGF-1 in skeletal muscle repair 
[76, 77]. More recently it has been shown that the mIGF-1 transgene also attenuates skeletal 
muscle degeneration and promotes regeneration in disease models of Duchene Muscular 
Dystrophy (DMD) and Amyotrophic Lateral Sclerosis (ALS), where supplemental mIGF-1 
transgene expression reduced myofiber breakdown and necrosis [90], protected against free 
radical induced damage [78], and promoted regeneration [130]. The mIGF-1-enhanced 
regeneration of skeletal muscle involves stimulating satellite cell proliferation, as well as the 
recruitment of progenitor cells intrinsic to the muscle and from the circulation (reviewed in 
[110], compare section 1.2.9). 
The work in the thesis is especially important in light of IGF-1-based therapies, which have 
long been in the center of interest. Depending on the disease condition, it might be 
preferable to protect the muscle and at the same time increase muscle mass. For other 
applications it might be preferable to protect the muscle without inducing muscle 
hypertrophy. Therefore it is crucial to determine if IGF-1 isoforms that do not display skeletal 
muscle hypertrophy bear a similar regenerative capacity described for the MLC/mIGF-1.
The preliminary results described in section 3.4 demonstrated an improved regeneration
process in response to CTX-injections in every IGF-1 transgenic line. However, the 
morphological analysis suggests differences in the initial regenerative response. While 
MLC/Class 2 IGF-1Ea displayed larger fibers containing between one and three nuclei at day 
five after injury, MLC/Class 1 IGF-1Eb and MLC/Class 2 IGF-1Eb showed more fibers when 
compared to WT and also to MLC/Class 2 IGF-1Ea. After ten days of regeneration, all 
transgenic lines displayed similar improvements in muscle morphology than the WT, 
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indicating that the presence of the different IGF-1 isoforms each resulted in enhanced 
regeneration, despite potential differences in the mechanisms involved. These findings 
suggest that IGF-1 isoforms can improve regeneration by either enhancing the growth of 
newly forming fibers (Class 2 IGF-1Ea) or by stimulating the proliferation of satellite cells and 
potentially other stem cell types (Class 1 IGF-1Eb and Class 2 IGF-1Eb). A connection 
between Eb-peptide-containing isoforms and proliferation was also suggested by the in vitro
experiments discussed earlier (compare section 4.2) and has been proposed in the literature 
[210, 214, 308]. Since the design of the transgenic expression cassette only provides post-
mitotic expression of the IGF-1Eb transgenes, these findings also imply that both IGF-1Eb 
isoforms could be secreted from intact fibers and act in a paracrine way to stimulate 
proliferation of myogenic precursor cells. 
Another result presented here describes the effects of CTX-induced injury on the 
endogenous gene in a WT or transgenic background (compare section 3.4.2). The 
expression pattern of endogenous IGF-1 isoforms upon injury revealed a pronounced up-
regulation of both Ea-peptide-containing isoforms throughout the process of regeneration, 
reaching highest induction levels at day ten after injury, while both Eb-containing isoforms
showed mild induction upon injury without being significant. The only exception was a 
transient up-regulation of Class 2 IGF-1Eb at day five after injury. Similar observations were 
described for IGF-1Ea and IGF-1Eb (the signal peptides were not defined) in previous 
studies on exercised-induced damage in skeletal muscle [210, 214]. However, the present 
study extends the previous ones in that both Class 1 and Class 2 IGF-1 isoforms with the 
different E-peptide combinations were screened. Moreover, the present work shows that both 
IGF-1Ea isoforms are implicated in the regeneration process in response to CTX injections in 
the WT muscle. Furthermore, although the two models of injury are very different, these 
findings suggest that the IGF-1Eb up-regulation reported by earlier studies [210, 214]
actually corresponds to the Class 2 version of IGF-1Eb, raising the possibility that “MGF” 
might originate from transcription initiation in exon 2. 
In the IGF-1 transgenic background, both Eb-peptide-containing isoforms significantly up-
regulated endogenous Class 1 IGF-1Ea after five days of regeneration when compared to 
WT levels, although MLC/Class 1 IGF-1Eb animals showed endogenous Class 1 IGF-1Ea 
up-regulation without injury as well (compare section 3.3.5). However, these findings indicate 
that the Class 1 IGF-1Ea isoform might be necessary to promote the regenerative process. 
None of the other transgenic lines induced significant changes in the endogenous IGF-1
isoform expression patterns observed in the WT. 
The differential Role of Insulin-like Growth Factor-I Isoforms in Skeletal Muscle
Discussion page 141
Recently, a naturally occurring calcineurin A splice variant, CnAß1, has been shown to 
promote regeneration in response to CTX injury when over-expressed in the skeletal muscle 
of transgenic mice, while over-expression of CnA?? ????????? ???? ????????????? ????????
(Lara-Pezzi E., manuscript submitted). The same study showed that the CnAß1 isoform is 
normally induced upon injury, while CnA? and CnAß2 are down-regulated in response to 
such damage. CnAß1 has also been shown to be up-regulated by mIGF-1 in the background 
of the SOD1 mouse (mIGF-1/SOD1), which serves a model for ALS [78] This isoform is not 
induced in healthy MLC/mIGF-1 animals, suggesting that its induction is specific to certain 
detrimental stimuli. Interestingly, up-regulation of the CnAß1 isoform was observed 
specifically in the MLC/Class 2 IGF-1Eb animals at every time point post-injury, while none of 
the other IGF-1 isoforms, including MLC/mIGF-1, regulated the expression of CnAß1. This 
suggests that Class 2 IGF-1Eb induces a specific response that differs from the other IGF-1 
isoforms. The enhanced regenerative response seen for transgenic CnAß1 animals has 
been linked to modulation of the inflammatory response and to a reduction of fibrosis (Lara-
Pezzi E., manuscript submitted). Very preliminary results obtained by RT-PCR, not included 
in this thesis, point towards a similar mechanism in the MLC/Class 2 IGF-1Eb animals, where 
MCP-1 (a marker for macrophages that induces the recruitment of inflammatory cells) was 
elevated two days post-injury and significantly increased at five days post-injury, and IL-10, 
an anti-inflammatory cytokine, was increased at two, five, and ten days post-injury. Collagen 
I was analyzed to determine the fibrotic response and was shown to be down-regulated at 
day ten post-injury. In contrast, analysis of these markers revealed no conclusive changes in 
response to the other IGF-1 isoforms. These results further implicate Class 2 IGF-1Eb in 
inducing a specific response that discriminates this isoform from the other IGF-1 isoforms in 
promoting the regeneration process. Further investigation of these findings with more 
quantitative and molecular evidence will be necessary to determine whether the specific role 
of Class 2 IGF-1Eb can be confirmed and consistently connected to CnAß1 up-regulation.
4.6 Future perspectives
The present study revealed a clear connection between the IGF-1 Ea-peptide and mediation 
of a hypertrophic phenotype in skeletal muscle. This increase in myofiber size was 
accompanied by an increase of the force generation and strength of the muscles affected. In 
contrast, the presence of the Eb-peptide in IGF-1 isoforms was not connected to an induction 
of skeletal muscle hypertrophy, and even though a mild increase of muscle mass was seen, 
this did not result in an increase in force generation or strength. Analysis of the regenerative 
capacity of IGF-1 isoforms in response to injury revealed that each IGF-1 isoform led to an 
improvement of the regeneration process that seemed to be mediated by an increased 
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number of fibers in response to both Eb-peptide-containing isoforms. The mechanism by 
which IGF-1 isoforms mediated these findings are not clear at this point and will have to be 
addressed in detail in the future to further understand the beneficial effects of IGF-1.
One of the possible tools that will prove useful in the future is the generation of doxicycline-
inducible IGF-1 transgenic mice that allow the induction of IGF-1 at a chosen time point 
specifically in skeletal muscle. This will be especially useful to investigate whether IGF-1 is 
needed at a certain time to enhance regeneration and whether IGF-1 isoforms can have 
different effects if the expression is induced later in life of the transgenic animal. Inducible-
mIGF-1 transgenic animals have been generated by Ekaterina Semenova in Nadia 
Rosenthal’s laboratory and I generated inducible Class 1 IGF-1Eb animals, as well as the 
skeletal muscle-specific MLC/rtTA mouse line (compare section 2.1.5.2). Generation of
inducible Class 2 IGF-1 animals is planned for future studies. Although the tools were 
developed during this thesis, the time schedule did not allow studying those animals in the 
end. In light of the results discussed in section 4.5, it will be of interest to include Class 2 
IGF-1Eb in further studies.
Other approaches to further investigate the beneficial effects of IGF-1 isoform over-
expression skeletal muscle have already been initiated for line MLC/Class 2 IGF-1Ea in 
collaboration with Professor Miranda Grounds (University of Western Australia, Perth, 
Australia). The MLC/Class 2 IGF-1Ea animals are currently crossed to the mdx mice, a 
model of Duchenne muscular dystrophy, to evaluate if this isoform can have similar effects 
as described for the MLC/mIGF-1 animals, such as protection form necrosis [90, 91], 
reduction of fibrotic tissue [90], and thereby enhance regeneration of the myopathic muscles. 
In the future, similar experiments are planned for Class 1 IGF-1Eb and /or Class 2 IGF-1Eb, 
to compare the beneficial effects of an isoform that is capable to induce hypertrophy and 
enhanced regeneration (one of the Ea-peptide-containing isoforms) to the effects of an IGF-1 
isoforms that does not induce hypertrophy, but nevertheless improves the regenerative 
response (one of the Eb-peptide-containing isoforms). These experiments will be especially 
important, since some disease conditions do not require the overall increase of muscle mass, 
but still an enhanced regeneration. One of the major questions concerning muscular 
dystrophies in this respect is if the improvement of skeletal muscle regeneration and 
morphology seen in the mdx/mIGF-1 animals was in part due to an increase of the muscle 
mass as well, or if the stimulation of the regenerative response and the protection form 
necrosis is enough to induce the observed improvements. If so, induction an overall increase 
of muscle mass (up to 40%) [90] may not be necessary in future strategies to treat muscular 
dystrophy.
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Another project that has been initiated in the Rosenthal laboratory is a profound investigation 
into the role of the six main IGF-binding proteins in the different IGF-1 isoform transgenic 
mice. This is a crucial point, which has not been addressed in the present thesis, but is 
clearly one of the factors that can determine IGF-1 isoform function in vivo.
In summery, different roads can be taken from this point to continue our approach of 
clarifying the role of different IGF-1 isoforms. On the background of the differential 
phenotypes described here, more functional, as well as mechanistic experiments can be 
preformed on the way to discover the right version of IGF-1 for treatment of a certain 
disease. The examples given in this section only provide a few possible directions that can 
be taken, but clearly show the significance of the present thesis, which finally constitutes a 
solid bases for selecting the IGF-1 isoform candidate for further therapy-based research.
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Appendix A: List of Abbreviations
aa Amino acid
AChR Acetylcholin receptor
ALS Acid-labile subunit
ALS Amyotrophic lateral sclerosis
ATP Adenosine triphosphate
Bcl B-cell lymphoma
bFGF basic fibroblast growth factor
bHLH basic Helix-Loop-Helix
BMP-4 Bone morphogenic protein-4
CaMK Calcium/calmodulin-dependent kinase
Cn Calcineurin
CSA Cross-sectional area
CsA Cyclosporin A
CTX Cardiotoxin
DHPR Dihydropyridine receptor
DM Dermamyotome
DM Differentiation
DMD Duchenne muscular dystrophy
DMSO Dimethyl sulfoxide
DPC Dystrophin-associated protein complex
EDL Extensor digitorum longus
EFP Epididymis fat pat
EGF Epidermal growth factor
E-peptide Extension-peptide
Erk Extracellular regulated kinase
FBS Fetal bovine serum
FGF Fibroblast growth factor
GH Growth hormone
GM Growth medium
GPE Glycyl-prolyl-glutamate
Grb-2 Growth factor receptor-bound protein-2
GSK-3 Glucose synthase-kinase-3
IGF-1 Insulin-like growth factor-1
IGF-1R Insulin-like growth factor-1 receptor
IGFBP Insulin-like growth factor binding protein
IP Immunoprecipitation
IRS Insulin receptor substrate
LM Lateral mesoderm
MAFbx Muscle atrophy F box = Atropin-1
MAP-kinase Mitogen activated protein-kinase
MCK Muscle creatine kinase
MDF Myogenic determination factor
MEF Myocyte enhancing factor
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MEK MAPK-Erk protein-serine kinase
MGB Major groove binding
MGF Mechano growth factor (= IGF-1Eb)
MLC Myosin light chain
MRF-4 Myogenic regulatory facto-4
mTOR Mammalian Target of rapamycin
MURF-1 Muscle ring finger-1
MyHC Myosin heavy chain
NADH-TR Nicotinamide adenine inucleotide nitro blue Tetrazolium
NBT Nitro blue tetrazolium 
Nc Notochord
NF-ATc Nuclear factor of activated T-cells
NT Neural tube
ORF Open reading frame
PAK p21-activated kinase
PBS Phosphate-buffered saline
PDGF Platelet-derived growth factor
PDK-1 Phosphoinisitol-dependent kinase
PEG Polyethylene glycol
PHAS Phosphorylated heat- and acid-stable protein
PI(3)-kinase Phosphatidylinositol-3-kinase
PK Proteinase K
PKC Protein kinase C
PVDF Polyenylidine difluoride
Rb Retinoblastoma protein
ROS Reactive oxygen species
RSK Ribosomal S6 protein-serine kinase
RT Room temperature
rtTA Reverse tetracycline trans-activator
Sc Sclerotome
SH2/3 src-homology-2 /-3 domain
SHC src-homolgy contining
Shh Sonic hedgehog
Sm Somite
SOD1 Superoxide dismutase-1
Sos Sons of sevenless
SP Side population
TA Tibialis anterior
TAE Tris-acetate-EDTA buffer
TBE Tris-borate-EDTA buffer
TGF-β Transforming growth factor-β
???? ???????????????????????
TSB Transform storage buffer
UTR Untranslated region
VEGF Vascular endothelial growth factor
(v/v) Volume per volume
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WT Wildtype
(w/v) Weight per volume
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Appendix B: Affymetrix analysis
GENE NAME 1EA 1EB 2EA 2EB
insulin-like growth factor 1 25.52 * 3.32 15.69 1.80
zinc finger protein, subfamily 1A, 1 (Ikaros) 2.91 * 2.79 * 2.07 * 2.55 *
DIX domain containing 1 2.82 2.00 * 2.29 3.29
TGFB-induced factor 2 2.34 1.46 1.44 * 1.69
solute carrier family 16 (monocarboxylic acid transporters), 
member 11
2.30 1.32 * -1.22 * -1.40
sarcolipin 2.15 * 1.11 -1.49 * 1.19 *
Bcl2-interacting killer-like 2.14 1.26 1.08 * 1.64
colony stimulating factor 3 receptor (granulocyte) 2.11 1.44 2.39 -1.13 *
RIKEN cDNA 9130019O22 gene
putative zinc-finger containing protein
1.94 1.69 1.05 * -2.50
hyaluronan mediated motility receptor (RHAMM) 1.91 1.20 1.05 1.35
pterin 4 alpha carbinolamine dehydratase/dimerization 
cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 1
-1.91 * 1.07 * -1.09 * 1.58
Sjogren syndrome antigen B -1.98 -1.11 -1.44 -1.10 *
src homology 2 domain-containing transforming protein 
C1
-2.01 1.04 1.37 1.14
elongation factor Tu GTP binding domain containing 2 -2.02 1.12 -1.47 -1.08
synaptotagmin III -2.04 * 1.02 * -1.77 1.14
RNA binding motif protein, X chromosome, mRNA -2.06 -1.85 -1.16 * 1.17 *
Expressed sequence AW538196 (AW538196), mRNA -2.08 1.12 * 1.20 -1.13 *
RIKEN cDNA 5730466C23 gene -2.11 1.27 -1.02 1.40
phenylalanine-tRNA synthetase-like, alpha subunit -2.12 1.17 1.20 -1.74
--- -2.12 -1.18 -1.18 -1.93
RIKEN cDNA 1810057C19 gene -2.17 -1.72 1.07 -1.50 *
melanoma antigen, family A, 7 -2.26 -2.04 1.12 1.75
plakophilin 3 -2.27 -1.52 -1.38 * -1.25 *
solute carrier organic anion transporter family, member 1c1 -2.28 -1.33 1.53 -1.36 *
3-hydroxybutyrate dehydrogenase (heart, mitochondrial) -2.36 -1.50 -1.04 1.55
contactin associated protein-like 2 -2.36 1.17 1.10 -1.13
forkhead box N4 -2.51 -2.09 -1.43 -1.87
forkhead box O3a -2.83 -1.19 * 1.12 * -1.26
reproductive homeobox on X chromosome, 9 -2.89 1.15 -1.00 -1.66 *
serine (or cysteine) peptidase inhibitor, clade D, member 1 -2.96 -1.00 1.08 -2.92 *
lysyl oxidase-like 4 -3.04 1.25 1.02 -1.08
CD28 antigen -3.10 1.01 -1.54 1.14
solute carrier family 35 (UDP-galactose transporter), 
member 2
-3.35 1.67 1.35 -1.25
aldo-keto reductase family 1, member C18 -3.67 -1.76 * -1.39 * 1.48
CD28 antigen -6.46 * 1.18 -1.14 1.02
solute carrier family 35, member A5 -6.63 -1.84 -1.25 -1.23
Table B1 MLC/Class 1 IGF-1Ea list of up- and down-regulated genes. A selection of genes that were either 
up- or down-regulated by 1.9-fold. Genes in bold are unique for the Class 1 IGF1-1Ea transgenic samples, i.e. 
they scored an increase or decrease of 1.9-fold in the Class 1 IGF-1Ea transgenic while at the same time scoring 
less than 1.3-fold up- or down-regulation in the other three transgenic models. The presence of a star on the right 
of some values indicates a higher variability of the signal intensity between the two RNA samples analyzed for 
each model. 
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GENE NAME 1 EA 1 EB 2 EA 2 EB
insulin-like growth factor 1 25.52 * 3.32 15.69 1.80
zinc finger protein, subfamily 1A, 1 (Ikaros) 2.91 * 2.79 * 2.07 * 2.55 *
matrix metallopeptidase 7 1.01 2.74 * -1.14 -1.54
bromodomain adjacent to zinc finger domain, 1B 2.14 * 2.68 -1.21 1.65 *
Monoclonal antiidiotypic antibody IgK (hypervariable region) 
mRNA 1.54 * 2.01 1.14 * 1.39
DIX domain containing 1 2.82 2.00 * 2.29 3.29
CEA-related cell adhesion molecule 1 1.11 1.96 1.46 1.79
N-terminal Asn amidase, mRNA (cDNA clone MGC:29106 
IMAGE:5037501) 1.53 1.95 1.22 1.78
T-cell receptor beta, variable 13 1.64 1.94 1.25 2.03
protein tyrosine phosphatase, non-receptor type 13 -1.41 -1.90 -1.18 1.13
Kruppel-like factor 4 (gut) -1.11 -1.93 -1.63 -1.07
CD3 antigen, zeta polypeptide 1.05 -1.93 -1.20 1.02
cytidine monophospho-N-acetylneuraminic acid hydroxylase -1.11 * -1.93 -1.80 -1.02
ecotropic viral integration site 5 1.12 -1.94 -2.29 * -2.40 *
uroplakin 1A -1.08 * -1.96 1.21 1.19
RNA binding motif protein, X chromosome, mRNA 1.07 -1.96 -1.14 -1.03
presenilin 2 -1.22 -1.97 -1.05 1.32
heat shock protein 1B -1.02 -1.98 1.16 * -1.98
fascin homolog 1, actin bundling protein 1.15 -1.99 1.18 1.09
deoxyuridine triphosphatase 1.29 -2.03 -1.10 1.31
sodium channel, nonvoltage-gated 1 beta -1.04 * -2.03 -1.07 -1.00
melanoma antigen, family A, 7 -2.26 -2.04 1.12 1.75
Ras association (RalGDS/AF-6) domain family 7 -1.81 * -2.05 * -1.21 -1.15
peroxisome biogenesis factor 16 1.38 -2.07 -1.56 * -1.88
forkhead box N4 -2.51 -2.09 -1.43 -1.87
RIKEN cDNA 1200007D18 gene 1.14 * -2.11 -1.15 -1.18
SH3 multiple domains 1 1.05 * -2.11 1.22 -1.10
membrane metallo endopeptidase 1.01 -2.11 * 1.08 -1.14
neuron specific gene family member 2 1.31 -2.12 1.09 -1.21
Ros1 proto-oncogene 1.37 * -2.13 1.04 1.25
glutamate receptor, ionotropic, NMDA2D (epsilon 4) 1.26 -2.23 -1.58 -1.18
heat shock protein 1A 1.02 -2.25 1.37 -1.88
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2, p49/p100 -1.28 * -2.46 -2.35 -2.09
DNA segment, Chr 7, ERATO Doi 462, expressed -1.09 * -2.61 -1.53 * -1.06
immunoglobulin superfamily, member 4B 1.00 -2.82 1.47 -1.23 *
target of myb1-like 1 (chicken) 1.42 -2.98 * -1.56 * -1.02
myo-inositol oxygenase -1.35 * -3.17 -1.06 -1.23 *
RIKEN cDNA 5730507H05 gene -1.21 * -4.58 -4.22 -2.61 *
Table B2 MLC/Class 1 IGF-1Eb list of up- and down-regulated genes. A selection of genes that were either 
up- or down-regulated by 1.9-fold. Genes in bold are unique for the Class 1 IGF1-1Eb transgenic samples, i.e. 
they scored an increase or decrease of 1.9-fold in the Class 1 IGF-1Eb transgenic while at the same time scoring 
less than 1.3-fold up- or down-regulation in the other three transgenic models. The presence of a star on the right 
of some values indicates a higher variability of the signal intensity between the two RNA samples analyzed for 
each model.
.
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GENE NAME 1 EA 1 EB 2 EA 2 EB
insulin-like growth factor 1 25.52 * 3.32 15.69 1.80
colony stimulating factor 3 receptor (granulocyte) 2.11 1.44 2.39 -1.13 *
gap junction membrane channel protein alpha 1 -1.03 1.13 2.33 -1.07
adaptor-related protein complex AP-4, mu 1 1.39 1.89 * 2.29 3.29
DIX domain containing 1 2.82 2.00 * 2.29 3.29
beta-site APP-cleaving enzyme 2 1.89 -1.32 2.27 -1.16 *
shroom -1.07 * -1.10 * 2.09 -2.63 *
zinc finger protein, subfamily 1A, 1 (Ikaros) 2.91 * 2.79 * 2.07 * 2.55 *
serine (or cysteine) peptidase inhibitor, clade A, member 3A 1.23 * 1.30 1.97 1.11
carbonic anhydrase 5a, mitochondrial 1.82 1.31 * 1.94 -1.02 *
FK506 binding protein 5 (immunophilin) 1.03 * 1.18 * 1.93 1.18
deltex 2 homolog (Drosophila) 1.09 * -1.01 1.91 1.81
transmembrane protein 54 1.08 -1.18 -1.94 1.24
Slit-like 2 (Drosophila) -1.30 -1.09 -1.95 -1.20
RNA binding motif protein, X chromosome, mRNA -1.07 -1.16 -1.95 1.18
chloride channel CLIC-like 1 -1.14 * -1.12 -1.99 -1.16
cytochrome P450, family 2, subfamily b, polypeptide 10 -1.03 -1.27 * -2.02 -1.07
Bcl2-like 2 -1.30 1.00 -2.05 * 1.21
RIKEN cDNA 2310043L02 gene 1.25 1.39 -2.09 1.10
splicing factor proline/glutamine rich -1.14 -1.42 -2.09 -1.18
phosphatidylserine synthase 2 -1.47 * -1.02 * -2.12 1.09
tRNA nucleotidyl transferase, CCA-adding, 1 -1.55 1.14 -2.14 1.36 *
C79248: similar to platelet-activated factor acetylhydrolase (PAF-AH) 1.50 -1.53 -2.15 -1.43
DnaJ (Hsp40) homolog, subfamily C, member 18 -1.34 -1.23 -2.16 -1.02
calcium regulated heat stable protein 1 1.20 1.09 * -2.23 1.44
B-cell CLL/lymphoma 6, member B 1.20 -1.32 * -2.25 1.36 *
cerebellin 1 precursor protein -1.20 -1.34 * -2.27 -1.64
CEA-related cell adhesion molecule 2 1.75 * -1.58 -2.31 2.11 *
proteasome (prosome, macropain) 26S subunit, ATPase, 6 -1.41 1.12 -2.31 1.18
suppressor of cytokine signaling 3 -1.06 -1.25 * -2.31 1.29 *
NF-kB 2, p49/p100 -1.28 * -2.46 -2.35 -2.09
cell division cycle associated 3 1.30 -1.18 * -2.42 1.14
tissue factor pathway inhibitor 1.18 -1.03 * -2.46 1.21 *
cyclic AMP-regulated phosphoprotein, 21 1.52 -1.01 -2.52 * -1.36
mutY homolog (E. coli) 1.15 -1.13 * -2.54 -1.46
apoptosis antagonizing transcription factor -1.04 1.36 -2.56 * -1.08 *
integrin alpha 5 (fibronectin receptor alpha) -1.81 * -1.04 -2.66 1.18
calsyntenin 3 1.15 -1.76 * -2.71 1.20
SRY-box containing gene 4 (Sox4), mRNA 1.68 -1.41 * -2.85 1.21
coagulation factor VII 1.31 1.11 * -2.86 1.09
aldehyde dehydrogenase 2, mitochondrial -1.71 * -1.12 -3.06 -1.51
tetraspan 1 -1.71 1.14 -3.12 -2.03 *
myelin basic protein expression factor 2, repressor -1.85 * 1.03 -3.36 * -1.06
Ubiquitin specific peptidase 7 (Usp7), mRNA -1.31 -2.27 * -3.39 -1.48 *
Notch-regulated ankyrin repeat protein -1.18 1.14 -3.51 * -1.11 *
scaffold attachment factor B2 -1.41 * -1.65 * -3.78 -2.41
zinc finger protein 503 1.12 -1.65 * -3.94 -2.09 *
per-pentamer repeat gene 1.35 -1.06 * -4.03 -1.27
thyroid stimulating hormone, beta subunit 1.07 1.17 * -4.03 * 1.12
contactin associated protein-like 2 1.71 1.39 -5.11 1.37
splA/ryanodine receptor domain and SOCS box containing 4 1.45 1.40 -7.87 * 1.58
Table B3 MLC/Class 2 IGF-1Ea list of up- and down-regulated genes. A selection of genes that were either 
up- or down-regulated by 1.9-fold. Genes in bold are unique for the Class 2 IGF1-1Ea transgenic samples, i.e. 
they scored an increase or decrease of 1.9-fold in the Class 2 IGF-1Ea transgenic while at the same time scoring 
less than 1.3-fold up- or down regulation in the other three transgenic models. The presence of a star on the right 
of some values indicates a higher variability of the signal intensity between the two RNA samples analyzed for 
each model.
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GENE NAME 1 EA 1 EB 2 EA 2 EB
DIX domain containing 1 2.82 2.00 * 2.29 3.29
adaptor-related protein complex AP-4, mu 1 1.39 1.89 * 2.29 3.29
zinc finger protein, subfamily 1A, 1 (Ikaros) 2.91 * 2.79 * 2.07 * 2.55 *
homeodomain interacting protein kinase 2 1.35 1.33 1.43 2.34
WAP four-disulfide core domain 2 1.23 * -1.05 * -1.02 * 2.18
CEA-related cell adhesion molecule 2 1.75 * -1.58 -2.31 2.11 *
ferritin mitochondrial 1.63 1.58 1.18 2.07
T-cell receptor beta, variable 13 1.64 1.94 1.25 2.03
EH-domain containing 1 1.14 -1.26 1.33 -1.93
angiopoietin-like 1 -1.29 1.03 1.09 -1.93 *
heat shock protein 1B -1.02 -1.98 1.16 * -1.98
homeo box C5 1.02 1.17 1.42 -1.99
tetraspan 1 -1.71 1.14 -3.12 -2.03 *
Rho GTPase activating protein 4 1.10 * -1.80 1.32 -2.04
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2, p49/p100 -1.28 * -2.46 -2.35 -2.09
RNA binding motif protein, X chromosome, mRNA 1.40 -1.20 1.01 * -2.09
ephrin B3 -1.13 1.00 * 1.29 -2.09
transmembrane protein 45b -1.18 -1.04 -1.09 -2.13
erythroid associated factor 1.07 -1.51 * 1.47 -2.18
procollagen, type II, alpha 1 -1.16 1.05 -1.59 -2.23 *
sphingomyelin phosphodiesterase 2, neutral -1.13 * -1.64 * 1.22 -2.23
PKD2 interactor, golgi and endoplasmic reticulum 
associated 1 -1.00 -1.03 * 1.22 -2.30
scaffold attachment factor B2 -1.41 * -1.65 * -3.78 -2.41
phosphoenolpyruvate carboxykinase 1, cytosolic -1.17 * -1.00 1.15 -2.49
RIKEN cDNA 9130019O22, putative zinc finger protein 1.94 1.69 1.05 * -2.50
mast cell protease 5 1.30 -1.34 1.13 -2.61 *
Shroom -1.07 * -1.10 * 2.09 -2.63 *
endothelin 1 -1.08 * 1.02 -1.10 -2.67 *
serine (or cysteine) peptidase inhibitor, clade D, member 1 -2.96 -1.00 1.08 -2.92 *
potassium channel, subfamily K, member 7 1.29 -1.23 -1.07 -3.12
myosin, light polypeptide 4 -1.20 * -1.12 -1.83 * -3.21
major urinary protein 1 and 3 -1.13 * 1.05 * -1.01 -3.38
cofactor required for Sp1 transcriptional activation, subunit 6 -1.92 * -1.20 -1.71 * -3.58
RIKEN cDNA 5730410I19 gene 1.05 -1.32 -1.18 -3.96
Sulfiredoxin 1 homolog (S. cerevisiae) (Srxn1), mRNA 1.01 -1.45 1.45 -4.44
Table B4 MLC/Class 2 IGF-1Eb list of up- and down-regulated genes. A selection of genes that were either 
up- or down-regulated by 1.9-fold. Genes in bold are unique for the Class 2 IGF1-1Eb transgenic samples, i.e. 
they scored an increase or decrease of 1.9-fold in the Class 2 IGF-1Eb transgenic while at the same time scoring 
less than 1.3-fold up- or down regulation in the other three transgenic models. The presence of a star on the right 
of some values indicates a higher variability of the signal intensity between the two RNA samples analyzed for 
each model. 
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GENE NAME 1 Ea 1 Eb 2 Ea 2 Eb
melanoma antigen, family A, 7 -2.26 -2.04 1.12 1.75
DNA segment, Chr 2, ERATO Doi 63, expressed -2.05 * -1.58 1.01 1.61
transmembrane channel-like gene family 1 -1.89 * -1.31 1.33 1.17
cofactor required for Sp1 transcriptional activation, subunit 2 -1.49 * -1.84 * 1.01 1.19
potassium voltage-gated channel, shaker-related subfamily, member 1 -1.63 * -1.56 * 1.06 1.14
potassium voltage-gated channel, shaker-related subfamily, beta 
member 1 -1.53 -1.35 1.04 1.25
melanophilin -1.45 -1.46 * 1.12 1.09
growth differentiation factor 11 -1.47 -1.33 1.04 1.03
3-hydroxybutyrate dehydrogenase (heart, mitochondrial) -2.36 -1.50 -1.04 1.55
small EDRK-rich factor 1 -2.06 -1.85 -1.16 * 1.17 *
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 -1.60 -1.74 * -1.17 * 1.08
PHD finger protein 2 -1.74 -1.30 1.22 -1.14
protein kinase C, gamma -1.34 -1.32 -1.21 * 1.46
Ras association (RalGDS/AF-6) domain family 7 -1.81 * -2.05 * -1.21 -1.15
toll-like receptor 9 1.43 1.59 1.11 * -1.02
ubiquitination factor E4B, UFD2 homolog (S. cerevisiae) 1.62 1.53 -1.03 1.08 *
syndecan 3 1.57 * 1.53 -1.37 1.10
Immunoglobulin kappa light variable region (IgKV gene) 1.90 1.36 1.02 -1.64 *
protocadherin beta 8 1.35 1.31 -1.30 * -1.00
apolipoprotein B editing complex 3 1.41 1.41 -1.06 * -1.10
Syntaxin 5A, mRNA (cDNA clone MGC:25518 IMAGE:3487476) 1.40 1.48 -1.12 -1.03
RIKEN cDNA 9130019O22 gene 1.94 1.69 1.05 * -2.50
antigen identified by monoclonal antibody Ki 67 1.46 1.32 -1.11 -1.23
bleomycin hydrolase 1.36 1.32 -1.35 -1.29
keratin associated protein 5-1 1.52 * 1.52 * -1.07 -1.38
zinc finger protein 30 1.45 1.52 -1.41 * -1.38
hyaluronidase 3 1.42 * 2.14 * -1.15 -1.23
midasin homolog (yeast) 1.72 1.30 * -1.67 * -1.32 *
solute carrier family 16 (monocarboxylic acid transporters), member 11 2.30 1.32 * -1.22 * -1.40
Table B5 List of up- and down-regulated genes only in response to Class 1 isoforms. A selection of genes, 
that were either up- or down-regulated by 1.3-fold only in the Class 1 IGF-1-expressing transgenic samples. The 
presence of a star on the right of some values indicates a higher variability of the signal intensity between the two 
RNA samples analyzed for each model.
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GENE NAME 1 Ea 1 Eb 2 Ea 2 Eb
cyclin D1 1.31 1.04 -2.13 * -1.89 *
interleukin 4 receptor, alpha 1.47 * 1.26 -1.56 -1.83
phosphatidylinositol glycan, class O 1.19 * 1.47 -1.58 -1.80 *
Prkr interacting protein 1 (IL11 inducible) 1.37 * 1.20 * -1.35 * -1.41 *
ADP-ribosylation factor 3 1.21 1.08 -1.32 * -1.68
protein tyrosine phosphatase, receptor type, C 1.47 1.12 -1.31 -1.36
REX4, RNA exonuclease 4 homolog (S. cerevisiae) 1.10 1.05 -1.53 -1.31
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 1.20 1.00 -1.35 -1.33
A kinase (PRKA) anchor protein 10 1.02 1.14 * -1.38 -1.31 *
cyclic AMP-regulated phosphoprotein, 21 1.52 -1.01 -2.52 * -1.36
TSC22 domain family, member 1 -1.04 1.12 * -2.20 * -1.45 *
procollagen, type II, alpha 1 -1.16 1.05 -1.59 -2.23 *
neurobeachin-like 2 1.16 -1.05 -1.53 -1.84 *
lactate dehydrogenase 3, C chain, sperm specific 1.11 -1.18 -1.50 -1.85 *
progesterone receptor membrane component 2 -1.14 1.35 -1.31 * -1.71 *
isopentenyl-diphosphate delta isomerase 1.02 -1.07 -1.54 -1.71
deiodinase, iodothyronine, type II 1.02 -1.01 -1.40 -1.77
tumor protein D52-like 1 1.06 -1.28 -1.50 -1.82
cDNA sequence BC002059 1.01 -1.08 -1.73 -1.41
annexin A2 -1.01 1.22 -1.39 -1.45 *
dystrobrevin alpha 1.18 -1.10 -1.53 -1.42
ring finger and FYVE like domain containing protein -1.07 1.09 -1.49 -1.47
myosin, light polypeptide 4 -1.20 * -1.12 -1.83 * -3.21
poly (A) polymerase alpha -1.02 -1.19 -1.69 -1.60 *
DNA segment, Chr 6, ERATO Doi 47, expressed -1.04 -1.29 -1.88 -1.46 *
leucine-zipper-like transcriptional regulator, 1 -1.15 -1.24 -1.69 -1.51
HIV-1 Rev binding protein-like -1.12 -1.15 -1.52 -1.52
hypoxia inducible factor 1, alpha subunit 1.21 * 1.07 1.36 1.76 *
alcohol dehydrogenase 1 (class I) 1.05 1.05 1.61 1.34
mitogen-activated protein kinase kinase kinase kinase 5 1.15 * 1.02 * 1.44 1.63 *
phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, type III 1.14 * -1.15 * 1.33 1.62
X-linked myotubular myopathy gene 1 -1.41 * 1.10 1.55 * 1.37
deltex 2 homolog (Drosophila) 1.09 * -1.01 1.91 1.81
decapping enzyme, scavenger -1.29 -1.41 1.39 1.38
Table B6 List of up- and down-regulated genes only in response to Class 2 isoforms. A selection of genes
that were either up- or down-regulated by 1.3-fold only in the Class 2 IGF-1-expressing transgenic samples. The 
presence of a star on the right of some values indicates a higher variability of the signal intensity between the two 
RNA samples analyzed for each model.
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GENE NAME 1 Ea 2 Ea 1 Eb 2 Eb
CD28 antigen -3.10 -1.54 1.01 1.14
proteasome (prosome, macropain) 26S subunit, ATPase, 6 -1.41 -2.31 1.12 1.18
synaptotagmin III -2.04 * -1.77 1.02 * 1.14
src homology 2 domain-containing transforming protein C3 -1.61 -1.66 * 1.17 1.07
myelin basic protein expression factor 2, repressor -1.85 * -3.36 * 1.03 -1.06
asparagine-linked glycosylation 1 homolog -1.36 -1.31 1.01 1.30
myosin, heavy polypeptide 6, cardiac muscle, alpha -1.37 -1.32 1.06 1.21 *
integrin alpha 5 (fibronectin receptor alpha) -1.81 * -2.66 -1.04 1.18
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 -1.42 * -3.14 * -1.10 * 1.12
phosphatidylserine synthase 2 -1.47 * -2.12 -1.02 * 1.09
elongation factor Tu GTP binding domain containing 2 -2.02 -1.47 1.12 -1.08
RecQ protein-like -1.70 * -1.66 -1.09 1.19 *
regulator of G-protein signaling 5 -1.37 -1.83 -1.03 1.27
zinc finger, FYVE domain containing 19 -1.40 * -1.67 1.19 * -1.06
Rho GTPase activating protein 21 -1.46 -1.50 * -1.04 * 1.02
protein kinase, cGMP-dependent, type I -1.47 -2.32 * -1.23 * -1.17
DnaJ (Hsp40) homolog, subfamily C, member 18 -1.34 -2.16 -1.23 -1.02
Sjogren syndrome antigen B -1.98 -1.44 -1.11 -1.10 *
ring finger protein 11 -1.50 -1.69 -1.06 -1.11
neutral sphingomyelinase (N-SMase) activation associated factor -1.33 -1.74 -1.01 -1.05
tumor necrosis factor receptor superfamily, member 19 -1.37 -1.78 -1.10 -1.06
enhancer of yellow 2 homolog (Drosophila) -1.49 -1.61 -1.11 -1.11
ATPase, H+ transporting, lysosomal accessory protein 2 -1.45 -1.38 -1.02 -1.02
CDC42 effector protein (Rho GTPase binding) 3 -1.42 * -1.46 -1.10 -1.02
methylenetetrahydrofolate dehydrogenase (NAD+ dependent) -1.31 -1.47 -1.04 -1.04
GTP binding protein 4 -1.49 -1.37 -1.14 -1.12
ADP-ribosylation factor-like 6 interacting protein 6 -1.42 * -1.44 -1.09 -1.29
fibroblast growth factor 11 -1.36 -1.50 -1.23 -1.28
RAS related protein 1b -1.33 -1.36 -1.23 -1.11
Rho GTPase activating protein 5 1.65 1.30 1.11 1.20
upregulated during skeletal muscle growth 1 1.40 1.47 1.17 1.04 *
sushi domain containing 4 1.45 1.43 1.16 1.04
growth factor receptor bound protein 2-associated protein 3 1.48 1.42 1.02 1.08 *
SH3-domain GRB2-like 2 1.32 1.76 * 1.22 * 1.02
trace amine-associated receptor 1 1.32 1.77 1.10 1.15
DNA segment, Chr 9, ERATO Doi 720, expressed 1.53 1.65 1.05 1.29
keratin complex 1, acidic, gene 24 1.88 1.56 1.05 * 1.27
leucine rich repeat containing G protein coupled receptor 5 1.91 * 1.58 * 1.24 1.02
adaptor protein with pleckstrin homology and src 1.38 1.57 -1.03 1.08
RASD family, member 2 1.66 1.40 1.16 * -1.01
synaptotagmin XII 1.31 1.62 1.09 -1.09
laminin, beta 3 1.37 1.56 1.17 -1.33 *
midasin homolog (yeast) 1.58 1.56 * 1.01 -1.11
ankyrin repeat and SOCS box-containing protein 6 1.53 * 1.70 * -1.04 1.02
CEA-related cell adhesion molecule 2 1.32 1.85 -1.54 1.06
Rho GDP dissociation inhibitor (GDI) gamma 1.32 1.32 -1.27 -1.06
mbt domain containing 1 1.32 1.35 -1.31 -1.02 *
endothelin converting enzyme 2 1.38 1.52 -1.23 * -1.06
expressed in non-metastatic cells 6, protein 1.64 1.50 -1.18 * -1.01
phosphatidylinositol membrane-associated 1 1.53 1.61 * -1.21 * -1.05 *
lin 7 homolog b (C. elegans) 1.34 1.41 -1.60 -1.10
beta-site APP-cleaving enzyme 2 1.89 2.27 -1.32 -1.16 *
proline rich protein HaeIII subfamily 1 3.83 * 2.99 * -1.42 -1.09
Table B7 List of up- and down-regulated genes only in response to Ea isoforms. A selection of genes that 
were either up- or down-regulated by 1.3-fold only in the IGF-1Ea-expressing transgenic samples. The presence 
of a star on the right of some values indicates a higher variability of the signal intensity between the two RNA 
samples analyzed for each model.
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GENE NAME 1 Ea 2 Ea 1 Eb 2 Eb
Sulfiredoxin 1 homolog (S. cerevisiae) (Srxn1), mRNA 1.01 1.45 -1.45 -4.44
heat shock protein 1A 1.02 1.37 -2.25 -1.88
mast cell protease 5 1.30 1.13 -1.34 -2.61 *
CD52 antigen 1.35 * -1.13 * -2.13 * -3.99
Rho GTPase activating protein 4 1.10 * 1.32 -1.80 -2.04
lactalbumin, alpha 1.45 1.26 * -1.63 * -1.91 *
erythroid associated factor 1.07 1.47 -1.51 * -2.18
activating transcription factor 3 1.01 1.34 -1.83 -1.41
leucine-rich repeat kinase 1 1.30 1.02 -1.48 -1.71 *
Immunoglobulin A heavy chain variable region (IGHV gene), 
clone WJ17 1.34 * 1.04 -1.50 * -1.63 *
heat shock protein 1B -1.02 1.16 * -1.98 -1.98
sphingomyelin phosphodiesterase 2, neutral -1.13 * 1.22 -1.64 * -2.23
early B-cell factor 3 1.01 -1.09 -1.39 -1.69
transient receptor potential cation channel, subfamily M, 
member 7 -1.06 1.00 -1.55 -1.49 *
thyrotroph embryonic factor -1.13 1.07 -1.30 -1.67
DNA segment, Chr 16, ERATO Doi 472, expressed 1.07 -1.04 -1.31 -1.34
solute carrier family 5 (choline transporter), member 7 -1.15 -1.05 -1.57 -1.69
chemokine (C-C motif) ligand 6 -1.04 -1.07 -1.66 * -1.39
cholinergic receptor, nicotinic, alpha polypeptide 4 -1.26 * -1.08 -1.77 * -1.50
ribosomal protein S9 -1.24 -1.15 -1.36 -1.76
RIKEN cDNA 4631403P03 gene -1.05 -1.09 -1.31 -1.36 *
EGF-like-domain, multiple 9 -1.24 -1.20 -1.35 -1.55
RER1 retention in endoplasmic reticulum 1 homolog (S. 
cerevisiae) 1.01 -1.03 1.32 1.61
scratch homolog 1, zinc finger protein (Drosophila) -1.01 * 1.19 * 1.48 1.76
eukaryotic translation initiation factor 3, subunit 6 interacting 
protein 1.02 * -1.35 1.31 1.85
Table B8 List of up- and down-regulated genes only in response to Eb isoforms. A selection of genes that 
were either up- or down-regulated by 1.3-fold only in the IGF-1Eb-expressing transgenic samples. The presence 
of a star on the right of some values indicates a higher variability of the signal intensity between the two RNA 
samples analyzed for each model.
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Appendix C: Ingenuity pathway analysis
Figure C1 Example of an IGF-1 network constructed with Ingenuity. The interaction network related to IGF-1
was build according to the information available at Ingenuity Inc. The different circles highlight genes involved or 
related to NF-kB, mTOR/Akt or IGF-1 receptor pathways, as well as to adhesion function, extracellular IGFBPs
and metalloproteases.
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Figure C2 MLC/Class 1 IGF-1Ea overlay of regulated genes in the Ingenuity IGF-1 network. Genes that are 
either up-regulated (red) or down-regulated (green) at least 1.3-fold in Class 1 IGF-1Ea transgenic muscles, 
compared to WT, were mapped against the IGF-1 network built by using the Ingenuity Pathway Analysis software 
platform.
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Figure C3 MLC/Class 1 IGF-1Eb overlay of regulated genes in the Ingenuity IGF-1 network. Genes that are 
either up-regulated (red) or down-regulated (green) at least 1.3-fold in Class 1 IGF-1Eb transgenic muscles, 
compared to WT, were mapped against the IGF-1 network built by using the Ingenuity Pathway Analysis software 
platform.
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Figure C4 MLC/Class 2 IGF-1Ea overlay of regulated genes in the Ingenuity IGF-1 network. Genes that are 
either up-regulated (red) or down-regulated (green) at least 1.3-fold in Class 2 IGF-1Ea transgenic muscles, 
compared to WT, were mapped against the IGF1 network built by using the Ingenuity Pathway Analysis software 
platform.
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Figure C5 MLC/Class 2 IGF-1Eb overlay of regulated genes in the Ingenuity IGF-1 network. Genes that are 
either up-regulated (red) or down-regulated (green) at least 1.3 fold in Class 2 IGF-1Eb transgenic muscles, 
compared to WT, were mapped against the IGF1 network built by using the Ingenuity Pathway Analysis software 
platform.
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Table C1 List of Ingenuity gene abbreviations
ACTN1 actinin, alpha 1
AGT angiotensinogen
AKT1 thymoma viral proto-oncogene 1
AKT2 thymoma viral proto-oncogene 2
B2M beta-2 microglobulin
BAD Bcl-associated death promoter
BCL2 B-cell leukemia/lymphoma 2
BMP7 bone morphogenetic protein 7
CAMK2A calcium/calmodulin-dependent protein 
kinase II alpha
CAV1 caveolin, caveolae protein 1
CCND1 cyclin D1
CCNE1 cyclin E1
CD28 CD28 antigen
CD36 CD36 antigen
CD80 CD80 antigen
CDC37 cell division cycle 37 homolog
CDH1 cadherin 1
CDK4 cyclin-dependent kinase 4
CDKN1A cyclin-dependent kinase inhibitor 1A (P21)
CDKN1B cyclin-dependent kinase inhibitor 1B (P27)
CHUK conserved helix-loop-helix ubiquitous 
kinase
COL18A1 procollagen, type XVIII, alpha 1
CSF1 colony stimulating factor 1 (macrophage)
CTNNB1 beta-catenin
CYR61 cysteine rich protein 61 (IGFBP10)
EDN1 endothelin 1
EGFR epidermal growth factor receptor
EGR1 early growth response 1
EIF4EBP1 eukaryotic translation initiation factor 4E 
binding protein 1
ERBB2 v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2
ESR1 estrogen receptor 1 (alpha)
FGF2 fibroblast growth factor 2
FMR1 fragile X mental retardation syndrome 1 
homolog
FN1 fibronectin 1
FRAP1 mTOR
GH1 growth hormone
GHR growth hormone receptor
GLI1 GLI-Kruppel family member GLI1
GRB10 growth factor receptor bound protein 10
GRIN2B glutamate receptor, ionotropic, NMDA2B
GSK3B glycogen synthase kinase 3 beta
HIF1A hypoxia inducible factor 1, alpha subunit
IGF1 insulin-like growth factor 1
IGF1R insulin-like growth factor I receptor
IGF2 insulin-like growth factor  2
IGFBP1 insulin-like growth factor binding protein 1
IGFBP2 insulin-like growth factor binding protein 2
IGFBP3 insulin-like growth factor binding protein 3
IGFBP4 insulin-like growth factor binding protein 4
IGFBP5 insulin-like growth factor binding protein 5
IGFBP6 insulin-like growth factor binding protein 6
IGFBP7 insulin-like growth factor binding protein 7
IKBKB inhibitor of kappaB kinase beta
IKBKG inhibitor of kappaB kinase gamma
INS insulin II
Ins1 insulin I
INSR insulin receptor
IRAK1 interleukin-1 receptor-associated kinase 1
IRS1 insulin receptor substrate 1
IRS2 insulin receptor substrate 2
ITGA5 integrin alpha 5
ITGB1 integrin beta 1
ITGB3 integrin beta 3
JAK2 Janus kinase 2
JUN Jun oncogene
KDR kinase insert domain protein receptor
KITLG kit ligand
MME membrane metallo endopeptidase
MMP19 matrix metallopeptidase 19
MMP2 matrix metallopeptidase 2
MYB MYB (myeloblastosis oncogene)
MYC c-myc
MYOD1 MyoD
MYOG myogenin
NFKB2 nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 2, p49/p100
NFKBIA nuclear factor of kappa light chain gene 
enhancer in B-cells inhibitor, alpha
PCSK5 proprotein convertase subtilisin/kexin type 
5
PIK3R1 phosphatidylinositol 3-kinase, regulatory 
subunit
PLAU plasminogen activator, urokinase
PLG plasminogen
PRKCA protein kinase C, alpha
PRKCD protein kinase C, delta
PTEN phosphatase and tensin homolog
PTK2 Focal Adhesion Kinase
PTPN11 protein tyrosine phosphatase, non-
receptor type 11
RB1 retinoblastoma 1
RELA v-rel reticuloendotheliosis viral oncogene 
homolog A
RPS6KA1 ribosomal protein S6 kinase polypeptide 1
RPS6KB1 ribosomal protein S6 kinase, polypeptide 1
SHC1 src homology 2 domain-containing 
transforming protein C1
SOCS1 suppressor of cytokine signaling 1
SOCS2 suppressor of cytokine signaling 2
SOCS3 suppressor of cytokine signaling 3
SPP1 secreted phosphoprotein 1
SRC src
STAT3 STAT 3
STAT5B STAT 5B
TF transferrin
TGFB1 transforming growth factor, beta 1
THBS1 thrombospondin 1
TJP1 tight junction protein 1
TNF tumor necrosis factor
TNFSF10 tumor necrosis factor (ligand) superfamily
TP53 transformation related protein 53
VEGF vascular endothelial growth factor A
VEGFC vascular endothelial growth factor C
VTN vitronectin
WT1 Wilms tumor homolog
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